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Abstract 
 
Pharmaceutical Co-crystals; Utility, Formulation and Performance 
Philip A. Corner MPharm 
Key words: Pharmaceutical, co-crystal, screening, optimisation, co-amorphous, ROY, ornidazole, 
zafirlukast. 
 
Co-crystallisation is currently a ‘hot topic’ in pharmaceutical development among other fields. 
Modification of the physicochemical properties of the parent material by inclusion of a second 
component within the crystal structure, with the potential to lead to large improvements in 
useful attributes, being the key reason for the interest in co-crystals. Being able to efficiently 
utilise co-crystallisation to ameliorate problem properties of drugs or other compounds would 
be a boon to many industries, the pharmaceutical being an ideal example. Limitations in current 
ability to predict co-crystal formation and potential property modification presents a great 
opportunity for development in this research area. 
The work presented in this thesis encompasses the optimisation of a high-throughput 
ultrasonication based physical co-crystal screen paired with a computational pre-screen, the 
application of this optimised screen and the analysis of both co-crystalline and co-amorphous 
materials resulting from the screening. An initial optimisation of a manual physical co-crystal 
screen was later transferred to an automated screen implemented on a robotics platform. The 
implementation of the screen and subsequent analysis of products led to the discovery of the 
stabilisation of an amorphous form of highly polymorphic compound, ROY, through a predicted 
co-former interaction. The interactions responsible for the stabilisation were further 
investigated in the ROY:pyrogallol co-amorphous material and it was found that certain 
analogues of pyrogallol exhibit the same behaviour with ROY depending on the presence and 
position of specific functionality. 
Implementation of the optimised co-crystal screen to the antiprotozoal drug ornidazole led to 
the detection of 23 hits and the crystal structure of the 1:1 co-crystal of ornidazole and 5-
nitroisophthalic acid being determined by single crystal X-ray diffraction. Characterisation of this 
co-crystal found that it crystallised much more readily than pure ornidazole, potentially 
improving its processing characteristics, but that unexpectedly had a lower intrinsic dissolution 
rate than either of the parent components. In comparison, formulation and characterisation of 
the already known zafirlukast:piperazine co-crystals showed that large improvements in 
dissolution rates and oral bioavailability in relation to the parent drug are possible. Specifically, 
the 1:1 zafirlukast:piperazine co-crystal showed a large increase in dissolution rate in vitro and 
an accompanying six-fold increase in in vivo oral bioavailability. 
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1 
 
Chapter 1 – Introduction 
 
1.1 General introduction to pharmaceutical co-crystals 
Crystalline material can be defined as ‘a regular arrangement of the constituent molecules, 
atoms or ions into some fixed and rigid pattern known as a lattice’.1 A co-crystal can very simply 
be described as a crystalline solid containing two or more different substances, however this is 
an oversimplified description. A multicomponent crystal is an umbrella term which can be used 
to describe many types of compounds including: salts, hydrates and solvates, and inclusion 
compounds such as clathrates. A universally accepted definition of a co-crystal has yet to be 
recognized and as such, debate continues within the community as to what should and should 
not be given this label. A recently proposed definition, ‘cocrystals are solids that are crystalline 
single phase materials composed of two or more different molecular and/or ionic compounds 
generally in a stoichiometric ratio which are neither solvates nor simple salts.’, attempts to be 
broad whilst still maintaining consistency with the scientific literature.2 This proposed definition 
is, on the whole, successful at differentiating co-crystals from other multicomponent complexes, 
however a prior debate regarding the state of matter of the constituents is left unclarified. 
Previously it had been suggested that only multicomponent crystals formed from reactants that 
were in the solid state under ambient conditions should be classed as co-crystals,3,4 and 
arguments made against this definition resulted.5 The importance of this is that if co-crystals 
could be formed from reactants in the liquid state, this would encompass solvates. Although 
relatively recent FDA guidance on pharmaceutical co-crystals states that co-crystals should be 
treated as drug product intermediates rather than a new drug entity,6 solvates and co-crystal 
are still different from a patentability perspective. This is because for a material to be patentable 
it must be novel, useful and non-obvious. Solvates, it could be argued, are obvious to someone 
skilled in the art, due to the quantity of prior art in existence. The desire for the definition of 
pharmaceutical co-crystals to be specific around this point is that they would therefore be more 
readily patentable as a novel phase. 
As well as in the pharmaceutical field, co-crystals have garnered interest in other communities 
such as those investigating porous solids for gas storage and separation applications, and those 
involved in ferroelectrics research.7 Broader areas in which co-crystals have potential application 
are agrochemicals,7 photographic film formulation,4 solid-state organic synthesis,8 and 
semiconductor,9 optical10 and explosive materials.11,12,13 Thus pharmaceutical co-crystals are a 
subset of a larger group and are distinguished by containing an active pharmaceutical ingredient 
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(API) as at least one of the constituent components. To be termed a pharmaceutical co-crystal 
the other non-API component(s) of the co-crystal should be safe for use in humans with no toxic 
or serious adverse effects. Although theoretically any co-former could be used, human safety 
testing would be required to be performed if not previously completed for any particular 
substance, adding significant cost to the development process. Therefore co-formers for 
pharmaceutical co-crystals are generally limited to substances found in the FDA’s Generally 
Recognized as Safe (GRAS) or Everything Added to Food in the United States (EAFUS) lists.7 
 
1.2 Crystallisation 
1.2.1 Crystal growth from solution 
The formation of a crystal is a two-step process of nucleation followed by crystal growth. These 
processes will only occur when there is supersaturation of the solute, that is, when the 
concentration of material in question is higher than its thermodynamic solubility, as this is the 
driving force for crystallisation. There are three categories of nucleation: homogeneous primary 
nucleation, heterogeneous primary nucleation and secondary nucleation. The first of these 
describes nucleation which occurs spontaneously in a supersaturated solution without the 
presence of any other matter. The second is when nucleation is induced by foreign particles 
which act as a template for growth. Finally, secondary nucleation is that which is induced by 
‘seeding’ with the desired crystallite. 
In terms of homogeneous primary nucleation, classical nucleation theory suggests that the 
formation of a nucleus occurs through a sequence of bimolecular additions, where collisions 
between molecules form a cluster which grows in size with the further addition of molecules. As 
a cluster grows, its free energy increases until it reaches a threshold size known as a critical 
nucleus, at which point it becomes stable and as size increases further, free energy decreases, 
leading to further growth. Before reaching this critical point, the cluster is likely to dissolve due 
to its unfavorable energetic situation. With an increase in supersaturation, the free energy 
barrier and the size of the critical nuclei decrease to the point where it becomes possible for 
nucleation to occur spontaneously.1 
Once a critical nucleus has formed, the crystal growth process will occur. There are a number of 
theories for crystal growth and the model that is followed is influenced by the surface roughness 
of the growing crystal, a property which is commonly characterised by the α-factor. Low values 
indicate a rough crystal surface with a low energy barrier for continued growth and high values 
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a smooth surface with a greater energy barrier. Rough crystal surfaces, with an α-value of less 
than two, will allow continuous growth to proceed which will be diffusion controlled. This is 
where molecular diffusion to the crystal surface occurs, followed by a first order ‘reaction’ of 
the solute molecules arranging in the lattice. The growth rate in this case would be linear with 
respect to supersaturation. Smooth surfaces, with an α-value of greater than five, lead to growth 
proceeding via the screw dislocation mechanism. This is where a dislocation occurs on the 
surface of the crystal and thus prevents the need for surface nucleation to occur. Instead growth 
can occur perpetually in a spiral manner. In surface roughness between α-values of two and five, 
the birth and spread mechanism of growth is most probable. In this mechanism, surface 
nucleation occurs followed by a monolayer spreading outwards from the initial nucleation at the 
centre. Further surface nuclei can develop on these ‘islands’.1 These growth mechanisms are 
described in Figure 1.1. 
 
 
Figure 1.1 Mechanisms of crystal growth. I. Rough, II. Screw dislocation, III. Birth and spread. Adapted 
from reference.14 
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1.2.2 Glass-to-crystal growth 
Certain materials which form glasses display a fast mode of crystal growth known as the glass-
crystal (GC) mode which occurs near the glass transition temperature. This phenomenon was 
first observed in a study of o-terphenyl by Greet and Turnbull,15 and has since been observed in 
many other small molecule organic compounds including: phenyl salicylate,16 indomethacin17 
and ROY.18,19 The GC mode of crystal growth is not limited by molecular diffusion in the bulk 
liquid, leading some to term it ‘diffusionless’,20 and crystal growth in this mode has been shown 
to occur orders of magnitude faster than those predicted by standard models.17 
 
1.3 Phase diagrams 
Binary (two component) and ternary (three component) phase diagrams can be produced for 
multicomponent systems to show the environment in which each phase will be present. These 
are of use as the phase relationships between the two constituent components of a co-crystal 
can be quantitatively described by the construction of a phase diagram. 
 
 
Figure 1.2 The three fundamental types of binary phase diagram. Reproduced, with permission, from 
reference.14 
 
The three fundamental types of binary phase diagram are: eutectic, co-crystal and solid solution, 
as seen in Figure 1.2. In the eutectic binary phase diagram, there are two immiscible (in the solid 
state) components with a submerged eutectic, the lower melting point caused by the presence 
of the second component. The co-crystal diagram shows a solid co-crystal phase between the 
first and second eutectics, and the solid solution diagram shows two components which are 
miscible in the solid state.14 
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Figure 1.3 Example of ternary phase diagram for a 1:1 stoichiometric ratio co-crystal in which the API and 
co-former have different solubilities in the solvent. Adapted from reference.21 
 
Ternary phase diagrams introduce solvent to the represented substances. These diagrams are 
often displayed as a triangle and show the compositions at a specific temperature. They can 
show that, for example, evaporation of solvent would lead to the movement from one region to 
another (away from the solvent apex) and potentially into the co-crystal phase.22 This would be 
seen as moving from the white solution phase into the green co-crystal phase in the example 
ternary phase diagram in Figure 1.3. 
 
1.4 Crystal engineering 
Crystal engineering is a term used to describe the utilisation of the knowledge of intermolecular 
interactions in crystal structures in designing new crystalline materials with desired properties.23 
Much research into the rational design of co-crystals has been based on the crystal engineering 
approach of identification and utilisation of supramolecular synthons.24 Synthons are non-covalent 
bonds which reliably and reproducibly form the same kind of supramolecular interaction when 
forming between molecules with particular kinds of functional groups, known as tectons.25 The 
most significant interactions in synthon based design are conventional hydrogen bonds (OH∙∙∙O and 
NH∙∙∙O), however weaker bonds (e.g. CH∙∙∙O, CH∙∙∙N, O∙∙∙I) are also used. Due to the directional 
nature of these interactions, the orientation of the molecules within the crystal structure can be 
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predicted reasonably accurately. This allows the necessary functional groups to be placed in the 
correct area of the molecule to produce the desired synthon and hence, in theory, the crystal 
structure designed.26 
For the successful design of co-crystals, this means that the co-former selected should possess 
complimentary functional groups to those of the API, thereby being able to form the intermolecular 
interactions constituting the supramolecular synthon selected. Examples of synthons commonly 
used in the design of co-crystals include the amide-amide synthon, the acid-amide 
heterosynthon and the acid-pyridine heterosynthon.27 
 
 
Figure 1.4 Examples of synthons. I. Amide-amide homosynthon, II. Acid-amide heterosynthon, III. Acid-
pyridine heterosynthon. 
 
This approach however doesn’t take into consideration all of the weaker interactions that may 
be present between the two components of a co-crystal and thus a co-crystal designed in this 
way may not always be able to be produced experimentally. 
The Cambridge Structural Database (CSD) is a repository for small-molecule organic and metal-
organic crystal structures, currently containing over 875,000 structures. Statistical analysis of 
the large amount of data in the CSD can be carried out and analysis of data relating to co-crystal 
specific subset of the CSD has been reported.28 The aim was to identify factors beyond synthon 
matching that would be indicative of the ability to form a co-crystal. The strongest correlations 
found related to the polarity and the shape of the co-crystal components, whereas number of 
hydrogen bond donors and acceptors showed no obvious statistical relationship.28 This kind of 
statistical analysis can be used as a predictor for components likely to form co-crystals and could 
be used as an initial step in reducing the number of co-formers for physical screening. 
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1.5 Production of co-crystals 
In terms of high-throughput screening both reaction crystallisation and sonic methods have been 
employed.29,30 Many other methods of co-crystal production are possible, not all  amenable to high-
throughput work, the sections 1.51-1.5.5 below describe many of which that have been reported 
in the literature. 
1.5.1 Evaporative and reaction crystallisation 
Solution crystallisation methods can be used to produce co-crystals by, for example, evaporation of 
an undersaturated solution to form a supersaturated solution and induce crystallisation of the co-
crystal.  Ternary phase diagrams can be made use of in this method, for example to determine the 
region in the phase diagram in which the co-crystal is most likely to be stable in the solid phase and 
perform the necessary actions to reach this environment, as alluded to above.22 Reaction 
crystallisation involves the intentional addition of an excess of either of the co-crystal components 
to a solution which is undersaturated with respect to the co-crystal. This addition of excess 
component reduces the solubility of, and causes supersaturation with respect to, the co-crystal, 
leading to nucleation and co-crystallisation. 31,32,33 
1.5.2 Sonication 
The use of sonochemical techniques to produce co-crystals was introduced with the SonicSlurry 
method in which an ultrasonic probe is used to subject a slurry of the reactants and solvent to pulses 
of ultrasound.34 An alternative method for the successful production of co-crystals using sonication 
employed an ultrasonicator water bath rather than probe and was implemented as a high-
throughput screening technique using the 96-well plate format.30 
1.5.3 Grinding and liquid-assisted grinding 
Another method of screening for co-crystals is by grinding. This can be solid-state (‘dry’ or ‘neat’) 
grinding, devoid of solvent use, or can use a small amount of solvent, a technique which is known 
as solvent-drop grinding or liquid-assisted grinding (LAG). Grinding can be carried out by hand, using 
a pestle and mortar, or mechanically, employing a ball or vibratory mill.35 This process can be time 
consuming and hence limits the speed at which screening can occur, however the use of this 
mechanochemical process has led to the obtaining of certain structures or stoichiometries of co-
crystals which are unobtainable by other routes.36 The addition of a small amount of solvent in LAG, 
typically only a few microlitres, can provide further benefits, such as improved yield and a larger 
scope of reactants and products, compared to neat grinding.35 It can also act in a catalytic role, 
reducing the time taken for co-crystals to form versus solid-state grinding and in addition may 
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enable selective polymorphic and stoichiometric co-crystal synthesis.37 Although the mechanism is 
not fully understood, it has been suggested that the addition of the solvent improves effiency either 
by facilitating molecular diffusion or effecting the course of mechanochemical co-crystallisation.35 
The fact that solid-state grinding is a solvent-free process and only a very limited amount of solvent 
is used in LAG, means both of these processes are favourable from an environmental perspective 
due to the reduction or eradication of solvent waste. An additional benefit to the solvent-free 
nature of dry grinding is that the solubility of starting materials is no longer an issue and the problem 
of unexpected solvate formation is removed.36 It is also possible to use co-crystals obtained from 
these methods as seeds to induce crystallisation from solution.27 
1.5.4 Crystallisation from the melt 
Thermal methods such as hot-stage microscopy employing the Kofler technique have been used to 
determine the binary phase behaviour of co-crystal systems. This involves one component being 
melted, then re-crystallised, before the molten second component is brought into contact with the 
first. This causes solubilisation of a portion of the first component and a zone of mixing is created 
which is comparable to the composition of the binary phase diagram; one side representing 100% 
of one component and the other side representing 100% of the other component, with a 
concentration gradient across the zone. Once it has been determined from the melt that a co-crystal 
exists, production can be eased by seeding from melt material.38 
1.5.5 Others 
Freeze-drying has been demonstrated as an alternative technique for co-crystallisation and it has 
been suggested that it may be more suitable for large scale manufacture of co-crystals than other 
methods as the process is already used on an industrial scale.39 Formation of co-crystals by spray 
drying, a process which is in use in the pharmaceutical industry to produce amorphous material, 
has been reported.40 The large scale production of co-crystals by this method could be particularly 
useful due to its speed and the fact that it is a continuous, one-step process. Supercritical fluid 
technology, which again already has industrial use, has been shown to have feasible application to 
co-crystal screening methods and potential particle engeneering.41  Another method of co-crystal 
production which has been proposed as suitable for large scale manufacture is an extrusion based 
co-crystallisation process which is both solvent free and continuous. These attributes, along with 
process analytical technology (PAT), which has been demonstrated can be applied to this process, 
make it particularly relevant to industrial manufacture.42 Microwave synthesis has been 
attempted, both solvent-free without success, and with the addition of small amounts of solvent 
leading to the successful production of a number of co-crystals.43 In the attempted solvent-free 
9 
 
synthesis the molecular mobility of the reactants, compared to that in the presence of solvent, 
is likely to have been restricted to the extent that co-crystallisation could not occur. The addition 
of solvent therefore facilitating the interaction of the reacting components. 
 
1.6 Property modification by co-crystallisation 
Crystal structure can have a great influence on the physical properties of a material. This is seen 
in polymorphism, which is where molecules of a particular compound, that are identical in the 
liquid and vapour states, can form solid crystalline phases in at least two different arrangements. 
Polymorphs contain exactly the same molecules with the only difference between two 
polymorphic forms being the crystal structure, yet significant differences in physical properties 
can be displayed.44 Ibuprofen is an example of a compound which can exist in more than one 
crystal structure with molecules in the same conformation, this is known as packing 
polymorphism and is shown in Figure 1.5 below.  
 
 
Figure 1.5 Polymorphic form I and II of ibuprofen. 
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Figure 1.6, below, shows the categories by which materials in the solid form can be defined. It is 
worth noting that multicomponent crystals including co-crystals can also be polymorphic in 
nature, and as such the categories listed in Figure 1.6 are not necessarily exclusive. Examples of 
polymorphism in co-crystals include the phenazine:mesaconic acid system in which three 
polymorphic forms have been discovered,45 and the 3-hydroxybenzoic acid:acridine system 
which was found to be dimorphic. The second of these examples was found in a study looking 
at polymorphism in co-crystals formed from polymorphic co-formers, and in the limited number 
of systems under investigation it was found that the co-crystals produced were not inherently 
less prone to polymorphism than the individual components.46 
 
Figure 1.6 A chart showing the categories of forms in which materials can exist in the solid form. 
Adapted from reference.7 
 
Figure 1.7 below gives a structural representation of some of the solid forms described in Figure 
1.6 and introduces ionic co-crystals and solid solutions as potential forms in which materials may 
exist in the solid form. Hydrogen bond donor and acceptor regions are indicated by the blue and 
red colouration.  It is worth noting that although the inclusion compound shown (Figure 1.7, H) 
is stoichiometric, there is the potential for non-stoichiometric inclusion compounds to form, for 
example a channel hydrate; and that more complex multicomponent crystalline forms are 
possible such as ionic co-crystal hydrates or solvates, and polymorphs thereof.21,47 
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Figure 1.7 Structural representation of forms in which materials can exist in the solid form: A. polymorph 
A of API, B. polymorph B of API, C. stoichiometric solvate or hydrate, D. salt, E. molecular co-crystal, F. ionic 
co-crystal, G. solid solution, H. inclusion compound (stoichiometric), I. amorphous API. Adapted from 
reference.21 
 
Co-crystals, by virtue of modifying the crystal structure, are also able to improve the properties 
of an API without altering its molecular structure, or necessarily reducing its physical or chemical 
stability. A large proportion of research into the improvements in properties that co-crystals can 
attain has been focused on solubility and dissolution rate, leading to many examples of co-
crystals achieving improvements in these areas.27,48 It has been noted however that 
improvements in measured solubility in co-crystals should be treated with caution as they can 
transform via recrystallisation to the most stable form when brought into contact with a 
solvent.7,49 In terms of administering a pharmaceutical product, this could include the dissolution 
of the drug in the stomach and if the stable form of the drug was to be formed the improvement 
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in solubility the co-crystal achieved would be affected. The advantage in solubility offered by the 
co-crystal may not be entirely lost in this case though, as the route to the stable form of the drug 
may extend over a period of time of increased apparent solubility, sufficient for the required 
absorption for therapeutic effect. This has been explained by Babu and Nangia by the adaptation 
of the ‘spring and parachute’ concept for amorphous drug dissolution and its application to co-
crystals.48 Indeed accounts of co-crystals improving the bioavailability of the drug by as much as 
three fold have been published.50 The modification of solubility by a co-crystal does not 
necessarily have to be an increase in order for it to be of benefit from a formulation perspective. 
Reducing the solubility could prove useful in the formulation of a slow release dosage form and 
a lower solubility could be of benefit when needing to mask the taste of a drug product, as long 
as the necessary balance between this and bioavailability is achieved. 
In addition to improving solubility and dissolution rate, there are several other benefits that can 
be realised by utilising co-crystallisation, such as improved hygroscopicity, and physicochemical 
and photo-stability compared to the parent API.51,52 Hygroscopicity can be of particular 
importance in substances liable to hydrate at certain levels of humidity due to its implications 
for formulation, processing and storage.53 It is easy to overlook the fact that if the new ‘wonder-
drug’, that has been formulated to improve its solubility to allow for a satisfactory bioavailability 
via the oral route, has a hygroscopicity which would prevent effective processing to the extent 
that tablet production was unfeasible, then the drug might never reach the market, The reason 
being that it may not be economically viable to formulate the drug in any other manner for oral 
delivery and reduction in patient acceptance could negate the production of any other dosage 
form. The capacity for co-crystallisation to reduce hygroscopicity and thus improve stability to 
humidity has been demonstrated with co-crystals of caffeine and a number of co-formers.51 
Enhancement of stability in terms of photodegradation has also been displayed in co-crystal of 
nitrofurantoin and 4-hydroxybenzoic acid compared to the drug alone, this in addition to its 
increased stability to varying humidity and temperatures.52 
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1.7 Amorphous solids 
 
Figure 1.8 Diagrammatic representation of crystalline polymorphs and the amorphous phase of the same 
API. 
Solubility advantage can be conferred by the amorphous form of a given compound. Given the 
possibility for improvement in apparent solubility, the amorphous form is considered of great 
interest in the pharmaceutical industry when developing formulations of poorly soluble 
drugs.54,55,56 These phases however also have the potential to convert to a thermodynamically 
more stable crystalline form; the timescale of this conversion dictates the degree of opportunity 
or risk associated with the phase.57 Stabilisation techniques such as formulating the product with 
the addition of a polymer have been widely studied58,59,60 and can yield suitable stability at a cost 
– financial in terms of greater development needed for the formulation, additional regulatory 
requirements and issues surrounding drug loading. This refers to the quantity of API that is 
contained within a formulation.61  
1.7.1 Amorphous solid dispersions 
Current marketed products which contain the API in the amorphous form include: Sporanox®, 
Isoptin® SR-E and Gris-PEG®, these all employ polymeric compounds as stabilising agents in the 
formulation.54 Many of the polymers used in stabilising drugs in this way (such as PVP, PVPVA 
and HPMC)54 are hygroscopic62 and can lead to faster re-crystallisation of the drug through 
modification of the glass transition (Tg), removing the solubility benefit. There are also issues 
associated with HPMC which can cause a laxative effect.63 
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Polymer stabilised amorphous formulations may only be able to support a limited quantity of 
API while maintaining stability as increasing the API loading could lead to crystallisation of the 
drug. If the maximum drug loading afforded is poor then larger or multiple tablets/doses will be 
required; drug loading in amorphous-solid-dispersion formulations means that for one part of 
API there needs to be generally somewhere between 2.5 to 9 parts polymer. With drugs where 
a single dose is only a few milligrams or less this is not a problem but if a 100mg dose is needed 
with a 10% drug loading limit then each tablet would need to be a gram in weight and at that 
size the acceptability to the patient may come into question. If the formulation no longer meets 
patient acceptability, the drug product will not be used, no matter how innovative a formulation 
or extensively developed the API. 
1.7.2 Co-amorphous materials 
The deficiencies in polymer stabilised amorphous formulations discussed above have led to an 
expansion in research in co-amorphous materials.64,65 Co-amorphous phases have been the 
subject of significant study since 2009 as they have the potential to solve the problems of drug 
loading and toxicity. The co-amorphous approach has been defined as ‘the combination of two 
or more low molecular weight components that form a homogeneous amorphous single-phase 
system’.66 The stabilising interactions have been seen to occur via a number of mechanisms 
including hydrogen bonding, π- π stacking and salt formation. There are currently no purported 
means of predicting which small molecules will create such interactions and stabilise APIs in the 
desired fashion. This means many thousands of potential molecules could be used as the second 
entity, therefore some mechanism for practical selection would be beneficial. 
 
 
Figure 1.9 Diagrammatic representation of a co-amorphous material consisting of an API and co-former. 
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1.8 Summary 
Research into the ability to predict suitable co-formers and the prediction of property 
modification is taking place in the academic community. Aakeröy et al. have investigated the 
ability to predict the changes in certain properties including the melting point, which would 
occur in the production of co-crystals using a particular set of co-formers. Their predictions of 
co-crystal properties were based on an observed trend in a small number of co-formers, they 
then produced the co-crystals and measured the actual properties compared to those 
predicted.67 This, although a process involving prediction and physical characterisation, did not 
employ computational prediction and was limited to a small population of co-formers and not a 
large scale screen for an API of interest. 
Research into computational prediction specifically of co-crystals has shown that methods used 
to calculate whether a potential co-crystal is thermodynamically more stable than the crystals 
of its components, can reliably predict whether the co-crystal can form.68,69 These studies were 
focused on the computational methods and  did not feature physical co-crystal production or 
apply the process to a larger screen for a particular API. 
Luu et al. reported a high-throughput co-crystal screen using solvent mediated sonic blending. 
The process involved physical screening followed by analysis of the properties to identify 
improvements in solubility and physical stability. This investigation however did not employ any 
initial co-former prediction prior to the physical screening, instead selecting many of the 
potential co-formers from those previously shown to form co-crystals.30 A situation which is not 
always achievable and may not lead to the determination of the most appropriate co-former.  
A staged approach to screening has been suggested as the most sensible and efficient method 
for discovery of novel co-crystals. An initial stage to select the most promising co-formers for a 
given API would be carried out, either by computational prediction or by utilising informatics 
tools such as the CSD. This would allow for a reduction in the overall cost associated with 
screening, as the physical, resource intensive, screening can be reduced to only those potential 
co-formers which display a high likelihood of successful co-crystal formation, without wasting 
resources on the many materials that are unlikely to do so.37,70 
In this project, a two-step process for co-crystal screening was employed. Computational 
prediction was carried out to determine the most likely co-formers to form co-crystals with a 
number of chosen APIs and a physical screen of this shortlist of co-formers followed, with the 
resultant co-crystals analysed. The project not only aims to develop an optimised, efficient high-
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throughput screening methodology which can be applied to a range of APIs, but also to 
determine structure property relationships between the co-formers and the modified properties 
of the co-crystals compared to the API, by analysis of the co-crystals obtained from applying the 
screen. 
 
1.9 Aims and objectives 
The overall aim of the project is to allow prediction of the most suitable co-former selection for 
a given API, to produce a co-crystal with desired alterations in properties compared to the API 
alone. To achieve this, a robust, reliable screening method must be determined and utilised to 
ensure all reasonably accessible potential co-crystals are found for a given system, to allow a 
robust dataset to be built for subsequent property prediction. Determination of the property 
modification that will occur based upon the structure of the co-former used must then be 
developed. Further aims of the project include the determination of robust formulation 
approaches for co-crystal materials to facilitate their wider use and to predict and control in-
vivo behaviour of co-crystals. 
1.9.1 Aims 
1. Produce co-crystals of model APIs with a range of chemistries representative of 
compounds relevant to the pharmaceutical industry. 
2. Characterise the produced co-crystals, the APIs and the co-formers. 
3. Measure the performance and properties of the co-former and parent compounds. 
4. Determine the predictability of property modifications based on API and co-former 
properties. 
1.9.2 Objectives 
1. In order to efficiently produce co-crystals, necessary for use throughout the project, the 
following set of objectives were devised. 
a.  Optimise a co-crystal screen for the efficient production of co-crystals. To do 
this a number of sub-objectives must be carried out: 
i. Produce a manual co-crystal screening procedure to best mimic the 
high-throughput robotic co-crystal screening process currently being 
implemented in industry. 
ii. Utilise a suitably efficient yet thorough method for optimisation of the 
chosen screening method. 
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iii. Undertake validation testing of the newly optimised screening 
procedure to ensure it achieves the required performance. 
iv. Depending upon adequate access to the robotics platform, transfer the 
optimised parameters from the manual co-crystal screen to the 
automated process and carry out a further optimisation. 
b. Implement the optimised and validated co-crystal screening process to multiple 
APIs which represent a range of chemistries. More thoroughly this will require: 
i. Choosing and sourcing relevant model APIs for co-crystal screening 
based on their structure and properties. 
ii. Performing a computational pre-screen to determine a shortlist of 
potential co-formers, calculated to be most likely to co-crystallise with 
the API, for physical co-crystal screening. 
iii. Performing the physical co-crystal screen for each API against the 
shortlisted co-formers, using the optimised parameters. 
c. Perform efficient analysis of the co-crystal screens in order to detect ‘hits’ (any 
product of the screen which could potentially be a co-crystal). Steps necessary 
to accomplish this are: 
i. Utilise an available analytical technique which allows relatively rapid 
analysis of material produced from the physical co-crystal screen and 
that is capable of detecting solid state form change between samples. 
ii. If necessary, perform further analysis of the material to confirm its 
status as a ‘hit’, to prevent inefficiencies in the screening process 
developing by unnecessary characterisation of material. 
2. Characterisation of the parent components (API and co-former) and co-crystal is 
necessary to understand the nature of the binary system. For the purposes of identifying 
the make-up of said system the following objectives are set. 
a. Measure characteristic properties e.g. melting point and thermal behaviour of 
the materials. 
b. Determine from these results and any necessary characterisation, for example 
single crystal X-ray diffraction, the form of the material, i.e. co-crystal or 
otherwise. 
3. Measuring the properties of both the co-crystal and the parent materials is useful for 
determining the improvements or modifications available by co-crystallisation 
compared to those inherent to the pure API. Specifically looking at those relevant to 
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pharmaceuticals affords the following objectives: 
a. Investigate properties such as solubility and dissolution to determine the 
potential improvements relating to bioavailability of the co-crystal compared to 
the API. 
b. Investigate properties related to processing of material to determine the 
potential improvements of the co-crystal in this regard. For example, 
measuring: 
i. Moisture sorption to aid in informing of potential improvements in 
powder handling, stability and tableting. 
ii. Physical stability to investigate potential enhancement of shelf life 
and/or storage requirements. 
iii. Outcomes of alternative methods of manufacture to guide potential 
scale-up of co-crystal production. 
4. Using the results from the measurements of co-crystal and parent material properties, 
correlations between the properties and/or structure of the APIs and co-formers and 
the effect of these on the properties and performance of the co-crystals, should be 
sought. This could lead to the resolution of the final objectives: 
a. Determine structure-property relationships between the APIs, co-formers and 
co-crystal to allow prediction of property modification between the API and co-
crystal based on the structure or properties of the chosen co-former. 
b. Relate these such findings to those already present in the literature. 
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Chapter 2 – Materials and methods 
 
2.1 Materials 
2.1.1 Solids 
Most of the materials used as part of the work presented in this thesis were the co-formers for 
the co-crystal screens. Two full co-crystal screens are documented, each of which required 48 
co-formers that were selected from a computational pre-screen as detailed both later in this 
chapter and in Chapter 4. Many of the co-formers featured in both co-crystal screens however 
there were over 60 unique compounds used as co-formers for the two co-crystal screens (see 
Table 2.1 (list) and Figure 2.1 (structures)). Sourcing eight of these compounds in their pure 
form, either at all, or in sufficient time, proved unfeasible and they were substituted with 
alternative stock. The eight compounds where this was necessary are highlighted in Table 2.1 
along with the substituents which were either a salt or hydrate form or not enantiomerically 
pure forms of the original chemicals. The structures of the seven compounds used in the place 
of those unavailable are shown in Figure 2.2. Note that DL-isocitric acid trisodium salt hydrate 
was used in place of both isocitric acid and allocitric acid. 
It was chosen to substitute the compounds which were unavailable with similar material 
containing the same chemical either with the addition of a second substance (in the case of salts 
and hydrates) or a stereoisomeric variation, rather than excluding the compounds. The rationale 
for this decision was that individual molecules of the material must become available for the 
formation of a co-crystal, whether by solvation, melting, sublimation or other means, and given 
the inclusion of solvent in the physical screening method employed, molecules of the predicted 
co-formers would be present for co-crystallisation to occur. In the case of stereoisomeric 
variation, the different enantiomers often show very little difference, if any, in calculated excess 
enthalpy and as such a substitution would allow for much less variation from predicted co-
former excess enthalpy than excluding the compound and including the compound with the 
incrementally next most calculated excess enthalpy. 
Table 2.2 and Figure 2.4 show the list and structures, respectively, of compounds used in the 
validation testing of the optimised co-crystal screen in Chapter 3 (where not already listed). The 
model APIs used are listed in Table 2.3 and their structures displayed in Figure 2.5. 
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Table 2.1 List of compounds used. (*substituted compounds and their replacements (#65-71)) 
# Compound Alternative name 
1 Acesulfame* - 
2 Aconitic acid 1-Propene-1,2,3-tricarboxylic acid 
3 Allocitric acid* erythro-Isocitric acid 
4 4,4-Bipyridine 4,4′-Bipyridyl 
5 Carnitine* - 
6 Catechol 1,2-Dihydroxybenzene 
7 5-Chlorosalicylic acid 5-Chloro-2-hydroxybenzoic acid 
8 Citric acid - 
9 2,4-Dihydroxybenzoic acid - 
10 2,5-Dihydroxybenzoic acid Gentisic acid 
11 3,4-Dihydroxybenzoic acid Protocatechuic acid 
12 3,5-Dihydroxybenzoic acid 3,5-Dihydroxybenzoic acid 
13 2,6-Dimethylpyrazine - 
14 3,5-Dinitrobenzoic acid - 
15 DL-Valine* - 
16 Ethanesulfonic acid - 
17 Etidronic acid* - 
18 Fumaric acid 2-Butenedioic acid 
19 Gallic acid 3,4,5-Trihydroxybenzoic acid 
20 4-Hexylresorcinol 4-Hexylbenzene-1,3-diol 
21 Hydroquinone 1,4-Dihydroxybenzene 
22 1-Hydroxy-2-naphthoic acid - 
23 3-Hydroxy-2-naphthoic acid - 
24 6-Hydroxy-2-naphthoic acid - 
25 3-Hydroxybenzoic acid - 
26 4-Hydroxybenzoic acid p-carboxyphenol 
27 Indole 2,3-Benzopyrrole 
28 Isocitric acid* - 
29 Ketoglutaric acid 2-Oxoglutaric acid 
30 L-Lysine - 
31 Maleic acid 2-Butenedioic acid 
32 Malonic acid 1,3-Propanedioic acid 
33 Methanesulfonic acid - 
34 Methyl gallate Methyl 3,4,5-trihydroxybenzoate 
35 3-Methyl-2-oxobutanoic acid* α-Ketoisovaleric acid 
36 m-Nitrobenzoic acid 3-Nitrobenzoic acid 
37 5-Nitroisophthalic acid - 
38 o-Cresol 2-Methylphenol 
39 Octadecylamine Stearylamine 
40 o-Phenylphenol 2-Phenylphenol 
41 Orcinol 3,5-Dihydroxytoluene 
42 Oxalic acid - 
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# Compound Alternative name 
43 2-Oxo-3-phenylpropionic acid Phenylpyruvic acid 
44 p-tert-butylphenol 4-tert-Butylphenol 
45 p-Cresol 4-Methylphenol 
46 Pentafluorophenol 2,3,4,5,6-Pentafluorophenol 
47 p-Ethylphenol 4-Ethylphenol 
48 Phenol Hydroxybenzene 
49 Piperazine 1,4-Diazacyclohexane 
50 Quercetin 3,3′,4′,5,7-Pentahydroxyflavone 
51 Resorcinol 1,3-Benzenediol 
52 Salicylic acid 2-Hydroxybenzoic acid 
53 Skatole 3-Methylindole 
54 Succinic acid 1,4-Butanedioic acid 
55 Sulfamic acid Amidosulfonic acid 
56 Tartaric acid* 2,3-Dihydroxysuccinic acid 
57 tert-Butylhydroquinone TBHQ 
58 Thymol 2-Isopropyl-5-methylphenol 
59 1,2,3-Trihydroxybenzene Pyrogallol 
60 Trimesic acid 1,3,5-Benzenetricarboxylic acid 
61 2,5-Xylenol 2,5-Dimethylphenol 
62 2,6-Xylenol 2,6-Dimethylphenol 
63 3,4-Xylenol 3,4-Dimethylphenol 
64 4-Aminobenzoic acid PABA 
65 Acesulfame K* Acesulfame potassium 
66 (±)-Carnitine hydrochloride* - 
67 DL-Isocitric acid trisodium salt hydrate* - 
68 Etidronic acid monohydrate* - 
69 L-(+)-Tartaric acid* - 
70 L-Valine* - 
71 3-Methyl-2-oxobutanoic acid sodium salt* - 
 
 
 
 
 
 
 
Table 2.1 (Continued) 
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Table 2.2 List of compounds used for validating co-crystal screen optimisation (excluding those present in 
Table 2.1). 
# Compound Alternative name 
72 Aspirin Acetylsalicylic acid 
73 Benzoic acid - 
74 Caffeine - 
75 Carbamazepine Tegretol 
76 Glutaric acid 1,5-Pentanedioic acid 
77 Ibuprofen - 
78 Nicotinamide Niacinamide 
79 Paracetamol Acetaminophen 
80 Saccharin - 
81 Sulfamethazine Sulfadimidine 
82 Sulfamethoxypyridazine - 
83 Trimethoprim - 
 
 
Table 2.3 List of model APIs used. 
# Compound Alternative name 
84 Ornidazole Xynor 
85 ROY 5-Methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile 
86 Zafirlukast Accolate 
 
All compounds listed in Tables 2.1 to 2.3 were purchased from Sigma-Aldrich and used as 
received, with the exceptions of ROY which was synthesised in-house (see Chapter 4 for details) 
and zafirlukast which was supplied by AstraZeneca.  
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Figure 2.1 Chemical structures of compounds used as co-formers in co-crystal screens. 
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Figure 2.2 Chemical structures of compounds used as co-formers in co-crystal screens. Continued from 
Figure 2.1. 
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Figure 2.3 Chemical structures of compounds substituted for unavailable compounds, for use as co-
formers in co-crystal screens. 
 
 
Figure 2.4 Chemical structures of compounds (not previously listed), which were used for validation 
testing of the optimised co-crystal screening method. 
 
 
Figure 2.5 Model APIs: Ornidazole (left) and ROY (middle), the two APIs used for co-crystal screening, 
and zafirlukast (right). 
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2.1.2 Solvents 
Acetone, acetonitrile, dichloromethane (DCM), ethanol and hexane were used in the co-crystal 
screening procedure. In addition, toluene and tetrahydrofuran (THF) were used in the second 
optimisation experiments (Chapter 3). These were all of at least reagent grade and purchased 
from Sigma-Aldrich. Water was obtained from the on-site Purelab Option-Q purification system, 
and the acetonitrile used for HPLC mobile phase was purchased from Fisher Scientific and was 
of HPLC grade. 
2.2 Methods 
2.2.1 Differential scanning calorimetry 
Differential Scanning Calorimetry (DSC) is a technique used to investigate the thermal behaviour 
of materials. An accurate definition of DSC is given by Höhne et al. as ‘the measurement of the 
change of the difference in the heat flow rate to the sample and to a reference sample while they 
are subjected to a controlled temperature program’.71 The DSC technique is able to measure the 
heat capacity of materials and detect the temperature at which phase transitions occur, as well 
as being able to, with the appropriate method, quantify such phenomena.72,73 The equipment 
used to perform DSC is the differential scanning calorimeter, of which there are two 
fundamental designs: power compensation and heat flux. 
The concept of power compensation DSC is to measure the energy required to keep two sample 
containers (pans) and their contents at the same temperature as each other, as the immediate 
environmental temperature is altered. One of these pans contains the sample material and the 
other, reference pan, is empty. In heat flux DSC, the sample and reference pans are heated in 
the same furnace and the signal measured is derived from the difference in temperature of the 
sample and reference pans detected by the temperature sensors under each pan. To achieve 
this, the calorimeter consists of four main parts: furnace, sample stages, temperature sensors 
and a controller, a diagrammatic representation of which is shown in Figure 2.6. 
The stage assembly consists of a stage each for the sample and reference pans, attached to 
which are thermocouples to monitor the temperature of each pan. All of this in housed within a 
sealable furnace which is used to vary the temperature external to the pans. The final 
fundamental part is the controller which sets the temperatures and measures the energy use of 
the heating stages and temperatures of the pans.73 Nitrogen can be flowed through the furnace 
to keep the samples under an inert atmosphere in many contemporary DSCs, and amenities 
such as autosamplers are widely available. 
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Figure 2.6 Diagrammatic representation of a heat flux differential scanning calorimeter. 
 
In this thesis, DSC was used for various purposes, the most basic of which was to determine the 
melting point of certain materials for identification. A significant use was to probe crystallisation 
behaviour of many materials investigated which required the use of a ‘heat-cool-heat’ method. 
DSC was also employed as a useful tool for investigating combinations of compounds where 
presence of multiple melting endotherms, or lack thereof, is effective information for 
determination of the binary behaviour of the components.74 
The following sets of parameters were used as the standard ramp and standard heat-cool-heat 
methods respectively for collecting DSC thermograms throughout this thesis unless stated 
otherwise. 
Experimental DSC method 
DSC thermograms were recorded on a TA Q2000 using standard aluminium pans. Standard 
mode was used throughout and a heating rate of 10°C/min up to 300°C was used for the 
standard ramp method. Where heat/cool/heat cycles were used, the initial heating phase was 
at a rate of 10°C/min to a maximum temperature slightly above the melting point of the material 
(from literature if experimental data not available and of the component with the higher melting 
point if a multicomponent system), cooling cycle at 50°C/min to -90°C and the second heating 
cycle at 10°C/min to the maximum temperature described above. 
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2.2.2 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) is another technique used to investigate the thermal 
behaviour of materials. Specifically with TGA, the mass of sample is measured as temperature is 
varied; a definition given by the International Confederation for Thermal Analysis and 
Calorimetry states that TGA ‘is a technique in which the mass change of a substance is measured 
as a function of temperature whilst the substance is subjected to a controlled temperature 
programme’.75 This program is usually in the form of a steadily increasing temperature and a 
detection of a loss of mass, either at a given temperature where desolvation or dehydration 
occurs and at a higher temperature where decomposition may occur.76 
 
 
Figure 2.7 Diagrammatic representation of a thermogravimetric analyser. 
 
The equipment required to perform this technique is called a thermogravimetric analyser, 
shown in diagrammatic for in Figure 2.7, and consists of a microbalance with two sample 
holders, one for a reference pan (not shown in Figure 2.7) and the other for the sample pan. The 
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sample pan is encased in a furnace during the running of an experiment and the temperature 
varied according to the method parameters set. As temperature increases, any solvent present, 
either residual or present in the crystal structure of a solvate for example, will be released and 
a consequent reduction in weight of the sample will be detected. A controller is present to 
monitor and record the temperature and weight and control the furnace temperature.76 
Nitrogen can be flowed through the furnace to keep the samples under an inert atmosphere and 
with some TGA equipment secondary apparatus can be connected to an exhaust port to analyse 
the exhaust gases. As an example, a mass spectrometer could be used to identify the solvent 
which is released from the material during the experiment.77 
The following sets of parameters were used as the standard method for collecting TGA profiles 
throughout this thesis unless stated otherwise. 
Experimental TGA method 
TGA profiles were recorded on a TA Q500 using standard platinum pans. The method used was 
a ramp at a rate of 10°C/min to 300°C maximum. 
2.2.3 Powder X-ray diffractometry 
Powder X-ray diffraction (PXRD) is used mainly for the identification of compounds based on 
their diffraction pattern, which is unique to each crystalline material.78 Measurements are 
undertaken using an X-ray diffractometer in which X-rays are generated, a monochromatic beam 
of which the rotated powdered crystalline sample is exposed to over a range of angles, and the 
intensity of the resulting diffracted X-rays detected. The X-rays are generated in a vacuum tube 
in which a large voltage (around 40kV) is applied, resulting in a beam of electrons from the 
cathode which impinge on an anode, which is in the form of a pure metal plate usually copper 
or molybdenum.79 This causes X-rays to be generated in the surface layers of the anode, both by 
deceleration of the impinging high-energy electrons by the atomic electrons of the target metal 
ions, resulting in continuous radiation; and by the production of fluorescent X-ray photons by 
the transfer of electrons from outer orbitals to fill vacancies produced by the ejection of 
electrons by incident particles with greater energy than that binding the ejected electrons to the 
nucleus – characteristic radiation.78,79 
Characteristic radiation, so called as it is of a defined wavelength related to the energy difference 
between the shells from which an electron falls from and to when filling a vacancy, as described 
above, is of higher intensity than continuous radiation. For a copper anode, the wavelengths of 
this characteristic radiation are Kα1 1.5406Å, Kα2 1.5444Å and Kβ1 1.3922Å.78 
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When X-rays interacts with matter, such as sample material in a diffractometer, photons of the 
incident beam are either scattered (either coherently where no energy is absorbed (Thomson 
scattering) or incoherently where some of the energy of the photon is absorbed and the rest 
reemitted as an X-ray photon of lower energy (Compton scattering)) or absorbed by the atoms 
of the target, increasing its temperature.80  Each scattering point can be thought of as a source 
of reemitted spherical waves, expanding outwards with the consequence of interference 
between waves. This may be constructive or destructive interference and in crystalline material 
where scattering atoms are arranged in a periodic manner and given that the wavelength of the 
X-rays are on the order of the interplanar distance between these, diffraction will occur at 
specific angles.78 
 
Figure 2.8 An optical analogy to crystallographic planes reflecting X-rays, representing the geometry for 
interference of a wave scattered from two planes separated by the spacing given by d. Adapted from 
reference.81 
 
W. L. Bragg reported in 1912 an equation for calculating the angle at which the reflection 
conditions for diffraction are satisfied;82 it has come to be known as Bragg’s Law and is given 
below. 
𝑛𝜆 = 2𝑑 sin 𝜃 
Where n is an integer representing number of planes, λ is the wavelength of the X-rays, d is the 
distance between lattice planes and θ the angle of incidence of the X-ray beam, which is equal 
to the scattering angle. In Figure 2.8 the two horizontal parallel lines represent lattice planes in 
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a crystal and X-ray beams are shown by the two parallel lines coming from the left and reflecting 
from each of the two lattice planes. The angle of incidence of the two parallel X-rays is θ and the 
difference in path length between the top and bottom X-rays is 2d sinθ, shown by the thicker 
line highlighted in the figure. Due to the additional path length, waves that reflect from lower 
planes will be phase retarded with respect to the first wave resulting in interference. When the 
difference in path length between the two X-rays in Figure 2.8 is equal to one wavelength, and 
multiples of this for further planes, the wave interference is maximally constructive and this is 
diffraction.78,80,81 Although the Bragg equation was developed from an analogy, it was later 
proven correct using the concept of reciprocal space as introduced by P. P. Ewald.83 
 
 
Figure 2.9 Diagram showing diffraction from: a single crystal (A), four single crystals of different 
orientations (B), a polycrystalline material with multiple orientations (C) and a diffraction pattern (D), 
produced from the extracted intensities from (C) plotted against the 2θ angle. Adapted from 
reference.84,85 
 
The intensity of the diffraction from a material is determined by a number of factors, and in the 
case of single crystal X-ray diffraction, when diffracted X-rays are recorded on photographic film 
(an outdated technique, now replaced by electronic detectors), the result is spots of differing 
brightness being observed, when the position of the crystal allows for the diffraction conditions 
of the Bragg equation to be satisfied. As these conditions are limited, a fixed single crystal 
produces few reflections and must be rotated to generate a complete diffraction pattern.86 With 
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PXRD, there are many crystals in different orientations, all exposed to the radiation at the same 
time, each which diffract, given the correct geometry, and the diffraction patterns are 
superimposed producing a complete circle (Debye ring) for each reflection.78,86 
Figure 2.9 shows the relationship between increasing number of crystals or crystallites and the 
resulting diffraction patterns. The rings are converted into an intensity and plotted against the 
2θ angle to produce the unique powder pattern for the material being analysed. 
In this work PXRD was used for the analysis of samples from co-crystal screening and its 
optimisation, in Chapters 6 and 3 respectively; the detection of crystallisation from amorphous 
material in Chapters 4 and 5 and for material identification throughout, with the following 
parameters used as the standard method for collecting powder patterns unless stated 
otherwise. 
Experimental PXRD method 
Powder diffraction patterns were recorded on a PANalytical Empyrean diffractometer using Cu 
Kα radiation (λ = 1.54Å), tube voltage of 40kV and 40mA current. Intensities were measured 
from 2° to 40° 2θ with 0.04 rad. Soller silts and an incident beam divergent slit of 1/8°, anti-
scatter slit of 1/4° and diffracted beam anti-scatter slit of 7.5mm (PIXcel). 
2.2.4 Infrared spectroscopy 
The basis of infrared (IR) spectroscopy is the measurement of the absorption of infrared 
radiation, that which falls within the region of the electromagnetic spectrum having 
wavelengths of between 0.8 and 1000µm, at specific wavelengths due to vibrational transitions 
in molecules.87 The frequency at which absorption occurs is dependent upon vibrational modes 
present in the molecule and give rise to peaks in the spectrum which are characteristic of many 
specific functional groups. The environment of the analyte molecule may influence the IR 
absorption, for example molecular interactions such as hydrogen bonding may cause alterations 
in vibration and thus the frequency at which absorption occurs.88 A complex absorption 
spectrum is produced due to the multiplicity of simultaneously occurring vibrations which is 
uniquely characteristic of the overall configuration of the molecule.89 As such the IR spectrum 
can be thought of as a fingerprint, making it useful for the identification of substances,90 or 
changes therein, which is pertinent to its use in this work for the analysis of co-crystal screening.  
The following parameters were used as the standard method for collecting spectra throughout 
this thesis unless stated otherwise. 
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Experimental FTIR method 
FTIR spectra of solid phases were collected on either an Agilent Cary 630 FTIR spectrometer with 
diamond attenuated total reflectance (ATR) crystal accessory and 128 scans for each sample 
were collected at a resolution of 2 cm-1 over a wavenumber region of 4000-650 cm-1; or a 
PerkinElmer Spectrum Two FTIR spectrometer with diamond universal ATR accessory and 4 
scans for each sample were collected at a resolution of 2 cm-1 over a wavenumber region of 
4000-600 cm-1. 
 
2.2.5 Dynamic vapour sorption 
Dynamic vapour sorption (DVS) is a gravimetric technique which measures moisture sorption 
behaviour of materials over a range of solvent vapour concentrations. Although the sorption of 
other solvents may be investigated, water is the most commonly used solvent, applicable 
especially in the pharmaceutical field as atmospheric water vapour may be influential in the 
physical and chemical stability of drugs and dosage forms and thus study of material behaviour 
in relation to relative humidity (RH) is particularly useful.  
The apparatus used for DVS is somewhat like that of a thermogravimetric analyser (see Section 
2.2.2) but which measures sample mass change over a range of relative humidities at a constant 
temperature. To achieve this a sample and reference pan, attached to a microbalance, are held 
in two separate chambers which are kept at the same RH as each other. The RH is changed in a 
stepwise manner according to the programmed method and held at each RH until the mass of 
the sample equilibrates to within a defined ranged. The difference in weight between the sample 
and reference pans can be attributed to the uptake or release of water by the sample. Water 
uptake can either be by adsorption onto the surface of the material, or by absorption, into the 
bulk material if amorphous or by hydrate formation if crystalline.91  
The measurement of moisture sorption and hydration behaviour of materials was the main use 
of DVS in this work, however it is also a sensitive technique for the detection of small quantities 
of amorphous content in otherwise crystalline samples,92 as seen with some samples in Chapter 
7.  The following parameters were used as the standard method for DVS analysis throughout 
this thesis unless stated otherwise. 
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Experimental DVS method 
DVS was undertaken using a Surface Measurement Systems (London UK) DVS-1 with a 10% RH 
step between humidity values with equilibrium achieved at 0.1% weight change before moving 
to the next step. Methods were started at the humidity of the room at ambient (to the nearest 
10% RH, measured by a Rotronic A/H hygrometer) with subsequent increase to 90% RH before 
cycling to 0% RH, to 90% RH, to 0% RH. Sample weights of between 5-20mg were used for all 
samples. 
2.2.6 Chromatography 
2.2.6.1 General 
Chromatography encompasses a number of techniques which separate individual components 
from a mixture based on the rates in which they move through a medium. Chromatographic 
techniques can be gas or liquid based and the two types used in this thesis, both forms of liquid 
chromatography, are thin layer and high-performance liquid chromatography. 
2.2.6.2 Thin layer chromatography 
Thin layer chromatography (TLC) involves using a plate coated with a thin layer of stationary 
phase; commonly, and used in this work, a sheet of aluminium coated in silica. The procedure 
to separate components begins by adding an amount of mobile phase to the development tank 
sufficient to give an approximately 5mm depth of liquid. The range of solvents available to use 
as the mobile phase for TLC is extensive and combinations of solvents are often used to vary 
polarity and eluting power.87 Small amounts of other components can be added to alter the 
solubility of acidic or basic solutes, for example the mobile phase used in this work was 
DCM:ethanol:ammonia in the ratio 200:8:1. 
After allowing the atmosphere in the tank to become saturated with the solvent vapour, the 
plate is spotted with the liquid samples to be analysed along with any necessary standards and 
placed in the tank. As the mobile phase is drawn through the thin layer of stationary phase by 
capillary action, the sample components are separated by their adsorption affinity to the 
stationary phase, and are observed as spots at varying distances along the plate. The plate may 
require viewing under a UV lamp, or the use of a locating agent which reacts chemically with the 
solute resulting in coloured spots, for visible observation. The distance these spots have 
migrated in relation to the solvent front can then be measured to characterise the solute.87 TLC 
was used to monitor the course of reactions during the synthesis of ROY in Chapter 4. 
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2.2.6.3 High performance liquid chromatography 
High performance liquid chromatography (HPLC) is a more advanced form of chromatography 
in which a mechanical pump is used to pass mobile phase, at a constant flow rate, through a 
column which is packed with a microparticulate stationary phase. Similarly, to TLC, a wide range 
of solvents and mixtures thereof can be used for the mobile phase. The stationary phase used 
for HPLC and found within the column is predominantly a chemically modified silica, although 
unmodified silica and polymeric resins or gels can also be used.87 
To conduct HPLC, a constant pressure flow of mobile phase is achieved before injection of the 
sample for analysis. The sample is injected, via a valve from the sample loop, into the mobile 
phase stream resulting in no significant interruption to the flow. The sample, now within the 
flowing mobile phase, is passed through the column. The differential in affinity of the solute for 
the mobile and stationary phases determines the retention time in the column for the 
components of the sample.  Each species from the sample will elute from the column and be 
presented to the detector after differing periods of time since injection. Numerous types of 
detector can be used with HPLC including: mass spectrometers, fluorometric, electrochemical 
and UV-vis spectrophotometers, with the latter the most widely used.87,89 In this work, a UV-vis 
spectrophotometer was used as a detector, in which, similar to the other detector types, an 
electrical signal is generated, amplified and processed by a computer to produce a 
chromatogram of solute concentration over time. 
 
2.2.7 Intrinsic dissolution 
Intrinsic dissolution rate (IDR) is the rate of mass transfer per area of dissolving surface and is a 
useful parameter to measure which is independent of many of the factors that affect the 
standard the dissolution rate. For example, the effect of varying exposed surface area, 
unavoidable due to disintegration in traditional dosages forms,93 can be nullified when 
measuring the IDR. If sink conditions are assumed, the IDR is therefore directly proportional to 
the solubility of the drug in the dissolution media.94 IDR is commonly determined using the 
rotating disk method, whereby the compound to be assessed is compressed into a non-
disintegrating disc which is placed into the dissolution medium with only one face exposed. The 
disc is then rotated at a fixed speed and samples from the dissolution medium are taken at 
specific time points, filtered and analysed, usually by UV spectrometry, to monitor release of the 
compound, with IDR being obtained by the amount of substance dissolved per unit surface area 
and time.95 
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The Sirius surface dissolution imager (SDI) is a piece of apparatus used for IDR determination 
which differs from the rotating disc method. It is a flow through cell approach that maintains 
sink conditions and exposed sample surface area using a laminar flow cell, with concentration 
detected by a UV sensor array. Figure 2.10 shows a false colour image as an example output 
from an IDR experiment. The red arrow indicates the direction of flow of the dissolution medium 
and the green arrow the position of the sample in the cell. The UV senor array allows 
visualisation of the increased downstream concentration of the sample compound, which is 
interpreted by the software to allow calculation of the IDR. 
  
 
Figure 2.10 False colour image from an IDR experiment, annotated to show media flow and sample 
position. 
 
Intrinsic dissolution testing was employed for the determination of IDR of ornidazole, 5-
nitroisophthalic acid and the 1:1 co-crystal of these compounds in Chapter 6, and using a 
modified method to compare the intrinsic dissolution profiles of co-crystals of zafirlukast and 
the parent API in Chapter 7. Details of the experimental parameters for the intrinsic dissolution 
testing performed are given in the appropriate sections of the relevant chapters. 
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2.2.8 Computational methods 
2.2.8.1 COSMOtherm 
COSMOtherm is a computer program designed for predictive property calculation of liquids and 
is based on the COSMO-RS theory of interacting molecular surface charges.96,97 The Conductor-
like Screening Model (COSMO) is the quantum chemical basis of COSMO-RS and is an efficient 
form of quantum mechanical dielectric continuum solvation methods.98 In COSMO calculations, 
a virtual conductor environment is used to calculate solute molecules in which a polarisation 
charge density (σ) is induced on the molecular surface, where there is an interface with the 
conductor. The molecule is converged into a state in which it is energetically optimal in terms of 
electron density within the conductor. From this a σ-profile is produced by converting the 
polarisation charge density, which is related to molecular surface polarity, into a distribution-
function. Hydrogen bonding interactions are identified based on the polarisation charges of the 
interacting surfaces where hydrogen bond donor and acceptor atoms are located, with less 
specific van der Waals interactions being accounted for in a more approximate manner. The 
time-consuming quantum chemical calculations to produce the σ-profile only need to be 
performed once per molecule as the σ-profiles are stored for future use.99,100 
Computational co-crystal screening in COSMOtherm is achieved by calculating the excess 
enthalpy (Hex) of an API (A) and co-former (B) pair, which is obtained by mixing the two 
components from a virtually subcooled liquid to yield the subcooled co-crystal (AmBn). The mole 
fractions are accounted for by xm=m/(m+n) and xn=n/(m+n) and the Hex calculated by the 
following equation. 
𝐻𝑒𝑥 =  𝐻𝐴𝐵 − 𝑥𝑚𝐻𝑝𝑢𝑟𝑒,𝐴 − 𝑥𝑛𝐻𝑝𝑢𝑟𝑒,𝐵 
Where HAB and Hpure represent the molar enthalpies in the pure reference state and in the m:n 
molar mixture. The Hex of the API and co-former pairs, relative to the pure components, 
represents the predicted propensity for co-crystallisation and can then be ranked to find the 
most highly predicted API-co-former pairs. This method neglects the long-range interactions in 
the crystals and there are a number of known limitations and approximations inherent to the 
method,100 which could lead to artefacts in the calculated API:co-former enthalpies resulting in 
higher or lower ranking for certain co-formers than may be achieved with more complex 
methods. However, the approximations and method employed by COSMOtherm has been 
shown to give accurate and efficient results on a set of potential co-crystal formers.101  
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Figure 2.11 Charge surface for a molecule of ROY where blue indicates positive and red negative. 
 
A similar approach to computational co-crystal screening was reported by Musumeci et al.,102 in 
which sets of potential hydrogen bond donor and acceptor sites were identified on calculated 
gas phase molecular electrostatic potential surfaces to estimate interaction site pairing energies 
in the solid form. An example of a calculated charge surface is shown in Figure 2.11 and the 
method by which the interaction site pairing energies are calculated depicted in Figure 2.12. 
 
 
Figure 2.12 Diagram depicting the method by which the interaction site pairing energies are calculated 
in the computational co-crystal screening method used by Musumeci et al.,102 showing interactions 
between hydrogen bond donors (α) and acceptors (β) in the API (blue) and co-former (red) molecules. 
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The co-crystal prediction method is based on the concept that the best hydrogen bond donor 
(α1) and best acceptor (β1) will form the strongest hydrogen bond, followed by the next best of 
each donor (α2) and acceptor (β2), until all of the interaction sites are satisfied. At this point a 
set of hydrogen bond interaction sites αi (hydrogen bond donor parameters) and βj (hydrogen 
bond acceptor parameters) are defined and the total interaction site pairing energy of the solid 
is estimated as the sum over all contacts given by the equation in Figure 2.12. The difference in 
this total interaction site pairing energy between the API and co-former pair and the two pure 
components, which is based on the formation of the most favourable intermolecular 
interactions, provides a measure of the probability of co-crystallisation occurring.102 This method 
of computational co-crystal screening has also proved largely successful.103,104  
The computational co-crystal screening undertaken in this work (the computational pre-screen 
for the co-crystal screening of ROY (Chapter 4) and ornidazole (Chapter 6)), used COSMOtherm 
software (F. Eckert and A. Klamt, COSMOtherm, Version C3.0, Release 16.01; COSMO logic 
GmbH & Co. KG, Leverkusen, Germany, 2015) and screen specific details are given in the 
respective chapters. 
 
2.2.8.2 Design of experiments 
Design of experiments (DOE) is a statistical based method for developing a set of experiments 
to more efficiently perform an investigation as compared to standard experimental undertaking. 
The concept of DOE was first introduced by Fisher in 1935,105 and the field has since developed, 
more recently making use of the advances in computer technology leading to software 
applications allowing for rapid construction and evaluation of designs and improved features 
such as complex plots for visualisation of experimental models.106 DOE is often used for 
optimisation and improving efficiency of processes and has been demonstrated in many 
disciplines such as biofuel production,107 process engineering108 and pharmaceuticals.109  
Factorial designs are the basis for all classical designs used in optimisation, screening and 
robustness testing, and are used in this work. Factorial designs involve the varying of variables 
(factors) simultaneously between separate experiments which allows for the investigation of 
interaction effects between factors, which cannot be achieved by a series of ‘one-at-a-time’ 
experiments. Each factor, for example temperature or pressure, can be varied between different 
settings (levels) which must be defined in the experimental design. Factorial designs can either 
be full factorial, in which observations are made for every level of each setting, or fractional 
factorial, in which a reduced set of observations is made.110 
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For a process with many factors, each with multiple levels, a full factorial design can require an 
extremely large number of observations, i.e. experiments repeated with varying levels of the 
variables. To reduce the resource burden the number of levels for each factor can be reduced 
to a high and low level, with a centre level or midpoint. This is called a two-level full factorial 
design and an example of an experimental plan for a process with two factors is shown in Table 
2.4. The other option is to use a fractional factorial design in which all possible combinations of 
levels for factor are not observed but which can still feasibly result in good estimates of main 
effects and interaction effects between factors.110 
Table 2.4 Example of a full factorial experimental design for two variables (factors) at high (+), low (-) 
and midpoint (M) levels. 
Experiment number 
Factor 
Variable A Variable B 
Experiment 1 + + 
Experiment 2 + - 
Experiment 3 - + 
Experiment 4 - - 
Experiment 5 M M 
Experiment 6 M M 
Experiment 7 M M 
 
Factorial designs can be represented geometrically, with an example for the experimental design 
given in Table 2.4 shown in Figure 2.13, where the points at the edges of the rectangle represent 
high and low levels of variable A (x-axis) and variable B (y-axis), and the points in the centre 
relate to the three repeated midpoints. In designs where more factors are involved the number 
of dimensions of the geometric representation increases, such that a design with three variables 
would result in a three-dimensional cube and so on.111 
 
Figure 2.13 Geometric representation of a two-level full factorial design with two variables and a 
midpoint with two replicates (three total). 
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After a design is defined, it is carried out experimentally and the responses, also previously 
defined, are measured and recorded. Regression analysis, of which numerous variations are 
available depending upon the design, is undertaken computationally and the data fit to a model. 
Assuming a good statistical fit of the model, the effect of alterations to variable settings on the 
measured response(s) can be determined and visualised, for example as response surface or 
contour plots,111 an example of which is shown in Figure 2.14. 
 
Figure 2.14 Example of a two-dimensional contour plot showing the response (red = high, blue = low) in 
the plot area with variable A increasing along the x-axis and variable B increasing along the y-axis. The 
highest response is seen at approximately the midpoint for both variables. 
In this work, DOE was utilised in the optimisation of a physical co-crystal screening method 
(Chapter 3), employing Umetrics MODDE (version 10) software for both experimental design 
and analysis. An initial manual screen was first optimised using a fractional factorial design as 
numerous variables were involved and a smaller set of experiments was required to ensure 
practicality of the optimisation. A second stage of optimisation was applied to the automated 
version of the physical screening procedure and a reduced set of variables, which made the use 
of a full factorial design feasible in this instance. 
2.2.9 Summary 
This section has covered most of the methods used within this body of work, especially those 
which feature in multiple chapters. Where methods have been used which deviate from those 
described here, or where they are specific to one particular piece of work and not covered here, 
they are detailed in the appropriate sections.  
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Chapter 3 – Optimisation of physical co-crystal 
screening 
 
3.1 Introduction 
3.1.1 Screening 
There has been much interest in recent times in pharmaceutical co-crystals and their ability to 
modify the physical and chemical properties of a parent drug. There is little surprise considering 
the improvements in many pharmaceutically relevant characteristics that have been reported. 
From orders of magnitude greater solubility and dissolution behaviour,27 to large reductions in 
hygroscopicity and photodegradation.51,52 The ability to obtain these improvements in 
properties without modifying the molecular makeup of the active pharmaceutical ingredient 
(API), and before any further formulation, is another advantage of employing co-crystals in 
development of pharmaceuticals and other solid forms. The downside is that there is no 
guarantee that the formation of a co-crystal will bring about an improvement in a particular 
property of interest, or that there will be any improved characteristic at all. There is also no fool-
proof method of predicting which compounds will form co-crystals, although advancements in 
computational prediction are certainly helping in this respect. These in silico approaches will be 
discussed later within this thesis (Chapter 4). 
Even with perfect prediction an optimised method of physical screening is required to assess the 
ease of production of the co-crystal phase, so a robust physical screening retains an inescapable 
presence within the development process of co-crystals. Therefore, the current best practice for 
developing pharmaceutically relevant co-crystals must encompass a screening process which 
includes many potential co-formers to, hopefully, produce a number of co-crystals.112 Analysis 
of the co-crystals obtained allows the determination of the improvements, or lack thereof, in 
relevant properties, and a decision as to which, if any, co-crystals to take into further 
development. 
Methods of co-crystal screening utilising ultrasonication have been reported which demonstrate 
the feasibility of the technique.30,34 ,113,114 Details of optimisation of this type of screening process 
have not been published and so any method for screening for co-crystals in an efficient manner 
using ultrasonication requires development. A screening process which is not optimised 
increases the likelihood of under detection of drug-co-former pairs which can form co-crystals 
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and as such will lead to a screen which is not effective or fit for purpose. For these reasons, a 
body of work focused on optimisation for a co-crystal screening method has been undertaken. 
3.1.2 Computational pre-screen 
Prior to physical screening for co-crystals, an optional, but advantageous step, is a 
computational pre-screen. This involves the use of computational chemistry to predict drug-co-
former pairs that are likely to form co-crystals.112 Different methods are available including 
comparison of lattice energies calculated using anisotropic intermolecular atom-atom 
potentials,69 to full crystal structure prediction115 and the decision on which is most appropriate 
will be based on the size of the screen and the resources available. The benefit of employing a 
computational pre-screen is that a reduction in the scale of physical screening can be justified 
based on the outcome of the pre-screen. The co-formers predicted most likely to form a co-
crystal with the API being investigated can be prioritised for physical screening and any co-
formers predicted to be unlikely to form co-crystals can be dropped from the physical screen. 
Although current computational methods have been shown to be effective,103,115 the extent to 
which this influences the inclusion of compounds in the physical screen must be considered as 
it is likely that some inconsistencies may occur due to methodological artefacts. These are 
discussed in more depth in Chapter 2. 
3.1.3 Design of experiments 
Throughout this project, the computational pre-screen has been undertake using COSMOtherm, 
a piece of commercial off-the-shelf software, which by its nature is already optimised by its 
designers. The aim for this section of work is to optimise the screening process and as the 
computational pre-screen is ‘taken care of’, the physical section of the screen is the focus. To 
perform the optimisation, the design of experiments approach has been identified as a suitable 
methodology to employ based on its advantages as laid out in Chapter 2. 
3.1.4 Automation 
Automation, for example by the use of robotics, is used extensively in industry to improve the 
efficiency of many processes of which solid form screening is included. Therefore, automation 
should be a primary consideration to improve the practical relevance of any high-throughput 
co-crystal screening optimisation work. The work presented in this chapter is divided into an 
initial or preliminary screen optimisation in which a manual method which aimed to be a close 
representation of an automated process was first carried out. The results from this were then 
used to inform the design of a second optimisation of an actual automated process. Gaining 
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access to the use of an industrial robotics platform was vital for this work to be carried out. 
Several limitations in relation to the customisation of the processes, which were required for 
optimisation testing purposes, presented themselves. However, with state of the art technology 
which is designed to solely run validated screening processes and is currently implemented in 
active projects some limitations are inevitable. The issue that arose and the solutions used to 
overcome them are discussed in a later section of this chapter. 
3.1.5 Physical screening 
Salt and polymorph screening are common practice in the pharmaceutical industry and high-
throughput methods of both have been developed to make extensive investigation feasible.29 
Co-crystal screening is much like salt screening, in that the production of new solid forms 
consisting of an API and second entity is the desired outcome and that similar high-throughput 
screening methods can be employed. However, due to the significantly greater number of 
acceptable co-formers compared to counter-ions, the necessity for a high-throughput process 
is even greater. There are a relatively limited number of well-established pharmaceutically 
acceptable counter ions; those which are safe for human consumption at the required 
dosage.116,117 
As co-crystals rely on weaker intermolecular forces rather than ionic bonding there are more 
potential second entities which can be combined with the API. The constituent molecules are 
not required to be ionisable, but those that are, are not necessarily excluded from a co-crystal 
screen, as such a much wider range of potential co-formers are available than salt counterions. 
Given that all pairs of compounds will display some intermolecular interaction, no matter how 
weak, there is potential for almost all compounds to be co-formers if paired with a suitable API 
to overcome the thermodynamic and kinetic factors prerequisite for a viable crystal structure 
containing the two compounds to form. 
With seemingly endless possible co-formers available, a commonly applied practical solution is 
to screen against one or more lists which are available containing compounds regarded to be 
safe to be used in products for humans. These include the ‘generally recognized as safe’ (GRAS) 
list and the ‘everything added to food in the United States’ (EAFUS) list, both maintained by the 
FDA.118,119 This approach improves the feasibility of co-crystal screening however it limits the 
investigated co-formers to a fraction of the potential candidates as the lists mentioned contain 
only around 4000 compounds combined. A co-former not present in these lists of compounds 
may still be pharmaceutically acceptable and if it forms a co-crystal with desired properties it 
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could prove worthwhile to perform the necessary toxicity studies to gain approval for its use in 
a product.  
Regarding the methodologies for screening for co-crystals, numerous techniques have been 
assessed. These methods include: dry or solid-state grinding,35 solvent-drop or liquid assisted 
grinding (LAG),35,36 microwave,43 hot-stage microscopy,38 hot-melt extrusion (HME)42 and freeze-
drying.39 These techniques are all relatively time consuming or impractical in terms of high-
throughput screening and so for more situations where efficient screening of a large number co-
formers is required, other methods have been considered such as reaction crystallisation and 
sonic methods.29,30 
It is accepted that the method implemented for producing co-crystals can influence the 
formation or lack of formation of certain co-crystals. For example, it has been reported that 
when utilising LAG a particular co-crystal form can be produced, whereas the same reagents 
when processed using solid-state grinding form a different co-crystal,120 or no co-crystal at 
all.121,122 A co-crystal screen incorporating multiple methods for producing co-crystals may be 
argued to be the ideal, however practicality in terms of time and resources is likely to render 
this unfeasible. The use of automation is highly prized in the modern pharmaceutical 
development process.29,123 No literature method presented has yet detailed a means by which 
an optimised screen could be applied to a robotics platform. As such we set out to determine a 
method by which this could be readily and robustly achieved to deliver an efficient physical 
screening process to build into a broader screening paradigm. To achieve this an ultrasonication 
based screening method utilising an ultrasonic probe on a 96-well plate format was chosen due 
to its ability to be easily implemented on a robotics platform allowing automation of the process. 
This approach, by replacing mechanical grinding with sonication and including a small amount 
of solvent during the process, enabled the advantages of solvent drop grinding methods and the 
robotics practicality that was our ambition. The parameters at which features of the screen will 
be carried out are the focus of the optimisation.  
3.2 Initial optimisation 
3.2.1 Methods 
3.2.1.1 General 
For the initial round of optimisation, the caffeine and malonic acid system was selected. It is 
known that a co-crystal can form between these two materials and the optimisation approach 
was based around tuning the parameters of the screening method to lead to the greatest 
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proportion of conversion of these starting materials to the caffeine:malonic acid co-crystal. The 
co-crystal is also known to form spontaneously,33 but it has been shown that the spontaneous 
formation is humidity dependent and that formation of the co-crystal from contact of the two 
starting materials at ambient relative humidity (≤40%) over multiple days is negligible, requiring 
a much higher relative humidity to cause significant conversion.124 This environment was not 
present in the laboratory in which the work was undertaken and as such any co-crystal formation 
seen is due to experimental factors and not spontaneity. 
The caffeine:malonic acid co-crystal has also been reported to form by shaking of the two 
starting components, with the rate that this occurs influenced by particle size.125 Although 
shaking was used to produce the physical mixture of the components for comparative analysis, 
the length of time shaking was used in this work (combined total of 10 minutes at a low shaking 
rate) was much less than the time required for even the smallest particle size (fastest rate) to 
form the co-crystal in the referenced article which was on the order of days. This, again, 
substantiating the lack of influence of spontaneous co-crystal formation on the co-crystalline 
material produced throughout the experimentation presented in this work. Three solvents were 
used in the screening process as part of the optimisation; these were: acetone, ethanol and 
hexane. These solvents were chosen to cover a range of solvent properties and represent the 
three main categories of solvent: non-polar (hexane), polar protic (ethanol) and polar aprotic 
(acetone). 
3.2.1.2 Design of experiments 
The Design of Experiments (DOE) approach was used for the optimisation of the screening 
parameters. Umetrics MODDE software was used both for experimental planning and analysis 
of the results. The parameters chosen to investigate were: ultrasonication power, 
ultrasonication time, temperature, solvent and solvent amount. A larger set of potential 
parameters were considered for investigation which also included: light exposure, humidity and 
pressure; most of these proved to be impractical to investigate requiring either the purchase of 
equipment and/or extensive modification to the experimental setup. The response which was 
selected to be measured was percentage conversion of starting material to co-crystal. Although 
other parameters were considered for study such as pressure and light exposure, the feasibility 
of implementing them in the screening process prevented them from warranting inclusion in 
the optimisation experiments. 
The method used in the DOE software was an optimisation and the experimental plan laid out 
in Table 3.1 was produced. This was a fractional factorial design which was deemed to be the 
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most appropriate type given the number of factors being investigated. This approach was 
suitable as a relatively large number of experiments were carried out, meaning a good model 
could be achieved without the need for a full factorial design which would have required an 
unreasonably large amount of time and resources given the number of variables implicated in 
the optimisation. 
 
Table 3.1 Experimental plan as produced by MODDE DOE software. 
Experiment 
number 
Ultrasonication 
power (%) 
Ultrasonication 
time (minutes) 
Temperature 
(°C) 
Solvent 
Solvent 
volume (µl) 
1 0 0 20 Acetone 5 
2 100 20 20 Acetone 5 
3 100 0 60 Acetone 5 
4 0 20 60 Acetone 5 
5 100 0 20 Acetone 50 
6 0 20 20 Acetone 50 
7 0 0 60 Acetone 50 
8 100 20 60 Acetone 50 
9 0 10 40 Acetone 27.5 
10 0 20 20 Ethanol 5 
11 0 0 60 Ethanol 5 
12 100 20 60 Ethanol 5 
13 100 20 20 Ethanol 50 
14 100 0 60 Ethanol 50 
15 0 20 60 Ethanol 50 
16 0 0 20 Ethanol 27.5 
17 0 0 40 Ethanol 50 
18 0 10 20 Ethanol 50 
19 100 0 40 Ethanol 5 
20 100 10 20 Ethanol 5 
21 50 0 20 Ethanol 50 
22 50 20 40 Ethanol 27.5 
23 50 10 60 Ethanol 27.5 
24 100 0 20 Hexane 5 
25 0 20 20 Hexane 5 
26 0 0 60 Hexane 5 
27 100 20 60 Hexane 5 
28 0 0 20 Hexane 50 
29 100 20 20 Hexane 50 
30 100 0 60 Hexane 50 
31 0 20 60 Hexane 27.5 
32 50 20 60 Hexane 50 
33 50 10 40 Hexane 5 
34 50 10 40 Hexane 27.5 
35 50 10 40 Hexane 27.5 
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3.2.1.3 Physical DOE experiments 
The experimental setup used during the optimisation experimentation consisted of an ultrasonic 
probe (Sonics Vibra Cell, 130W, 20kHz) with 8-tip adapter positioned using a retort stand above 
a 96-well plate (borosilicate glass, Zinsser). The well plate was positioned on a hot plate (IKA C-
MAG HP 4). Infrared spectroscopy was carried out using an Agilent Technologies Cary 630 FTIR 
spectrometer with diamond ATR. 
 
Figure 3.1 Photograph showing experimental setup. 
 
The experimental plan listed which experiments to carry out with variations in the parameter 
values between each experiment. The method implemented for the undertaking of these 
experiments was as follows: 
Approximately 50mg of the physical mixture of caffeine and malonic acid in a 2:1 molar ratio 
was weighed out into each of the required number of wells in the 96-well plate as dictated by 
the experimental plan. This required the use of multiple plates as experiments were carried out 
at different temperatures. The powder was gently compacted to the bottom of each well before 
the plate was placed on the hot plate and allowed to reach the instructed temperature. The 
plate was then removed and a Gilson pipette was used to quickly add the correct amount of the 
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appropriate solvent to the wells, again as stated in the experimental plan. Immediately after 
addition of the solvent, the plate was returned to the hot plate and the 8 tips of the ultrasonic 
probe placed in the necessary wells. The ultrasonic probe was set at the desired power setting 
and left for the stipulated time. Upon completion, the resultant material was removed from the 
wells using a spatula and analysed by infrared spectroscopy. For analysis, infrared spectroscopy 
was used to measure the response of conversion of starting material to co-crystal. This required 
a set of reference standards to be produced and analysed so that comparisons of the spectra of 
experiment samples could be carried out to determine the quantity of co-crystal present in said 
samples. 
 
3.2.1.4 Preparation of calibration standards for analysis 
Using infrared spectroscopy to successfully detect and quantify the presence of particular solid 
forms within a sample has been reported previously for both polymorphs126,127 and co-
crystals.128 A method similar to those used in the referenced literature was employed in which 
calibration standards containing varying ratios of co-crystal to parent components were 
produced. 
An amount each of caffeine and malonic acid were milled separately at 25Hz for 15 minutes in 
a Retsch Mixer Mill MM 400 ball mill using PTFE coated balls and vessels. The resultant powders 
were used to produce a 2:1 molar ratio physical mix of the two components. This was achieved 
by weighing out the appropriate amount of each component, transferring into ball mill vessels 
and shaking at 10Hz for 5 minutes without the presence of the balls. 
The 2:1 caffeine:malonic acid co-crystal was produced, following the method published by Trask 
et al.,51 by weighing out the appropriate amount of each component, transferring into a ball mill 
vessel and milling at 25Hz for 30 minutes (with the ball bearing present). Subsequent to this, six 
100mg samples were produced by weighing out the necessary quantity of both the 2:1 mixture 
and co-crystal (as described by Table 3.2 below) into a small sample vial and blending in the ball 
mill, again at 10Hz for 5 minutes without the presence of the ball bearings, in order to thoroughly 
mix the materials. The vials were wrapped in paper to prevent breakage during blending. 
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3.2.1.5 Infrared spectroscopy 
Each sample was analysed by infrared spectrometry using an Agilent Cary 630 FTIR spectrometer 
with diamond ATR and a resolution of 2cm-1, see Appendix 3.1 for spectra. 
 
Table 3.2 Compositions of the caffeine:malonic acid calibration standards. 
 
The infrared spectra for the 0% and 100% sample are shown in the plot below (Figure 3.2).  
 
 
Figure 3.2 Infrared spectra of 0% co-crystal (2:1 molar ratio physical mixture of milled caffeine and 
milled malonic acid, top) and 100% co-crystal (bottom). 
There are differences in these spectra and the most prominent is the peak at a wavenumber 
around 3100cm-1, an enlargement of which is shown below (Figure 3.3). The wavelength range 
in which this peak occurs corresponds to the literature values for a C-H stretch.129 Figure 3.4 
shows the hydrogen bonding present in the 2:1 caffeine:malonic acid co-crystal; the image was 
produced from the entry in the CSD (GANYAW) using Mercury. It is evident that there are two 
Sample 
(co-crystal 
content) 
Percentage 
of co-crystal 
by mass (%) 
Mass of co-crystal 
weighed (mg) 
Percentage of 
physical mixture 
by mass (%) 
Mass of physical 
mixture weighed 
(mg) 
0% 0 0 100 99.65 
20% 20 20.06 80 80.76 
40% 40 40.38 60 59.99 
60% 60 59.74 40 41.61 
80% 80 79.76 20 19.91 
100% 100 100.22 0 0 
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hydrogen bonds between each molecule of caffeine and malonic acid. One between the 
carboxylic O-H of malonic acid and one of the nitrogen atoms in the imidazole ring of caffeine, 
and the second between the C-H of the imidazole ring of caffeine and carbonyl O of malonic 
acid. This second hydrogen bond, when formed would alter the environment of the C-H bond, 
causing the difference in the peak observed in the spectra. 
 
 
 
Figure 3.3 Enlargement of peak used for comparison. 
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Figure 3.4 Image showing the hydrogen bonding (cyan dotted lines) between molecules of caffeine and 
malonic acid in the 2:1 caffeine:malonic acid co-crystal. 
 
 
A scatter graph was produced using this data and the 40% sample data pointed omitted due to 
its deviation from the trend. The graph with trend line and equation are shown in Figure 3.5. 
 
 
Figure 3.5 Scatter graph showing the wavenumber of absorption for the peak maximum for samples of 
varying co-crystal composition. 
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The R2 value of 0.941 indicates a reasonably good correlation, however determination of 
percentage co-crystal content calculated using the equation obtained from this data will only be 
an approximate value due to the less than perfect correlation. The resolution of the spectra 
achievable from the spectrometer used is great enough that multiple steps based on peak 
position between the spectra for 0% and 100% co-crystal are detectable. A minimum useful 
number of steps for the purposes of evaluating the parameters of the screening method would 
be two, equivalent to co-crystal is produced and co-crystal is not produced. The FTIR analysis 
used allows greater separation of the outcome of the experiments and in turn an improved DOE 
analysis. Although multiple steps in terms of co-crystal conversion could be detected, this was 
over a relatively narrow wavelength range (3109 to 3121) and the resolution of the 
spectrometer resulted in six detectable measurements, based on increments of 2cm-1 
throughout the range. The results are listed as a calculated conversion to co-crystal (Table 3.3), 
however it can be seen that only certain values are possible due to the grouping based on the 
detectable ranges. These values then can be thought of as an indicator of the amount of 
conversion to co-crystal without being misinterpreted as an exact expected value. 
 
3.2.2 Results 
The approximate percentage conversion to co-crystal observed in the experimental samples as 
determined by infrared analysis (spectra presented in Appendix 3.2) is shown in Table 3.3 below. 
Where there is no value in the result column, that particular experiment was not carried out. 
This was due to improving efficiency in the practical undertaking of the experiments; in order to 
minimise the number of consecutive runs required, multiple experiments were carried out on 
the same plate. By planning to combine certain experiments for example those requiring the 
same temperature, a resource efficient experimental plan was produced and followed. This 
however led to the exclusion of five out of the 35 experiments due to the limits of the 
experimental setup, for example by the layout of the 8-tip ultrasonic probe preventing adjacent 
wells to be sonicated at different sonication intensities. 
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Table 3.3 Experimental plan showing approximate percentage conversion to co-crystal as determined by 
infrared analysis of experimental samples. 
Exp. 
number 
Sonication 
power (%) 
Sonication 
time 
(minutes) 
Temp. 
(°C) 
Solvent 
Solvent 
volume 
(µl) 
Conversion to 
co-crystal (%) 
1 0 0 20 Acetone 5 80 
2 100 20 20 Acetone 5 65 
3 100 0 60 Acetone 5 73 
4 0 20 60 Acetone 5 73 
5 100 0 20 Acetone 50 80 
6 0 20 20 Acetone 50 80 
7 0 0 60 Acetone 50 73 
8 100 20 60 Acetone 50 80 
9 0 10 40 Acetone 27.5 80 
10 0 20 20 Ethanol 5 73 
11 0 0 60 Ethanol 5 80 
12 100 20 60 Ethanol 5 80 
13 100 20 20 Ethanol 50 80 
14 100 0 60 Ethanol 50 80 
15 0 20 60 Ethanol 50 80 
16 0 0 20 Ethanol 27.5 - 
17 0 0 40 Ethanol 50 73 
18 0 10 20 Ethanol 50 80 
19 100 0 40 Ethanol 5 80 
20 100 10 20 Ethanol 5 - 
21 50 0 20 Ethanol 50 80 
22 50 20 40 Ethanol 27.5 80 
23 50 10 60 Ethanol 27.5 - 
24 100 0 20 Hexane 5 22 
25 0 20 20 Hexane 5 22 
26 0 0 60 Hexane 5 73 
27 100 20 60 Hexane 5 73 
28 0 0 20 Hexane 50 29 
29 100 20 20 Hexane 50 22 
30 100 0 60 Hexane 50 80 
31 0 20 60 Hexane 27.5 - 
32 50 20 60 Hexane 50 - 
33 50 10 40 Hexane 5 65 
34 50 10 40 Hexane 27.5 73 
35 50 10 40 Hexane 27.5 73 
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3.2.3 DOE analysis 
3.2.3.1 Model fitting 
Table 3.3 contains the experiments and the resultant conversion to co-crystal calculated. These 
results were input into the MODDE software and analysis undertaken. The outcome was data fit 
to a multiple linear regression (MLR) model which overall did not show a good fit. Figure 3.6 
shows the summary of fit with good R2 (goodness of fit) and reproducibility but not satisfactory 
Q2 (goodness of prediction) or model validity. Following further processing of the results which 
involved excluding two data points which did not fit the trend line (highlighted in Table 3.3), as 
advised in the software literature,130 the fit of the data to the model was much improved as is 
evidenced by the updated summary of fit plot in Figure 3.7. 
 
 
Figure 3.6 Plot showing the summary of fit for the model after initial DOE analysis, with bars 
representing R2 (green), Q2 (dark blue), model validity (yellow) and reproducibility (light blue). 
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Figure 3.7 Plot showing summary of fit for the model after further processing, with bars representing R2 
(green), Q2 (dark blue), model validity (yellow) and reproducibility (light blue). 
 
The improvement in the fit of the model is demonstrated by the increased Q2 seen in Figure 3.7. 
The model validity does not see the same improvement, however as the R2 and Q2 are high, the 
likelihood is that the lack of fit is artificial. This is a known issue with the chosen analysis method 
whereby an artificial error can lead to a model validity calculated to be low, ostensibly indicating 
a lack of fit, when all other indicators show excellent calculated values.130 
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3.2.3.2 Analysis and plot generation 
Using the improved model, the following contour plots resulted from the data analysis. 
 
 
Figure 3.8 A 4D contour plot showing the relationship between ultrasonication power, temperature, 
solvent and solvent amount on the conversion of starting material to co-crystal, with the ultrasonication 
time set at 20 minutes. 
 
The above 4D response contour plot (Figure 3.8) shows the effects of the variables on the 
conversion of starting materials to co-crystal, with the exception of ultrasonication time which 
is fixed at 20 minutes, the maximum value. By determining from the 4D contour plots the best 
settings for each variable the below 2D contour plot was produced (Figure 3.9), with the 
parameters ultrasonication time, temperature and solvent, set at their ‘best’ values i.e. those 
that led to the greatest conversion to the co-crystal from the starting components. This leads to 
the plot area showing the effect on response of the final two variables, ultrasonication power 
and solvent amount. 
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Figure 3.9 A contour plot showing the relationship between ultrasonication power and solvent amount 
on the conversion of starting material to co-crystal when using acetone as the solvent, with all other 
parameters fixed at their optimum levels, showing the best possible response in the plot area. 
Ultrasonication time: 10 minutes, Temperature: 20°C, Solvent: acetone. 
 
The results as displayed in the 4D contour plot allow the observation that when using acetone 
or ethanol as the solvent, the settings of the other parameters did not significantly influence the 
response as a large conversion to co-crystal occurred at all of the values. Similarly, with a 
temperature of 60°C the same applies. There is however a general trend that increasing 
ultrasonication power and solvent amount show a higher conversion to co-crystal. When using 
hexane as the solvent the conversion to co-crystal is much more dependent on temperature and 
solvent amount. Optimum and 4D contour plots for each of the three solvents which graphically 
represent these findings are presented in Appendix 3.3. 
The 2D contour plot allows ‘best’ values for the two variables which are not already fixed at their 
optimum to be determined. Using these values for all of the parameters should allow for the 
most conversion to co-crystal from starting material possible with the method used for 
screening. 
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3.2.4 Validation testing 
Before applying this optimised screening process to APIs of interest, it was deemed prudent to 
perform some validation activities to ensure the physical screening methods used would 
produce the required outcomes i.e. detectable form change from the starting components. 
 
3.2.4.1 Method 
A number of co-crystal systems had previously been found, in unpublished work (see Appendix 
3.4), to be producible using ultrasonication. These materials were used to test the utility of the 
ultrasonication based well plate method with optimised parameters with material other than 
that which it was optimised. To be valid the optimised process should produce co-crystal from 
the starting materials, as to not achieve this would indicate that although optimised for the 
caffeine:malonic acid co-crystal the method would not be appropriate for other materials. The 
method used was to apply the ultrasonication screening process using the optimised parameters 
to a single sample for each of the systems used and measure the response by comparison of 
FTIR data. The spectra from the IR analysis are shown in Appendix 3.5. Multiple reference data 
for each system were not produced for the validation activities as the comparison of the IR data 
for the product of the method to a single spectrum of the physical mixture was decided to be 
sufficient to determine whether production of a new form had occurred. 
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3.2.4.2 Results 
Table 3.4 List of API and co-former pairs, which have previously been determined to form co-crystals 
using liquid assisted sonication, the stoichiometric ratio used and whether conversion to a new form was 
detected based on FTIR analysis. *Uncertain due to very subtle changes in spectra. 
API Co-former 
Stoichiometric 
ratio 
Detection of conversion 
based on IR 
Caffeine Oxalic acid 2:1 Yes* 
Caffeine Maleic acid 2:1 Yes* 
Caffeine Malonic acid 2:1 Yes 
Caffeine Oxalic acid 1:1 Yes 
Caffeine Maleic acid 1:1 Yes 
Caffeine Malonic acid 1:1 Yes 
Caffeine Glutaric acid 1:1 Yes 
Sulfamethazine Aspirin 1:1 Yes 
Sulfamethazine Benzoic acid 1:1 Yes 
Ibuprofen 4,4-bipyridine 2:1 Yes 
Ibuprofen 4,4-bipyridine 1:1 Yes 
Ibuprofen Nicotinamide 1:1 Yes 
Trimethoprim Sulfamethoxypyridizine 1:1 Yes 
Carbamazepine Saccharin 1:1 Yes 
Carbamazepine Nicotinamide 1:1 Yes 
Paracetamol 4,4-bipyridine 1:1 Yes 
Aspirin 4,4-bipyridine 1:1 Yes 
 
Having verified that the optimised settings determined in the initial screening optimisation were 
applicable to efficient detection, across a broad range of chemistries, of known co-crystals we 
then employed the screen to find a new co-crystal in order to undertake a second round of 
optimisation. To achieve this, model APIs: ROY and ornidazole, were chosen to represent a range 
of drug like chemistry, which was of interest to the project team. A co-crystal screen was then 
conducted in both systems. The experimental details, analysis and results of these screens are 
presented in Chapters 4 and 6; in summary, no co-crystals were discovered in the ROY screen 
however a total of 23 hit were found from the ornidazole screen. 
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3.2.5 Summary of initial optimisation 
 
Table 3.5 Optimised values determined for the investigated variables specific for each solvent. 
Solvent 
Sonication time 
(minutes) 
Sonication power 
(% of full power) 
Solvent volume 
(µl) 
Temperature (°C) 
Acetone 10 50 50 20 
Ethanol 10 65 50 20 
Hexane 20 55 50 60 
 
The screening method employed combines aspects of other methods to give a procedure that 
is effective at producing hits and is efficient for high-throughput screening. Considering the plate 
preparation where the API in solution is added to the co-former, assuming that the co-former 
has equal to or greater solubility in the solvent as the API then the drying stage is effectively an 
evaporative crystallisation step. This will not always be the case as it is very unlikely that all co-
formers would have greater solubility than the API but even if the solubility was only half that 
of the API there is still the possibility of a 2:1 co-crystal forming. It is therefore possible that in 
some cases a co-crystal may form before the addition of the solvent drop and sonication steps. 
This second part of the method mimics solvent drop grinding (LAG) by simply replacing grinding, 
either by hand, or using a mill, with sonication using an ultrasonic probe. By adding the small 
amount of solvent to the 1:1 molar ratio of compounds it is more likely that the system will be 
in a favourable position of its ternary phase diagram to result in the formation of a co-crystal.22 
By combining these two steps there are effectively two chances for co-crystallisation to occur 
and this is perhaps a factor in the consistently high conversion to co-crystal seen in the DOE 
experiments and the successful detection of all hits in the validation testing. 
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3.3 Second optimisation 
3.3.1 Methods 
3.3.1.1 General 
The initial optimisation experiment and associated validation proved successful in indicating that 
the physical screening method employed was adequate to detect conversion of starting 
components to new, potentially co-crystalline, forms. It was also shown to be robust in terms of 
reproducibly causing a large percentage conversion to co-crystal over a wide range of settings 
for the variables investigated. This screening method was the best manual representation 
achievable to the automated screening process which was the ultimate target for optimisation. 
The automation involved a robotics platform as depicted in Figures 3.10 and 3.11. The process 
began by manually filling a vial with stock API solution and a deep-well plate with the required 
co-former stock solutions. These were placed in the appropriate place in the robot along with a 
quartz plate into which the materials would be dispensed. A method file with parameters for 
the experiment was input into the control computer and the program initiated. The robotic arm 
moved the plates to the required locations within the robot and the volumes of API and co-
former solution dictated in the method file were dispensed into the 96-well plate by the 
dispensing needles. The solvents were evaporated and the solvent drop for 24 of the 96 well 
added followed by sonication of said wells. This last section was repeated a further three times 
until all 96 wells had been sonicated. The plate was finally moved to the optical microscopy area 
for imaging which is the last stage of the automated process. 
 
 
Figure 3.10 Split image of robot with key areas labelled. 
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Figure 3.11 Photograph of sonication stage showing the 24-tip adapter in the wells of a quartz 96-well 
plate mid sonication. 
When access to the robotics platform was gained, a second optimisation was planned using the 
optimal parameters determined from the initial experiments as a guide from which to set 
appropriate limits. Four hits from the ornidazole screen (see Chapter 6 for full details of this 
screen) were used in this second experiment to attempt to broaden the range of representative 
compounds employed for the optimisation. Only four co-formers were chosen as the number 
was limited by the layout of the 96-well plates used as a compromise to be able to run the 
experiments as efficiently as possible by varying multiple factors per plate. The co-formers 
picked were based on the crystallisation propensity of the materials produced compared to 
other hits from the screen, with the chosen four taking less time to crystallise than others. Four 
solvents were used for this second optimisation, these were: acetonitrile, ethanol, 
tetrahydrofuran (THF) and toluene. These solvents were again chosen to cover a wide range of 
solvent properties and represent the three main categories of solvent: non-polar (toluene), 
polar protic (ethanol) and polar aprotic (acetonitrile and THF). 
3.3.1.2 DOE plan and plate layout 
The plate diagram in Figure 3.12 displays the layout used for the second optimisation 
experiments. The colours of the well in columns one and two indicate the co-former used: 
orange for 5-nitroisophthalic acid, purple for oxalic acid, green for 2,4-dihydroxybenzoic acid 
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and blue for trimesic acid. The letters each well is labelled with identifies the solvent used: A for 
acetonitrile, E for ethanol, O for oxolane (tetrahydrofuran (THF)) and T for toluene. This layout 
meant that for each run in which sonication time and solvent volume were being altered, four 
co-formers and four solvents were also being included to produce a full factorial dataset. 
Theoretically columns three and four, and five and six could have been used to increase the 
number of co-formers investigated however given that the PXRD analysis stage of these 
experiments was still being carried out manually, this was not a feasible option due to the 
excessive increase in time required per experiment. The design of the robot and the software 
limitations alluded to in the introduction to this chapter, specifically that the software was 
written to follow a set method which did not inherently allow for the use of different solvents 
for the solvent-drop on one plate, meant that the maximum number of solvents able to be 
tested per plate was limited to four. The platform uses a 24-tip probe for sonication which 
sonicates one quadrant of the plate immediately after solvent addition. The plate is then 
returned for the addition of solvent to the next quadrant of wells before the process repeats 
until all four quadrants have had solvent added and sonication occurred. This gives rise to the 
layout of the solvent and co-former placements on the plate. The second half of the plate 
denoted by the yellow wells had the API to co-former ratio at 2:1. This was not a significant part 
of the experiment and an unfortunate waste of material but again a necessary limitation of using 
a platform which must adhere to strict validated processes in an industrial setting.  
 
 
Figure 3.12 Layout of the 96-well plates used for the second optimisation DOE experiments. Wells of 
interest are those in columns 1 and 2 and are colour coded by co-former and labelled by solvent. 
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Table 3.6 Experimental plan for the second optimisation listing the settings used for each of the seven 
runs. 
Plate 
number 
Sonication time Solvent volume 
Minutes DOE setting µL DOE setting 
1 6 High 10 Low 
2 6 High 25 High 
3 2 Low 25 High 
4 2 Low 10 Low 
5 4 Mid 17.5 Mid 
6 4 Mid 17.5 Mid 
7 4 Mid 17.5 Mid 
 
 
3.3.1.3 Physical DOE experiments 
Although the co-formers chosen were based on the crystallisation propensity of the product of 
the co-former:API material (‘hit’), the time scale (and/or variation in scaling the method to the 
robotics platform) at which the second optimisation experiment was run and then analysed, 
resulted in only two of the four co-formers tested (5-nitroisophthalic acid and trimesic acid) 
crystallising within a sufficiently short time as to be analysed fully. One of the other co-
former:API pairs (2,4-dihydroxybenzoic acid) showed minimal signs of crystallisation in most 
plates, however mainly sticky, possibly partially amorphous material was present at the at time 
of analysis and so suitable analysis was not possible. The products of the final co-former:API 
(oxalic acid) pair had not crystallised at all, or not sufficiently, on any of the plates in the given 
timescale and were excluded from any PXRD analysis. Figure 3.13 shows an example tiled image 
of the optical micrographs of each well of a 96-well plate (plate number 7 but representative of 
all plates) after the sonication stage of the automated process. It can be seen that the wells 
containing ornidazole and 5-nitroisophthalic acid or trimesic acid (see Figure 3.12 for reference) 
already show signs of significant crystallisation, whereas those containing ornidazole and 2,4-
dihydroxybenzoic acid or oxalic acid do not. These images were taken immediately after the last 
sonication step and further time for crystallisation to occur was left before analysis, however it 
is evidence of the disparity in crystallisation propensity between the ornidazole:co-former 
systems. This highlights a potential flaw in the screening method from a practicality point of 
view. Unless automated PXRD plate reading is introduced then manual recovery of the sample 
from the plate is required and can be very difficult depending on the properties/behaviour of 
the material under investigation. 
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Figure 3.13 Tiled image of the optical micrographs of each well of a 96-well plate (number 7) after the 
sonication stage of the automated process. 
A potential improvement would be to add a stage in the automated process on the robot, in 
which induced crystallisation is attempted by either temperature cycling or humidity cycling if 
sufficient crystallisation has not occurred by the time analysis is performed. This may not be as 
advantageous as it might seem initially though, as although more hits may be identified, that 
they were not produced easily and required further processing may be an indication that their 
manufacture could also require extensive processing in comparison to those more readily 
accessed co-crystals identified by the standard screening procedure i.e. the accessibility of a co-
crystal phase is in and of itself a criterion for its selection for future development where all else 
is equal. This potential discrimination between relatively easy and difficult to form co-crystal 
phases could be seen as an advantage to the current screen – effective enough to identify the 
majority of readily accessed co-crystal systems and acting as an indicator that if a hit isn’t 
detected then it is probably/possibly too hard to produce to be worthy of consideration for a 
pharmaceutical form for development. 
3.3.1.4 PXRD analysis 
After running the experiments using the automated robotic process, the material from the wells 
was to be manually removed and prepared for PXRD analysis (plots of the PXRD patterns can be 
found in Appendix 3.6). The condition/physical state of the materials meant that all of the 
samples for two of the co-formers (oxalic acid and 2,4-dihydroxybenzoic acid) were excluded 
from analysis and all of the samples for the two co-formers in which sufficiently crystalline 
material was present (5-nitroisophthalic acid and trimesic acid) were analysed. This was carried 
out at AstraZeneca and so the standard method detailed in Chapter 2 was not followed. Instead 
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X-ray powder diffraction patterns were recorded on a Bruker D4 Endeavor diffractometer with 
intensities measured from 2° to 40° 2θ. 
Subsequent to the discovery of the 1:1 ornidazole:5-nitroisophthalic acid co-crystal (see Chapter 
6 for details), its crystal structure was determined and a powder pattern from this, calculated 
using Mercury, was used in this analysis to allow a comparison of peak data of experimental 
samples to take place. The comparison focused on a specific peak unique to the co-crystal and 
measurements of its intensity and shape were used for the comparative analysis. For the 
products of the screen containing ornidazole and trimesic acid, an identical approach was not 
possible as crystal structure data was not available. Therefore, several similar methods were 
attempted identifying key characteristics of a peak unique to the powder pattern of the ‘hit’ 
from the co-crystals screen, and comparing these between the power patterns from the 
optimisation experiment to allow analysis using MODDE and ultimately optimisation of process 
parameters. 
The methods for the analysis of the ornidazole:trimesic acid samples included comparing net 
peak height (intensity) and the full width at half maximum (FWHM) between the individual 
sample patterns. A further comparison involved a combined function of the FWHM and peak 
height as an indicator of conversion to co-crystal/crystallinity and relative amount of the co-
crystal as part of the whole sample. The equation used to calculate this value is shown below, 
with the 100,000 term simply to produce more convenient numbers. 
𝐹𝑊𝐻𝑀: 𝑝𝑒𝑎𝑘 ℎ𝑒𝑖𝑔ℎ𝑡 𝑣𝑎𝑙𝑢𝑒 =
𝐹𝑊𝐻𝑀 × 100,000
𝑛𝑒𝑡 𝑝𝑒𝑎𝑘 ℎ𝑒𝑖𝑔ℎ𝑡
  
This is of course affected by the quantity of sample recovered which differed between wells, but 
as this is an optimisation of the method as a whole, and not just a quantification of co-crystal 
producible, then the optimisation based on this FWHM-peak height derivative number takes 
into account the practicalities of the method in as much as where less sample is able to be 
retrieved from the well, the value for the FWHM-peak height will be proportionally lower. i.e. 
Low amount of sample + low co-crystal content/crystallinity = higher value = bad  
Low amount of sample + high co-crystal content/crystallinity = mid value = reasonable 
High amount of sample + low co-crystal content/crystallinity = mid value = reasonable 
High amount of sample + high co-crystal content/crystallinity = low value = good 
68 
 
These values depend on the parameters of the PXRD analysis and of the material under 
investigation but are designed to be compared between samples of the same system and 
therefore as low a value as possible would be the aim of the optimisation. 
 
3.3.2 Results 
 
Table 3.7 Experimental plan showing measured FWHM as determined by PXRD analysis of experimental 
samples and FWHM as a percentage of that of the calculated powder pattern for ornidazole:5-
nitroisophthalic acid samples. 
Plate/Run Well Solvent 
Solvent 
volume (µL) 
Sonication 
time 
(minutes) 
FWHM 
FWHM as % 
of calculated 
4 A1 Acetonitrile 10 2 0.141 136.9% 
1 A1 Acetonitrile 10 6 0.084 81.6% 
4 B1 Ethanol 10 2 0.107 103.9% 
1 B1 Ethanol 10 6 0.122 118.4% 
4 A2 THF 10 2 0.098 95.1% 
1 A2 THF 10 6 0.139 135.0% 
4 B2 Toluene 10 2 0.098 95.1% 
1 B2 Toluene 10 6 0.120 116.5% 
3 A1 Acetonitrile 25 2 0.141 136.9% 
2 A1 Acetonitrile 25 6 0.120 116.5% 
3 B1 Ethanol 25 2 0.134 130.1% 
2 B1 Ethanol 25 6 0.104 101.0% 
3 A2 THF 25 2 0.104 101.0% 
2 A2 THF 25 6 0.118 114.6% 
3 B2 Toluene 25 2 0.108 104.9% 
2 B2 Toluene 25 6 0.111 107.8% 
5 A1 Acetonitrile 17.5 4 0.102 99.0% 
6 A1 Acetonitrile 17.5 4 0.116 112.6% 
7 A1 Acetonitrile 17.5 4 0.123 119.4% 
5 B1 Ethanol 17.5 4 0.125 121.4% 
6 B1 Ethanol 17.5 4 0.107 103.9% 
7 B1 Ethanol 17.5 4 0.147 142.7% 
5 A2 THF 17.5 4 0.138 134.0% 
6 A2 THF 17.5 4 0.108 104.9% 
7 A2 THF 17.5 4 0.118 114.6% 
5 B2 Toluene 17.5 4 0.120 116.5% 
6 B2 Toluene 17.5 4 0.107 103.9% 
7 B2 Toluene 17.5 4 0.133 129.1% 
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Table 3.8 Experimental plan showing measured FWHM and net peak height as determined by PXRD 
analysis of experimental samples and a calculated derivative of FWHM and net peak height for 
ornidazole:trimesic acid samples. 
Plate/Run Well Solvent 
Solvent 
volume 
(µL) 
Sonication 
time 
(minutes) 
FWHM 
Net 
peak 
height 
FWHM: 
peak 
height 
value 
4 G1 Acetonitrile 10 2 0.076 1757.3 4.32 
1 G1 Acetonitrile 10 6 0.064 1021.5 6.27 
4 H1 Ethanol 10 2 0.082 380.6 21.54 
1 H1 Ethanol 10 6 0.064 782.2 8.18 
4 G2 THF 10 2 0.077 282.0 27.30 
1 G2 THF 10 6 0.069 411.0 16.79 
4 H2 Toluene 10 2 0.050 180.3 27.73 
1 H2 Toluene 10 6 0.073 1322.1 5.52 
3 G1 Acetonitrile 25 2 0.072 587.7 12.25 
2 G1 Acetonitrile 25 6 0.071 575.2 12.34 
3 H1 Ethanol 25 2 0.074 251.2 29.46 
2 H1 Ethanol 25 6 0.083 3262.9 2.54 
3 G2 THF 25 2 0.076 120.6 63.02 
2 G2 THF 25 6 0.071 1064.7 6.67 
3 H2 Toluene 25 2 0.124 725.6 17.09 
2 H2 Toluene 25 6 0.123 1243.7 9.89 
5 G1 Acetonitrile 17.5 4 0.084 442.3 18.99 
6 G1 Acetonitrile 17.5 4 0.161 496.1 32.45 
7 G1 Acetonitrile 17.5 4 0.138 577.2 23.91 
5 H1 Ethanol 17.5 4 0.093 314.0 29.62 
6 H1 Ethanol 17.5 4 0.114 375.8 30.34 
7 H1 Ethanol 17.5 4 0.110 400.3 27.48 
5 G2 THF 17.5 4 0.094 272.5 34.50 
6 G2 THF 17.5 4 0.079 465.0 16.99 
7 G2 THF 17.5 4 0.085 521.9 16.29 
5 H2 Toluene 17.5 4 0.098 322.1 30.43 
6 H2 Toluene 17.5 4 0.135 593.4 22.75 
7 H2 Toluene 17.5 4 0.112 771.8 14.51 
 
Data viewer software (PANalytical) was used to automatically pick the peaks with manual 
verification and for samples where this was not possible, manual picking of peaks was 
undertaken (highlighted in Table 3.8). 
3.3.3 DOE analysis 
For DOE analysis FWHM as a percentage of that of the calculated powder pattern for 
ornidazole:5-nitroisophthalic acid was used as the outcome measured for ornidazole:5-
nitroisophthalic acid samples and FWHM, net peak height and the caluclated FWHM:peak height 
value were all used in separate analyses for the ornidazole:trimesic acid samples. 
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3.3.3.1 Model fitting 
 
 
Figure 3.14 Plots detailing model summary for ornidazole:5-nitroisophthalic acid results. Clockwise from 
top left: Replicates (results of repeated experiments shown by blue squares), summary of fit (R2 (green), 
Q2 (dark blue), model validity (yellow) and reproducibility (light blue)), residuals and coefficients. 
The results from the experiments show that conversion to co-crystal occurred in all cases for the 
ornidazole:5-nitroisophthalic acid samples. Figure 3.14 displays the model summary for this data 
and it is apparent that the variation in measured outcome from the experiments is very small 
relatively between the entire set of samples. This has led to a model from which gleaning useful 
parameter optimisation is not possible as any perceived possible improvements are not 
statistically significant. The same is true for the analysis of the ornidazole:trimesic acid data, in 
that conversion from starting components was seen in all of the samples to a relatively similar 
degree and as such the model’s ability to produce optimisation of any significance is diminished. 
Model summary plots from the analysis of the ornidazole:trimesic acid data are presented in 
Appendix 3.7. 
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3.3.3.2 Analysis and plot generation 
Due to none of the DOE analysis for the second optimisation experiments leading to models with 
statistical significance, any attempt to use the models to influence parameter value optimisation 
would be unfounded. That all of the samples showed easily detectable conversion from starting 
materials and within a similar enough range that meaningful models could not be produced from 
the data suggests that further optimisation may not be necessary and that the current process 
is at a suitable level of optimisation. This section then is a purely academic tangent into the type 
of optimisation that was envisioned may have resulted from the second optimisation 
experiment. 
Using the data from the ornidazole:5-nitroisophthalic acid samples, both FWHM and peak height 
were set as measured outcomes and a model produced which inevitably was not significant. 
Regardless, a plot was produced to show how using the DOE analysis, it is possible to determine 
the optimal parameters for certain variables so that two outcomes can be maximised. In this 
case setting sonication time to 6 minutes and solvent volume to 25µl would give high peak height 
but low FWHM. It is therefore necessary to compromise the outright maximum of both peak 
height and FWHM to be able to set the parameters so that reasonable values of each are 
achieved. The exact point at which parameter must be set to maximise both outcomes, assuming 
they are of equal importance, is shown in Figure 3.15. 
 
 
Figure 3.15 Response contour plots for FWHM and peak height from the orindazole:5-nitroisophthalic 
acid data showing the settings at which both outcomes are maximised. Note: this plot was produced 
from a statistically insignificant model, is for illustration of the concept only and was not used to inform 
optimisation. 
72 
 
3.3.4 Summary of second optimisation 
Similarly to the initial optimisation, to which this second optimisation shared a very comparable 
procedure, a combination of aspects from different screening techniques are incorporated. 
Unlike the initial method where API in solution was added to dry co-former, in the second 
method implemented on the robot, both the API and co-formers were added to the wells in 
solution. In the case of the four co-formers used in this work the same solvent, methanol, was 
used to make the solutions of the API and all co-formers. This may not always be the case though 
as if the API and any of the co-formers are not sufficiently soluble in the same solvent then 
different solvents would need to be used. This could lead to a situation where this first, plate 
preparation step of the procedure, is effectively an antisolvent crystallisation step. Again, this is 
a well-documented method of co-crystal production131 and may be a contributing factor to the 
expected efficacy of the screening method used for the second optimisation. 
 
3.4 Conclusions 
The first section of this chapter dealt with the initial optimisation of a manual co-crystal screen 
mimicking an automated procedure. The result of the experiments enabled the determination 
of a set of optimised values for each of the variables to be used with three different solvents. 
This outcome was of great importance for much of the work presented in the following chapters 
as it afforded an efficient and robust process for co-crystal screening employing the available 
resources. The latter section of the chapter involving the second optimisation experiment of the 
automated process can be seen as somewhat of a validation of the outcome of the initial 
optimisation and its scalability to a higher throughput, more efficient process. No further 
optimisation of the variables was achievable with the parameters used and the analysis method 
employed. As the detection rate for the co-crystal of the samples analysed was maximal, this 
serves only to confirm the effectiveness and suitability of the overall method. Using the DOE 
approach, it may still be possible to improve the efficiency of the process in some ways, such as 
reducing material use. This may require the investigation of different factors and use of 
alternative analysis techniques which could detect greater variation in the measured outcomes 
to allow for more meaningful variable optimisation. 
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Chapter 4 – ROY synthesis, co-crystal screen and 
discovery and analysis of a co-amorphous binary 
material 
 
4.1 Introduction 
Having developed and optimised a co-crystal screen in the previous chapter, the next step was 
to put the optimised method into practice and perform a screen on a novel material, i.e. a 
compound for which there were no reported co-crystals and which had not previously been 
screened. This chapter presents this work and includes a co-crystal screen of ROY, findings from 
the analysis and the investigation into an interaction which stabilised the binary composition as 
a co-amorphous material. 
ROY (5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile) is a highly polymorphic 
compound and is a precursor in the synthesis of the antipsychotic drug olanzapine. It is so named 
due to the red, orange and yellow crystal colours of its polymorphs and has been reported to 
exist in at least 10 polymorphic forms.132 With seven of these forms structurally characterised, 
it was until recently,133,134 the compound with the most polymorphs recorded in the Cambridge 
Structural Database(CSD).135 Due to its drug-like characteristics, being a precursor to and thus 
sharing some similar structure to a marketed drug, as well as its highly polymorphic nature, ROY 
was chosen as a model compound upon which to implement the optimised co-crystal screen. 
Availability of ROY commercially is limited and small quantities in the range of 10mg can cost 
hundreds of pounds. In order to carry out a full co-crystal screen we would require a significant 
amount of API, in the region of 5g, and so purchasing of ROY was not a feasible option. Although 
within my work this was inconvenient, this problem highlights why the optimisation of screening 
processes to improve efficiency is relevant. Limited and expensive API is often an issue in the 
early stages of drug development and any way to reduce the amount required, such as by 
making screening processes more efficient, is paramount. The development of microfluidics to 
further reduce the required API amount compared to well plate screening is an example of this 
trend.136,137 The acquisition and deployment of a new technology in industry can take many years 
and although microfluidic co-crystal screening may be implemented in the future, the currently 
accessible high-throughput co-crystal screening processes use the robotic well plate platform, 
hence its use in this work. 
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In order to achieve the required quantity of ROY the decision was taken to synthesise it in house. 
To achieve this a synthetic route to produce ROY was found in the literature138 and, as the 
starting materials were accessible financially and readily available, synthesis of a sufficient 
quantity of ROY for screening was undertaken. 
 
4.2 Synthesis of ROY 
4.2.1 Method 
The synthesis of ROY was conducted with the assistance of Dr Jonathan Harburn (Durham 
University), and followed a two-step process as detailed in the patent for olanzapine,138 with 
further guiding information found in a PhD thesis.139 
4.2.1.1 Step 1 
An amount of 11.68g (0.364mol) sulfur, 25.33g (31.5ml, 0.436mol) propionaldehyde and 75ml 
DMF were placed in a flange-necked flask fitted with an overhead stirrer, air condenser, 
thermometer, and dropping funnel. Triethylamine (30.9ml, 0.222mol) was added dropwise over 
35 minutes to the cooled stirred reaction mixture whilst maintaining the pot temperature 
between -5 and 10°C with an ice-bath. After addition, the pot was allowed to warm up to 20°C 
over 45 minutes, whilst keeping the mixture well stirred. A solution of 24.1g (0.365mol) 
malononitrile in 50ml dimethylformamide (DMF) was added drop-wise over 60 minutes keeping 
the pot temperature between 8-20°C throughout the addition. Once complete the mixture was 
stirred at 15-20°C for a further 45 minutes then sampled for thin layer chromatography (TLC). 
Having confirmed, from TLC, that a new chemical species was present, the mixture was then 
poured into a beaker containing approximately 600ml ice/water with stirring to cause the 
required product to precipitate for around 1 hour. After 10 minutes, the stirrer was switched off 
and the solid allowed to settle. The aqueous liquor was decanted away and the solid isolated by 
filtration. The solid was left to dry for approximately 65 hours. The isolated solid was further 
washed with 215ml deionised water, then subjected to a further drying cycle overnight in vacuo 
at 70-75°C to give 2-amino-5-methylthiophene-3-carbonitrile. 
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Figure 4.1 A schematic diagram of the first step of ROY synthesis. 
 
4.2.1.2 Step 2 
A solution of 32.05g (0.227mol) 2-fluoronitrobenzene and 31.36g (0.227mol) 2-amino-5-
methylthiophene-3-carbonitrile in 285ml dry tetrahydrofuran (THF) was added dropwise to a 
stirred slurry of 16.36g (0.682mol) sodium hydride in 57ml dry THF under nitrogen. The mixture 
was stirred at 25°C for 24 hours, poured onto cracked ice and extracted into dichloromethane 
(DCM) (3 x 570ml). The combined extracts were washed with 2M HCl (2 x 225ml) and water (2 x 
225ml), dried over magnesium sulfate and the solvent removed under reduced pressure using a 
rotary evaporator. The residue was crystallised from ethanol by evaporation to give ROY. 
 
Figure 4.2 A schematic diagram of the second step of ROY synthesis. 
 
4.2.2 Analysis of synthesised ROY 
Samples from batch one were analysed by 1H NMR (Figure 4.3), 13C NMR (Figure 4.4) and mass 
spectrometry (Figure 4.5) to confirm the identity of the synthesised material as ROY. The peaks 
observed in the 1H NMR spectrum integrate to represent the nine hydrogen atoms, as present 
in the ROY molecule. There are 12 peaks detected in the 13C NMR spectrum also representative 
of the 12 unique carbon atoms of ROY. The peaks observed in both NMR spectra correspond to 
those in a previously reported synthesis of ROY by Hartwig et.al.140 
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Figure 4.3 1H NMR spectrum of synthesised ROY. 
 
 
Figure 4.4 13C NMR spectrum of synthesised ROY. 
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Figure 4.5 Mass spectrum of synthesised ROY, focused around the molecular ion peak. 
The calculated exact mass of isotopically pure ROY (C12H9N3O2S) is 259.041549. Due to the 
electrospray ionisation (ESI) method being used in positive mode, the [M+H]+ peak is observed 
at 260.0492 and [M]+ at 259.0424 m/z. The NMR and mass spectroscopy analysis of batch one 
of synthesised ROY in combination with the PXRD analysis, detailed below, provide evidence of 
its identity as ROY. 
The ability of ROY to crystallise in multiple polymorphic forms simultaneously, due to the small 
differences in enthalpy between the forms, was observed in the crystallisation phase of the 
procedure. A number of polymorphic forms were recovered from consecutive crystallisations 
and collected into vials, a photograph of these is shown in Figure 4.6. 
 
 
Figure 4.6 Synthesised ROY in vials. Each batch was collected from consecutive crystallisations from the 
one synthesis. The batches are, from left to right: one, three, four, two and five. 
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Only material from batches one and three were used for work presented in this thesis. There 
are clear visual differences between all batches which can be attributed to the multiple 
polymorphic forms of ROY present with the exception of batches one and five in which the same 
polymorph is observed, and batch two. Batch two does not resemble any of the discovered 
forms of ROY and therefore might be suspected to be either a new polymorph or not in fact ROY 
at all. However, when crushed, the appearance of batch two is similar to other batches in that 
yellow crystals are present and the PXRD pattern obtain matches that of the calculated pattern 
of polymorph Y141 of ROY (Figure 4.7). 
It is therefore likely that the appearance of the batch two material is due to a fine coating of 
impurity on small ‘pellets’ of polymorph Y of ROY. The PXRD patterns for batches one and three 
of the synthesised ROY contain all of the peaks in the calculated pattern of polymorph Y, 
however the patterns of both batches also contain the peaks present in ROY polymorph R to 
differing extents. Only a very small peak at approximately 7.5° 2θ identifies batch one as 
containing a detectable quantity of polymorph R whereas the pattern for batch three contains 
much more prominent peaks associated with polymorph R indicating that it contains a much 
more even mixture of both polymorphs Y and R, as apparent by its visual appearance. 
The reference patterns for the known polymorphs of ROY were calculated using the CCDC’s 
Mercury software,142 from the CSD entry codes: QAXMEH (ON), QAXMEH01 (Y), QAXMEH02 (R), 
QAXMEH03 (OP), QAXMEH04 (YN), QAXMEH05 (ORP) and QAXMEH12 (YT04). PowDLL 
software143 was used to convert the data files to match those used for the experimentally 
obtained samples to facilitate the plotting of diffractograms. 
 
Figure 4.7 Powder patterns of batches one, two and three of synthesised ROY and calculated powder 
patterns of known ROY polymorphs Y and R for comparison. 
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Samples from both batch one and three were analysed by DSC (Figure 4.8) and the melting 
points measured compared to the literature values for ROY polymorphs (Table 4.1). 
 
 
Figure 4.8 DSC traces for batches one (green) and three (blue) of synthesised ROY. 
 
Figure 4.8 shows the DSC curves produced for samples from two of the batches of synthesised 
ROY using the standard ramp method detailed in Chapter 2.  On heating of the batch one sample, 
there is a large endothermic peak with an onset temperature of 109.9°C indicating melting of 
the sample. This melting point value is commensurate with the literature melting point of 
polymorph Y of ROY, which is the most thermodynamically stable form under ambient 
conditions.132 Heating of the batch three sample in the same manner gives rise to a more 
complex DSC trace. There is an initial small endothermic peak with an onset temperature of 
106.7°C, followed by an exothermic peak and a final larger endothermic peak with a 110.5°C 
onset. The likely explanation for these events is the melting of polymorph R contained within 
the sample, as identified by PXRD (Figure 4.7) and its melting point fitting that of the 
endothermic peak (Table 4.1). Following this, a conversion of polymorphic form by crystallisation 
from the now molten ROY to a second polymorph (Y) which then melted at a higher 
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temperature. This is not uncommon in polymorphic systems144 and is known as a melt 
recrystallisation melt event. 
 
Table 4.1 Selected properties of ROY polymorphs.132 
Form ORP YN R YT04 Y OP ON 
Description 
Orange-
red plate 
Yellow 
needle 
Red 
prism 
Yellow 
prism 
Yellow 
prism 
Orange 
plate 
Orange 
needle 
Melting point (°C) 97 99 106.2 106.9 109.8 112.7 114.8 
 
 
4.3 Co-crystal screen 
The optimised method from the previous chapter was used for the co-crystal screen of ROY. The 
initial step was to use COSMOtherm101 to predict the most likely co-formers to co-crystallise with 
ROY by performing calculations on a list of potential co-formers. This process is discussed in 
more detail in the method section below. After obtaining the results from this computational 
pre-screen, any of the top 48 predicted co-formers (Table 4.2) which were not already in stock, 
were obtained and the physical screen carried out using the parameters determined by the 
optimisation experiments. An issue in acquiring all of the required co-formers was caused by a 
lack of availability of one co-former which was ranked number 17 (p-vinylphenol) and was 
rectified by substituting it with the co-former ranked number 49 (2-oxo-3-phenylpropionic acid) 
at the appropriate place in the list. 
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Table 4.2 COSMOtherm rank order of co-formers used for ROY screen (48 selected from the top 49 
predicted using COSMOtherm with one excluded due to availability (p-vinylphenol #17)). 
Rank Co-former Rank Co-former 
1 Pentafluorophenol 25 Indole 
2 Acesulfame 26 3-Hydroxy-2-naphthoic acid 
3 Oxalic acid 27 2,5-Xylenol 
4 Quercetin 28 Salicylic acid 
5 Sulfamic acid 29 m-Nitrobenzoic acid 
6 3,5-Dinitrobenzoic acid 30 Skatole 
7 1,2,3-Trihydroxybenzene 31 Hydroquinone 
8 2,4-Dihydroxybenzoic acid 32 Fumaric acid 
9 5-Nitroisophthalic acid 33 Methyl gallate 
10 Gallic acid 34 p-Cresol 
11 tert-Butylhydroquinone 35 Methanesulfonic acid 
12 1-Hydroxy-2-naphthoic acid 36 p-Ethylphenol 
13 Catechol 37 3-Hydroxybenzoic acid 
14 4-Hexylresorcinol 38 6-Hydroxy-2-naphthoic acid 
15 5-Chlorosalicylic acid 39 Ethanesulfonic acid 
16 Resorcinol 40 Allocitric acid 
17 3,5-Dihydroxybenzoic acid 41 p-tert-butylphenol 
18 Orcinol 42 3,4-Xylenol 
19 2,5-Dihydroxybenzoic acid 43 2,6-Xylenol 
20 o-Cresol 44 Citric acid 
21 3,4-Dihydroxybenzoic acid 45 Etidronic acid 
22 Thymol 46 4-Hydroxybenzoic acid 
23 Phenol 47 o-Phenylphenol 
24 Trimesic acid 48 2-Oxo-3-phenylpropionic acid 
 
 
4.3.1 Methods 
4.3.1.1 Computational pre-screen 
The method used to produce the list of most favourable potential co-formers was to first gather 
the required COSMO files containing the optimised sigma surfaces for use with the 
COSMOtherm software. An AZ in-house list of potential co-formers with files in the correct 
format was made available for the computational pre-screen. This left calculation of the API of 
interest’s, in this case ROY, sigma surface to be calculated in order for the screen to proceed. 
Using the COSMOconf software this was a simple yet computationally time-consuming task. The 
SMILES string for the compound was entered into the software which then performed density 
functional theory (DFT) calculations to produce the COSMO file of the compound for further use. 
This is computationally intensive and can take multiple hours or longer per molecule; for the 
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combination of types of molecules and computer hardware used in this work, a time of 12 to 24 
hours would be normal. 
Once the COSMO file exists it can be used thereafter, so this time-consuming step need only be 
performed once per molecule. Having access to the precompiled list of potential co-formers 
helped greatly in this respect as it is not inconceivable that with its size (342 compounds) and 
only moderate computational resources available, it could take over a year to recreate it from 
scratch. COSMOtherm was then employed to systematically work through the list, in each case 
calculating the enthalpy excess of interaction of co-former to API compared to the sum of 
interactions of API to API and co-former to co-former. The end result was a list which could be 
sorted by excess enthalpy allowing the more likely potential co-formers to be identified. 
A table containing the full list of co-formers with excess enthalpy calculated for the given 
stoichiometry with ROY as produced by COSMOtherm can be found in Appendix 4.1. 
 
4.3.1.2 Physical screen 
The procedure for the physical screening was based on the optimised parameters previously 
determined (as outlined in Chapter 3). Three sets of the physical screening process were 
performed using separate 96-well plates for the screen, one for each solvent tested (acetone, 
ethanol and hexane). For each set of the screening process, 25mg of ROY dissolved in a DCM 
solution was added to an equimolar amount of solid, previously weighed, potential co-former in 
48 wells of a borosilicate glass 96-well plate. After leaving the initial solvent to evaporate, 50µl 
of appropriate solvent was added to eight wells and the 8-tips of the ultrasonic probe were 
placed in these wells and sonicated at the power setting, and for the time, dictated by the results 
from the optimisation experiment, using a Sonics Vibra Cell 130W 20kHz ultrasonic processor. 
This process was repeated for the remaining wells and the whole process repeated a further two 
times replacing the solvent and sonication parameters as required; thereby completing the 
screening process in three solvents for 48 potential co-formers. The optimal parameters for each 
solvent varied slightly, for example a higher temperature was used with hexane. See Figure 4.9 
for a diagrammatic representation of this process along with example images of the plate after 
each step. 
Once all of the wells on the plate had undergone sonication a spatula was used to remove as 
much of the contents as possible into small sample vials, these had lids attached and were then 
shaken by hand to distribute the material before undergoing analysis.  
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Figure 4.9 Steps involved in the physical co-crystal screening process, represented diagrammatically (A to 
E) with example images of a plate after each step from the ROY screen. 
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4.3.2 FTIR analysis 
Infrared spectra for all of the samples from the screen as well as those of the individual starting 
components were obtained using the method detailed in Chapter 2 on approximately 5-10mg 
of material which had been removed from the well as described above. Analysis was carried out 
by manually comparing the spectra of the screen product for each ROY:co-former pair to those 
of the two pure compounds using BioRad Know-it-all spectral viewing software. As infrared 
spectroscopy is additive in nature, the peaks found in the two pure components should also be 
found in the spectrum of the product. Intermolecular bond formation between the molecules 
of the two constituent components, as is the case when a co-crystal forms, would cause slight 
variation in the intramolecular bond length of the interacting atoms. This change in bond length 
would lead to variation in the position of the peak detected allowing the identification of a hit 
in screening terms. 
A hit would indicate only that a change in bonding or bond behaviour had occurred and not 
necessarily that a co-crystal had formed. Follow up investigation would be needed to confirm 
the nature of the resultant material and this level of identification is adequate for the type of 
high-throughput screening being employed. The forming of a salt or even degradation of the 
starting components are examples of other transformations which could lead to changes in IR 
spectra and possibly misidentification of a hit as a co-crystal. Much less subtle changes in spectra 
would be expected in these cases though and it is likely that such material could be discounted 
as a potential co-crystal with minor further analyses. Analysis of samples in which the 
wavenumbers at which the peaks are positioned are the same as the parent compounds, with 
no peak shift occurring, would be suggestive of no form change occurring and would be 
considered not hits.  
 
4.3.3 Results 
The results of the FTIR analysis of the ROY screen are presented in Table 4.3 in the form of a list 
of peak maxima relating to two peaks present in all spectra. A full set of spectra are presented 
in Appendix 4.2. The two peaks at wavenumbers of approximately 3300 and 2220cm-1, were 
identified due frequent variation of these peaks between samples. The variations in peaks 
positions occur in all samples from the screen and are therefore related to a covalent bond of 
the ROY molecule rather than the co-formers. These slight variations suggest a solid-state form 
change but the lack of any peaks not accounted for in the spectra of the parent compounds 
indicates that covalent bonding within the two molecules has not been altered. The 
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wavenumbers listed in Table 4.3 are however, all explained by conversion of ROY polymorphs 
as the peak maxima observed are all commensurate (within the accuracy of the instrument 
used) with those obtained for one or more polymorphs of ROY (Figure 4.10).  
 
 
Figure 4.10 FTIR spectra of a number of ROY polymorphs and a combination thereof, focused around the 
peaks at a wavenumber of approximately 2220cm-1. 
 
The spectra displayed in Figure 4.10 are of polymorphs of ROY which were obtained by 
evaporation from different solvents. The reference wavenumbers for which Table 4.3 below 
compares the products of screening to determine indication of significant intermolecular 
interaction are derived from the spectra in Figure 4.10. Unfortunately, the identity of the 
polymorph for each of these spectra is not known. The polymorph samples were produced in 
small quantities by solvent evaporation and analysed immediately by FTIR as access to PXRD was 
not available at the time. It has not been possible to recreate all forms experimentally, neither 
has identification the polymorphs solely by their IR spectra as this is not available in the 
literature. The utility of the polymorph spectra for comparison to those of the screen products 
is not diminished though as they still allow the identification of ROY polymorphism regardless of 
the polymorph. 
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Table 4.3 Wavelengths of infrared absorption peak maxima obtained from the products of the ROY co-
crystal screen listed by co-former rank and including results from each of the repeats with different 
solvents (acetone, ethanol and hexane). 
Co-former 
~3300 peak 
(acetone) 
~2220 peak 
(acetone) 
~3300 peak 
(ethanol) 
~2220 peak 
(ethanol) 
~3300 peak 
(hexane) 
~2220 peak 
(hexane) 
Pentafluorophenol 3280 2209+2230 3280 2229 3303+3281 2210+2230 
Acesulfame 3280 2209+2230 3280 2210+2230 3280 2210+2230 
Oxalic acid 3282+3302 2209+2230 3279 2228 3281 2221+2230 
Quercetin 3280 2230 3279 2230 3280 2222+2230 
Sulfamic acid 3280 2229 3280 2229 3283 2221 
3,5-Dinitrobenzoic acid 3280 2210+2229 3280 2230 3281 2223+2229 
1,2,3-Trihydroxybenzene 3278 2229 3279 2229 3280 2230 
2,4-Dihydroxybenzoic acid 3280 2229 3280 2230 3282 2222+2230 
5-Nitroisophthalic acid 3278 2229 3278 2229 3281+3300 2210+2230 
Gallic acid 3277 2209+2229 3276 2228 3278 2209+2230 
tert-Butylhydroquinone 3280 2230 3279 2229 3281 2211+2230 
1-Hydroxy-2-naphthoic acid 3279 2230 3282+3300 2209+2230 3280 2216+2230 
Catechol 3278 2229 3279 2230 3282 2218+2230 
4-Hexylresorcinol 3280 2229 3281 2226 3334 2223 
5-Chlorosalicylic acid 3278 2229 3278 2229 3281 2222 
Resorcinol 3277 2209+2229 3279 2230 3306 2227 
3,5-Dihydroxybenzoic acid 3278 2209+2229 3279 2230 3281 2210+2230 
Orcinol 3279 2229 3279 2229 3292 2221 
2,5-Dihydroxybenzoic acid 3278 2229 3280 2210+2230 3280 2230 
o-Cresol 3280 2229 3278 2229 3283 2222 
3,4-Dihydroxybenzoic acid 3280 2230 3278 2229 3281 2229 
Thymol 3279 2229 3279 2229 3282 2222 
Phenol 3280 2229 3281 2230 3280 2221+2230 
Trimesic acid 3280 2210+2230 3280 2229 3280 2222+2230 
Indole 3279 2229 3300 2218 3297 2217 
3-Hydroxy-2-naphthoic acid 3279 2229 3280 2230 3280 2210+2229 
2,5-Xylenol 3280 2229 3279 2229 3280 2230 
Salicylic acid 3280 2230 3279 2229 3280 2210+2222+2229 
m-Nitrobenzoic acid 3282 2215+2229 3295 2215+2230 3295 2215 
Skatole 3278 2229 3280 2216+2230 3289 2216 
Hydroquinone 3279 2229 3279 2210+2229 3280 2223+2230 
Fumaric acid 3279 2229 3280 2209+2230 3279 2229 
Methyl gallate 3280 2230 3280 2230 3281+3303 2209+2230 
p-Cresol 3279 2229 3281 2209+2230 3279+3303 2210+2229 
Methanesulfonic acid 3279 2229 3282+3301 2209+2230 3280 2230 
p-Ethylphenol 3280 2210+2230 3281 2229 3280 2230 
3-Hydroxybenzoic acid 3280 2230 3278 2229 3281 2222+2230 
6-Hydroxy-2-naphthoic acid 3280 2230 3294 2218 3281 2222+2230 
Ethanesulfonic acid 3280 2229 3282+3301 2210+2223 3274 2214+2226 
Allocitric acid 3279 2230 3280 2229 3280 2222+2230 
p-tert-butylphenol 3280 2210+2230 3279 2209+2229 3280+3303 2210+2230 
3,4-Xylenol 3280 2230 3279 2209+2230 3280 2230 
2,6-Xylenol 3281+3301 2209+2230 3284+3302 2209+2230 3279+3301 2209+2229 
Citric acid 3280 2210+2230 3280 2211+2229 3278 2223+2229 
Etidronic acid 3279 2228 3279 2229 3279 2229 
4-Hydroxybenzoic acid 3280 2229 3281 2211+2229 3281 2219 
o-Phenylphenol 3279 2211+2229 3279 2229 3303 2208 
2-Oxo-3-phenylpropionic acid 3279 2229 3278 2229 3281 2215+2229 
 
Based on the analysis of the FTIR spectra, the screen applied to ROY found no evidence of the 
formation of co-crystals. This was not the desired outcome in relation to progress of the project 
but also not surprising as a degree of excess enthalpy from prediction is no guarantee of co-
crystallisation in vitro, due to lack of consideration of the purported lattice in the adopted 
computational approach. As this was the first time the optimised co-crystal screen had been 
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applied to a real candidate for co-crystallisation in full, investigation of the negative result was 
undertaken to prove robustness of the method. 
 
4.4 Further investigations of the top 10 predicted co-formers 
Further efforts to produce co-crystals of ROY from the top 10 predicted co-formers were 
undertaken. This involved applying different methods of manufacture: liquid assisted grinding 
(LAG), evaporative crystallisation and reaction crystallisation, which have previously been shown 
in the literature to be robust screening tools.145,146,147 
4.4.1 Methods 
4.4.1.1 Liquid assisted grinding 
Approximately 50mg of ROY was weighed out, and with an equimolar equivalent of potential 
co-former, placed in a mortar. An addition of 25μl of acetone occurred before grinding by hand 
with a pestle for 5 minutes. This process was repeated for each of the top 10 predicted potential 
co-formers for ROY. The products were analysed by FTIR. 
4.4.1.2 Evaporative crystallisation 
Saturated solutions in acetonitrile of each of the top 10 predicted potential co-formers for ROY 
were produced and 1ml of each placed in 10 vials. To each of these 1 ml of a saturated solution 
of ROY in acetonitrile was added. The vials were shaken and left to allow evaporation of the 
solvent. The products were analysed by PXRD. 
4.4.1.3 Reaction crystallisation 
Saturated solutions in acetonitrile of each of the top 10 predicted potential co-formers for ROY 
were produced and 1ml of each placed in 10 vials. Solid ROY was added to each vial until no 
further dissolution occurred and the contents of the vial left stirring. The vials were inspected 
periodically and to those where complete dissolution had occurred, more solid ROY was added. 
This continued for 10 days at which point all vials had visible solid material present and further 
dissolution did not occur. The remaining liquid was removed by pipette, and the material left for 
residual solvent to evaporate before analysis by PXRD. 
 
88 
 
4.4.2 Analysis 
4.4.2.1 FTIR spectroscopy 
FTIR analysis of the samples produced by LAG was carried out as for the products of the original 
screen and the results displayed in Table 4.4. A full set of spectra can be found in Appendix 4.3. 
With the exception of the ROY:pentafluorophenol sample, the results of the FTIR analysis of the 
products of LAG again showed no evidence of the formation of co-crystals as the position of the 
peaks were all accounted for in the spectra of the parent compounds or one or more of the 
polymorphs of ROY. The peak maximum of 2240cm-1 measured for the product of LAG of ROY 
and pentafluorophenol is slightly higher than that seen in any of the measured polymorphs. It is 
possible that it is due to the formation of a polymorph of ROY of which the IR spectrum was not 
available due to the similarity in peak profile, however as there is no evidence of this, the result 
would count as a hit in term of screening and further investigation would be warranted. 
In addition to the peaks listed, the product of LAG of ROY and oxalic acid displayed an IR 
absorption peak not present in the spectra of either of the two parent compounds. It was 
determined by comparison of the spectra of oxalic acid as received, after hydration during a DVS 
experiment and after LAG with ROY, that the explanation of the presence of this peak was due 
to hydration of oxalic acid during the manufacture of the sample (see Appendix 4.3 for IR 
spectra). 
 
Table 4.4 Wavenumber of IR absorption peaks associated with bonds affected by hydrogen bonding 
within ROY polymorphs measured in the product of LAG of ROY and the top ten predicted co-formers. 
Potential co-former 
Wavenumber of peaks associated with bonds affected by 
hydrogen bonding within ROY polymorphs 
~3300 peak ~2220 peak 
Pentafluorophenol 3281 2230+2240 
Acesulfame 3281 2230 
Oxalic acid 3280 2229 
Quercetin 3281 2230 
Sulfamic acid 3280 2230 
3,5-Dinitrobenzoic acid 3281 2230 
Pyrogallol 3279 2230 
2,4-Dihydroxybenzoic acid 3279 2230 
5-Nitroisophthalic acid 3280 2230 
Gallic acid 3279 2230 
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4.4.2.2 Powder X-ray diffractometry 
For the reaction crystallisation experiments, comparatively large quantities of ROY were 
required to be added to the solutions over the 10 days of stirring while dissolution continued, 
possibly multiple times that of the co-former in solution depending on the co-former’s solubility 
in acetonitrile. Were any of these binary systems to form a co-crystal, the procedure 
implemented would have given plenty of opportunity for the solution to access the required 
space of the ternary phase diagram for co-crystal formation before the precipitation of ROY.  As 
co-crystalline material did not form, as inferred from the PXRD analysis (Table 4.5), and due to 
the excess quantity of ROY used, this lead to the main constituent of the analysed material being 
ROY, effectively formed from an acetonitrile slurry. When carried out at room temperature, it is 
known that polymorph Y will be produced by a solution-mediated (i.e. slurry) conversion from 
any other form of ROY,141 hence the ubiquity of the Y polymorph powder pattern in the reaction 
crystallisation results.  
Table 4.5 Summary of PXRD analysis of samples from the evaporative and reaction crystallisation 
experiments. 
Potential co-former 
Polymorph(s) of ROY detected 
in PXRD analysis 
Peaks not associated with either 
ROY or pure co-former 
Reaction 
crystallisation 
Evaporative 
crystallisation 
Reaction 
crystallisation 
Evaporative 
crystallisation 
Acesulfame Y Y No No 
Oxalic acid Y ON No No 
Quercetin Y ON No No 
Sulfamic acid Y R No No 
3,5-Dinitrobenzoic 
acid 
Y ON No No 
Pyrogallol Y ON No Yes 
2,4-Dihydroxybenzoic 
acid 
Y ON No Yes 
5-Nitroisophthalic acid Y ON No No 
Gallic acid Y Y No No 
 
Pentafluorophenol melts slightly above room temperature and it was impossible to obtain an 
accurate diffractogram without a variable temperature stage. Pentafluorophenol was therefore 
excluded from the reaction and evaporative crystallisation experiments due to the lack of a 
means of comparison for which to analyse the experimental samples against. The full set of PXRD 
patterns for the reaction and evaporative crystallisation experiments can be found in Appendix 
4.4 and a summary of the results is presented in Table 4.5. 
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Many of the experimentally obtained PXRD patterns vary very slightly from the calculated ROY 
patterns for example small peak shifts to higher 2θ (approximately 0.1°) and occasionally 
comparatively larger peaks than those in the calculated pattern. These discrepancies can be 
explained in all cases by the effects of zero-point error of the diffractometer and preferred 
orientation. The diffractograms for the samples from the evaporative crystallisation of ROY with 
pyrogallol and 2,4-dihydroxybenzoic acid contain peaks at positions not observed in either 
parent material which signifies the presence of a new form. In the case of ROY and pyrogallol, 
the new peaks were found to match those of pyrogallol tetartohydrate (pattern calculated from 
CSD entry QQQBKD02) as shown in Figure 4.11. 
 
 
 
Figure 4.11 PXRD patterns of the experimental samples of ROY and pyrogallol from reaction 
crystallisation (green) and evaporative crystallisation (pink), pyrogallol (blue), along with the calculated 
patterns of ROY polymorphs: Y (yellow) and ON (orange) and pyrogallol tetartohydrate (purple) for 
comparison. 
 
The new peaks in the powder pattern of the evaporative crystallisation product of ROY and 2,4-
dihydroxybenzoic partially match those of polymorph ON of ROY however there are two 
unexplained peaks between 8 and 10° 2θ (Figure 4.12) which render this a hit from a co-crystal 
screen perspective. 
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Figure 4.12 PXRD patterns of the experimental samples of ROY and 2,4-dihydroxybenzoic acid from 
reaction crystallisation (green) and evaporative crystallisation (pink), 2,4-dihydroxybenzoic acid (blue), 
along with the calculated patterns of ROY polymorphs: Y (yellow) and ON (orange) for comparison. 
 
4.4.2.3 Differential scanning calorimetry 
In addition to IR analysis, the products of LAG were also analysed by DSC employing the standard 
heat/cool/heat method detailed in Chapter 2. Nine of the 10 products of LAG displayed 
unremarkable thermal recrystallization behaviour, however the LAG product of ROY and 
pyrogallol stood out. Pure ROY and pyrogallol both show poor amorphous stability. Pyrogallol 
crystallises on cooling from melt and ROY crystallises during the second heating cycle (class (I-A) 
and class (II) materials following the classification system as described by Baird et al.148 
respectively), the product of the grind of both materials does not crystallise and remains in 
amorphous form throughout the temperature range tested. This suggests that an amorphous 
form was produced on cooling and this remained stable until at least 150°C resulting in a 
material categorised as class (III); producing a co-amorphous material.149 The second heating 
cycles for the two parent components and the product of the 1:1 molar ratio grind are shown in 
Figure 4.13. (See Appendix 4.5 for a full set of plots of initial heating, cooling and second heating 
cycles for all ROY:co-former pairs). This behaviour differs from all other ROY:co-former 
combinations, as they all crystallise either on cooling (class (I)), on the second heating phase 
(class (II)), or in one case both, as shown in Table 4.6. 
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Figure 4.13 Second heating phase DSC curves of pyrogallol (red), ROY (blue) and ROY:pyrogallol 1:1 grind 
(green). Peak onset temperatures displayed. Presence of Tg highlighted in inset. 
 
 
Table 4.6 Summary of the crystallisation behaviour of pairs of ROY and the top 10 predicted co-formers. 
Potential co-former 
Cycle in which crystallisation occurs during DSC of 
the grind of the respective co-former with ROY 
Pentafluorophenol Second heating 
Acesulfame Cooling 
Oxalic acid Cooling 
Quercetin Second heating 
Sulfamic acid Cooling 
3,5-Dinitrobenzoic acid Cooling 
Pyrogallol None 
2,4-Dihydroxybenzoic acid Cooling and second heating 
5-Nitroisophthalic acid Cooling 
Gallic acid Cooling 
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4.4.3 Summary 
After much more thorough screening of the top ten predicted co-formers for ROY, only two 
potential hits were encountered – pentafluorophenol using LAG and 2,4-dihydroxybenzoic acid 
with evaporative crystallisation. With the high-throughput nature of the original co-crystal 
screen and the significant extra effort required by employing three less time-efficient methods, 
it would be unreasonable to expect to incorporate this level of extensive investigation into the 
co-crystal screening process. Given that the optimised co-crystal screen passed validation 
testing by identifying form change in all of the test samples (Chapter 3) and later found 23 hits 
in a co-crystal screen of ornidazole (Chapter 6), and that to the best of the author’s knowledge 
there are no known co-crystals of ROY, it is suggested that the optimised screen is fit for purpose 
and that the resources required to find a co-crystal of ROY, vast (with the caveat of serendipity). 
Lack of access to an X-ray diffractometer at the time of analysis of the LAG experiment prevented 
immediate follow up of the hit, and interest in the ROY:pyrogallol thermal behaviour led to focus 
on this system for further investigation.  
 
4.5 ROY:pyrogallol investigations 
As a unique behaviour compared to all other tested co-formers was detected in the ROY-
pyrogallol pairing, work to further examine this interaction was undertaken. 
4.5.1 Hot-stage microscopy – Kofler technique 
One further experiment was carried out to confirm that a co-crystal of ROY and pyrogallol would 
not form from the melt. A method for using hot-stage microscopy to probe for co-crystalline 
forms, perhaps best known as the Kofler technique, was employed. The component with the 
higher melting point, in this case pyrogallol was first melted and allowed to cool and solidify on 
a glass microscope slide. The second component (ROY) was then placed on the other side of the 
slide and heated above its melting point but below that of the first component. This allowed the 
molten ROY to come into contact with the solid pyrogallol causing solubilisation of a small 
portion of the solid component and in doing so creating a zone of mixing. Within this zone of 
mixing a concentration gradient is formed with the concentration of each component decreasing 
as the distance from its original position towards the other component increases. The slide with 
both components on was placed on a hot-stage and viewed using cross polarised light 
microscopy (with photomicrographs captured every 20 second) while cooling until all of the 
material had crystallised and then heating following the method listed in Table 4.7. 
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Table 4.7 Details of the hot-stage method implemented. 
Method 
section 
Temperature Rate 
Terminating 
at 
Purpose 
1 Increasing 10°C/min 50°C Allowed time to ensure complete 
crystallisation had occurred before 
beginning temperature ramp. 2 Decreasing 1°C/min 35°C 
3 Increasing 1°C/min 160°C 
Slow increase of temperature to 
above melting points to detect 
melting of separate phases. 
 
 
Figure 4.14 contains eight photomicrographs (labelled A to H), each depicting a snapshot of the 
experiment at key points. In all of the photomicrographs the blue coloured crystalline material 
is pyrogallol, the orange-red coloured is ROY, and any black area is molten material, either ROY 
or pyrogallol due to viewing under cross polarised light. Due to the microscope slide being 
moved directly from a hot plate to the hot-stage, the temperature recorded for the first three 
(A-C) micrographs may be inaccurate as the slide may have been hotter than the stage at this 
point. 
In micrograph A, there is solid pyrogallol (blue area) and molten ROY (black area); the orange-
green area at the interface of the two phases is where the molten ROY had caused solubilisation 
of the pyrogallol and a zone of mixing had formed. Micrograph B shows the point at which ROY 
began to crystallise from the melt, nucleating from the solid material at the edge of the zone of 
mixing. By micrograph C, most of the molten ROY had crystallised and between C and D, 
complete crystallisation occurred and the hot-stage began increasing the temperature at 
1°C/min from 35°C. At around 90°C ROY began to melt from the zone of mixing outward (E), and 
by approximately 103°C it had almost completely melted (F). During this time, the pyrogallol also 
started to melt, again, from the zone of mixing outwards (G) and by 132°C it too had completely 
melted (H). Were co-crystalline material present, it would be expected that it would be 
observable, between the time of micrographs E and G, as a separate phase of crystalline material 
bordered by molten liquid. This was not observed and as such indicates that a co-crystal of ROY 
and pyrogallol is not readily obtainable from the melt. 
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Figure 4.14 Micrographs of ROY and pyrogallol under cross polarised light over the course of the Kofler 
technique experiment. 
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4.5.2 Amorphous stability 
Having determined that co-crystallisation of ROY and pyrogallol is not readily achievable but that 
presence of pyrogallol leads to the stabilisation of ROY in the amorphous form, further 
investigation into the nature of this interaction commenced. 
The glass transition temperatures for ROY and for the ROY:pyrogallol 1:1 grind, shown in Figure 
4.13 and in more detail in Appendix 4.6, vary by less than 4°C, and as such suggest that a change 
in molecular mobility great enough to affect molecular translational ability is not caused by the 
presence of pyrogallol. Three samples of ROY:pyrogallol grind were produced with varying 
pyrogallol content to see if smaller quantities of pyrogallol could still improve amorphous 
stability, potentially indicating nucleation inhibition as the source of the phenomenon. The 
samples were produced by grinding the following ratios of ROY and pyrogallol: 1:1 molar ratio, 
10% w/w and 1% w/w pyrogallol. The initial heating DSC traces for these samples are displayed 
in Figure 4.15 and it is worth noting that an endothermic melting peak at around 88.5°C is 
present in all three samples, with decreasing intensity as the pyrogallol content is reduced. The 
cooling and second heating cycles for the three samples are in Appendix 4.7 and show that the 
ROY:pyrogallol grinds containing 10%w/w and 1%w/w pyrogallol display similar behaviour to 
the 1:1 grind in that crystallisation does not occur during the cooling cycle and that glass 
transitions are observed. During the second heating phase, exothermic events occur for the two 
samples with lower pyrogallol content indicating that complete stabilisation of the amorphous 
phase did not occur.  
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Figure 4.15 Initial melting points for grinds of varying ratio of ROY:pyrogallol content. 
With the presence of smaller quantities of pyrogallol failing to prevent crystallisation from the 
amorphous phase and having a proportional effect on the initial endothermic peak, the 
significance of its relative content in the system is clear. To determine whether the amorphous 
stability elicited by the presence of the pyrogallol was related to its stoichiometric ratio with 
ROY, further ROY:pyrogallol samples were produced at 5% w/w increments from 0% to 100%, 
representative thermograms of the second heating cycle are shown in Figure 4.16. The initial 
melting point varies very little over the range 5% to 95% w/w pyrogallol (Figure 4.17) and 
therefore indicate that this is not a eutectic system, as, if it were, a single lower melting point at 
the eutectic composition would be expected.74  
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Figure 4.16 Second heating phase DSC curves of ROY (0%), pyrogallol (100%) and varying compositions 
of ROY:pyrogallol in 5% w/w increments. The red box highlights the range of compositions in which the 
amorphous form is stabilised. This equates to 1:1 stoichiometry. 
 
 
 
Figure 4.17 Initial melting points for grinds of varying ratios of ROY:pyrogallol content.  Melting points 
range between 86.9 to 88.5°C for 5-95% w/w pyrogallol. 
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When looking at the second heating cycle (Figure 4.16) at the 1:1 composition the lack of any 
endothermic or exothermic events in the given temperature range suggest the 1:1 stabilisation 
rather than a small amount of pyrogallol inhibiting the crystallisation of ROY. The approximate 
boundaries of this range (25% to 35% w/w pyrogallol content) equate to molar ratios (in the 
form 1 ROY to X pyrogallol) of 0.69 and 1.11 respectively. These data suggest that with a lower 
ratio of pyrogallol to ROY, there is excess ROY behaving as pure ROY and uninfluenced by the 
presence of pyrogallol. The formation of intermolecular interactions between individual 
molecules of ROY and pyrogallol in a one to one manner would give rise to such behaviour.  
 
4.5.3 Timescale of amorphous stability 
The timescale of the stability of the ROY:pyrogallol mix was also investigated by DSC and PXRD.  
4.5.3.1 Differential scanning calorimetry 
The DSC traces involved in this investigation are presented in Figure 4.18, where the blue DSC 
trace is of the initial ground sample of 1:1 ROY:pyrogallol, which was sealed within a standard 
DSC pan and subjected to the same heat-cool-heat method as previous samples. This sample 
was left sealed at RT for approximately 65 hours and then a cool-heat method (cool at 10°C/min 
from 25°C to -90°C then heat at 10°C/min to 150°C) which gave the green DSC trace. As is 
evident, no crystallisation has occurred and the sample remains in the amorphous state. 
Another ground sample of 1:1 ROY:pyrogallol was placed in an open Tzero aluminium DSC pan 
(no lid added) and the heat-cool-heat method run giving rise to the red trace. This sample was 
placed in a 75% relative humidity environment and was visually seen to crystallise immediately, 
with the purple trace generated around 18 hours later (cool-heat method). This evidence 
suggests that crystallisation from the amorphous phase is mediated by an increased humidity 
presumed to be due to the plasticising effect of water.149,150 
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Figure 4.18 Heating phase DSC curves of ROY:pyrogallol 1:1 grind: in sealed DSC pan (blue), after storage 
in sealed DSC pan for approximately 65 hours (green), in an open DSC pan (red) and after storage at 75% 
RH in an open DSC pan (purple). Presence of Tg in all samples except that stored at 75% RH (purple) are 
highlighted in the inset. 
 
4.5.3.2 Powder X-ray diffractometry 
Samples were also prepared of ROY and the 1:1 co-amorphous mixture and stored at ambient 
conditions and monitored for crystallinity by PXRD, the results of which are displayed in Figures 
4.19 and 4.20. 
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Figure 4.19 Evolution of crystallinity over a 70-hour period from an amorphous droplet of pure ROY, scan 
lengths of approximately 10 minutes at 30 minute intervals for two hours and a final scan after 70 hours. 
 
 
Figure 4.20 Evolution of crystallinity over a 70-hour period from an amorphous droplet of ROY:pyrogallol 
1:1 grind, scan lengths of approximately 10 minutes at 30 minute intervals for two hours and a final scan 
after 70 hours. 
 
In this case, crystallisation appears to have occurred earlier in the ROY sample than the co-
amorphous mixture. In the ROY sample, crystallinity is seen at 15 minutes with no change in 
crystallinity at 70 hours, as seen by the lack of change in patterns between these times. In 
contrast, the ROY:pyrogallol data suggests a gradual increase in crystallinity from the 15-minute 
scan to at least 90 minutes. 
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4.5.3.3 Summary 
The stability of the co-amorphous ROY:pyrogallol material was seen to be highly dependent on 
atmospheric moisture conditions. Indeed, samples stored under dry nitrogen flow, or in a lidded 
DSC pan were seen to be stable for up to 65 hours. It was not possible to verify this through 
vapour sorption study due to the fast recrystallization that was seen on the instrument, but 
storage at 75% RH 25°C showed immediate visual recrystallization, which was confirmed by DSC 
at 18 hours (Figure 4.18). However, samples exposed to atmospheric conditions were only stable 
for around 30 minutes, as determined by PXRD analysis (Figure 4.20) and compared to pure ROY 
this is a significant improvement, as complete recrystallization from the amorphous form was 
seen after 15 minutes (Figure 4.19). 
4.5.4 Intermolecular interaction investigation 
Having determined that intermolecular interactions between individual molecules of ROY and 
pyrogallol in a one to one manner are likely to be the cause of the stabilisation seen in the co-
amorphous material, further investigation into the interaction was undertaken. This involved 
the use of both computational and physical methods. 
4.5.4.1 Computational 
In order to explore the nature of the interactions between ROY and pyrogallol in the amorphous 
form, hydrogen bond propensity prediction and an amorphous cell were produced, with the 
assistance of Dr David Berry (Durham University). The hydrogen bonding propensity of ROY, with 
the addition of aromatic hydroxyl to represent the potential pyrogallol interaction, was 
calculated using the logit hydrogen bonding propensity (LHP) model.151 The calculations resulted 
in an area under ROC curve of 0.86. (See Appendix 4.8), and predicted strong hydrogen bonds 
between molecules of ROY only (Table 4.8). 
Table 4.8 Summary of predicted hydrogen bonding. 
Type of 
interaction 
Donor Acceptor Propensity 
Intermolecular N1 of sec amine 1 N3 of cyano 0.31 
Intermolecular N1 of sec amine 1 O2 of ar nitro 0.25 
Intermolecular N1 of sec amine 1 O1 of ar nitro 0.19 
Intermolecular N1 of sec amine 1 S1 of cyclic thioester 0.01 
Intramolecular N1 O1 0.89 
Intramolecular N1 O2 0.89 
Intramolecular N1 N3 0.09 
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Figure 4.21 Amorphous cell displaying all 200 molecules made up of 100 pyrogallol and 100 ROY 
molecules. 
Further modelling utilised a 200-molecule amorphous cell, generated in Materials Studio 
(Dassault Systemes, BIOVIA Ltd.). The cell of 100 of each molecule (1:1 ratio ROY and pyrogallol) 
was produced with charges defined by Gasteiger, utilising a Dreiding forcefield with molecular 
conformations taken from the entries in the CSD. This was allowed to minimise yielding the 
amorphous cell displayed in Figure 4.21, which displayed no change to the N-H bond of ROY, but 
changes to the environment around it. The hydrogen bonding observed within the amorphous 
cell is shown in Appendix 4.9 and is summarised in Table 4.9. 
Table 4.9 Number of strong H-bond contacts in the amorphous cell between molecules. 
*The interactions between ROY and pyrogallol were supported by a total of 44 pyrogallol molecules, i.e. 
some molecules supported more than one interaction. A further 32 pyrogallol molecules bonding self:self 
and 24 taking no part in any strong hydrogen bonding. 
Molecule (group) 1 Molecule (group) 2 Number 
ROY (nitro) ROY (amine) 100 (all) intramolecular bond 
Pyrogallol (OH) Pyrogallol (OH) 32 
ROY (nitro) Pyrogallol (OH)* 20 
ROY (cyano) Pyrogallol (OH)* 32 
ROY (amine) Pyrogallol (OH)* 4 
ROY (sulfur) Pyrogallol (OH)* 8 
 
These results correlate with the H-bond propensity prediction, as all ROY molecules possess the 
characteristic intra-molecular bond (propensity) and pyrogallol would be expected to alter the 
environment of this through its interaction.  
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4.5.4.2 FTIR spectroscopy 
FTIR analysis was carried out using the standard method detailed in Chapter 2 and the spectra 
obtained for ROY and the ROY:pyrogallol 1:1 grind, in both amorphous and crystalline forms are 
displayed in Figure 4.22. 
 
Figure 4.22 FTIR spectra of ROY (blue), ROY:pyrogallol 1:1 grind (green) and amorphous ROY:pyrogallol 
1:1 grind (orange). Focused area of wavenumbers 3200-3400 cm-1 shown in inset. 
 
Figure 4.22 displays the FTIR spectra of an amorphous sample of the ROY:pyrogallol 1:1 grind 
and a peak shift corresponding to the N-H bond in ROY is apparent. A possible rationale, 
supported by the amorphous cell prediction, could be that of pyrogallol forming intermolecular 
bonds in proximity to the N-H bond of ROY causing the slight alteration in environment of the 
N-H bond. Such interactions in co-amorphous materials have previously been reported.64 
Polymers such as PVP, PVPVA and HPMC are often used for stabilising the amorphous API,54 
however this can lead to certain issues, for example side effects and limited drug loading of the 
formulation.61 With ROY being the model API, a comparison between a traditional polymer 
stabilisation of the amorphous API using PVP was compared to the use of the small molecule, 
pyrogallol, as the stabilising agent, with the aim of addressing these issues. 
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4.5.5 Polymer comparison 
Having discovered the co-amorphous nature of the ROY:pyrogallol system, exploration of its 
possible utility was considered. Due to the inherent improvement in solubility of the amorphous 
form of drugs, development of formulations utilising amorphous API has been of interest for 
poorly soluble drugs.54,55 Often these formulations require the inclusion of stabilising agents to 
prevent the crystallisation of the API within a timescale which would prevent adequate shelf life 
of the product.152  
 
4.5.5.1 Method 
In order to compare the pyrogallol-stabilised amorphous ROY form to a more traditional 
polymer stabilised form, a grind of ROY with polyvinylpyrrolidone (PVP) was created. This was 
at both a typical 10%w/w drug loading, with regards to ROY, and also at a 1:1 molar ratio, based 
on the molecular weight of the PVP monomer. These samples were analysed by DSC employing 
the standard heat/cool/heat method and PVP and pyrogallol were analysed by DVS, again 
employing the standard method, both detailed in Chapter 2. 
 
4.5.5.2 Differential scanning calorimetry 
Both of these ROY:PVP ratios led to stabilised amorphous forms being produced. The second 
heating cycle DSC traces are shown in Figure 4.23 and the lack of any exothermic peaks, having 
also been none in the previous two cycles (Appendix 4.10), is indicative of the stabilised 
amorphous form. The similarity of the ROY:pyrogallol sample to the behaviour seen with the 
ROY:PVP grind adds further evidence to the possibility of replacing polymer with small molecule 
stabilising agents in some situations. 
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Figure 4.23 Second heating phase DSC curves of ROY:pyrogallol 1:1 grind (green), ROY:PVP 1:1 grind 
(teal) and ROY:PVP 10%w/w grind (maroon). 
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4.5.5.3 Dynamic vapour sorption 
 
Figure 4.24 Isotherms (top) and change in mass plot (bottom) for pyrogallol. N.B. see scale. 
 
In the initial sorption cycle, relative humidity above 80% displays moisture uptake indicative of 
an absorption of ¼ mole of water seen in Figure 4.24, this is followed by very little change against 
humidity in the following desorption/sorption cycles. This indicates that the pyrogallol sample 
hydrated from its initial form. In this case, there is approximately 3.3% change in mass 
correlating to the tetartohydrate being formed.153,154 
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Figure 4.25 Isotherms (top) and change in mass plot (bottom) for PVP. N.B. see scale. 
 
PVP displays much greater hygroscopicity across the humidity range tested (Figure 4.25) than 
that of pyrogallol. Use of a material which displays greater resistance to moisture uptake, such 
as pyrogallol, especially at lower humidity levels, may prove beneficial for use as an amorphous 
stabilising agent where the uptake of water can negatively impact the stability of the phase. 
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4.5.5.4 Summary 
The possibility of replacing polymer with small molecule stabilising agents when developing 
formulations with amorphous API could potentially allow greater drug loading and the use of 
compounds with more suitable side effect profiles. With the example of pyrogallol showing 
reduced moisture uptake in comparison to PVP, the possibility of further reducing the chance of 
crystallisation from the amorphous form by careful selection of co-former is highlighted. 
 
4.6 Conclusions 
In this work, the application of an optimised co-crystal screen, utilising computational tools to 
predict the most energetically favourable co-formers, has led to the discovery of no co-crystals, 
but has highlighted a 1:1 interaction between ROY and pyrogallol. This interaction stabilises ROY 
in the amorphous form, although this stability is moisture dependent. Although predictive 
technology exists for single component amorphous phases,155 currently no predictive method 
for co-amorphous phases has been suggested and all screening is by trial and error. The 
discovery of this behaviour stemmed from a screen of 342 co-formers, in three stoichiometries, 
in which predicted interaction had been ranked highly in the gas phase. This suggests that co-
crystal screening approaches can be modified to enable study into co-amorphous phases and 
that ‘negative’ co-crystal hits should be investigated for alternative utility as co-amorphous 
materials. Such an approach would enable a broader palate of pharmaceutical development 
options and improve process efficiency. 
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Chapter 5 – Investigation into co-amorphous 
interactions 
 
5.1 Introduction 
Having made the discovery of the co-amorphous behaviour of the combination of ROY and 
pyrogallol in the previous chapter, further work to better understand this behaviour, and its 
applicability beyond pyrogallol, was explored and will be presented in this chapter. To aid in 
understanding of the interactions leading to the stabilisation of the amorphous material, 
experiments employing analogous compounds to pyrogallol were combined with ROY in the 
same manner. These compounds included other trihydroxybenzenes (1,2,4-benzenetriol and 
phloroglucinol) as well as dihydroxybenzenes (resorcinol, catechol and hydroquinone) to 
investigate the effect of position of the hydroxy functional group and two dihydroxycylohexanes 
(1,2- and 1,4-cyclohexanediol) to probe the effect due to the presence or lack of aromaticity in 
the co-former. 
To summarise the steps of the investigation; after producing the ROY:co-former grinds using the 
same method as that for ROY:pyrogallol in Chapter 4, the materials were first analysed by PXRD 
to check for co-crystallisation or other form change. The ROY:co-former samples as well as the 
pure compounds were analysed by DSC to allow comparison between their thermal behaviour 
and that seen in the ROY:pyrogallol system. Consideration of the structure of the pyrogallol 
analogues and the outcome of the DSC experiments allowed conclusions relating the structure 
to the stabilisation interactions. A brief comparison of stability of the co-amorphous systems 
was also conducted. 
 
5.2 Production and analysis of ROY:co-former pairs 
5.2.1 Method 
The required amount of ROY to achieve 25mg of a 1:1 molar ratio with each specific co-former 
was weighed out, and with the equimolar equivalent of potential co-former, placed in a mortar 
before grinding by hand with a pestle for five minutes. The resultant materials were 
characterised as described below. 
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5.2.2 Characterisation 
5.2.2.1 Powder X-ray diffractometry 
Before using thermal techniques to investigate the amorphous stabilisation behaviour of the 
ground ROY:co-former materials, they were first analysed by PXRD to confirm that in their 
current form they consisted of a physical mixture of the two parent compounds and no form 
change had taken place during the grinding process. Figure 5.1 is an example PXRD pattern 
comparison between the patterns of pure ROY (red), pure co-former, in this case 1,2,4-
benzenetriol (blue) and the 1:1 molar ratio grind of these two compounds (green). The 
comparison shown is representative of all but one of the other co-formers in that all of the peaks 
observed are present in either of the parent components and therefore not indicative of form 
change. The only exception is that of the comparison of ROY and phloroglucinol, in which either 
a new peak has been detected or a peak shift occurred and there is a lack of presence of 
relatively small but still significant peaks which feature in the PXRD pattern of pure 
phloroglucinol (Figure 5.2, peaks at 17.25° 2θ, green pattern and 14.15 and 19.80° 2θ blue 
pattern). These differences in PXRD patterns indicate the formation of a new form, which is 
discussed in the TGA section below. A full set of PXRD patterns is presented in Appendix 5. 
 
 
Figure 5.1 PXRD patterns for ROY (red), 1,2,4-benzenetriol (blue) and the product of the grind of a 1:1 
molar ratio of these two compounds (green). 
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Figure 5.2 PXRD patterns for ROY (red), phloroglucinol (blue) and the product of the grind of a 1:1 molar 
ratio of these two compounds (green). 
 
Figure 5.3 compares the experimentally measured PXRD patterns of phloroglucinol and the 
product of the grind of a 1:1 molar ratio of ROY and phloroglucinol to a predicted pattern of 
anhydrous phloroglucinol and a predicted pattern of phloroglucinol dihydrate.156 The predicted 
patterns were produced using Mercury software and are based on the CIF files of the CSD entries 
for phloroglucinol (PHGLOL) and phloroglucinol dihydrate (PHGLOH04) as these were the only 
structures determined from a room temperature experiment. The experimental phloroglucinol 
pattern is very similar to that of the predicted anhydrous phloroglucinol pattern but clearly also 
contains peaks specific to the dihydrate, for example the two peaks at around 13° 2θ. The 
presence of these peaks indicates that there is some amount of phloroglucinol dihydrate 
impurity within the phloroglucinol sample. The pattern for the product of the grind of a 1:1 
molar ratio of ROY and phloroglucinol obviously additionally contains peaks caused by the 
presence of ROY. However, the phloroglucinol dihydrate characteristic peaks are also more 
prominent in this sample than those of the experimental phloroglucinol sample, suggesting 
greater conversion to phloroglucinol dihydrate than in the phloroglucinol sample. The more 
prominent phloroglucinol dihydrate peaks may potentially be causing peak overlap at around 
17.25° 2θ explaining the presence of this peak which is not present in either of the pure ROY or 
phloroglucinol samples. 
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Figure 5.3 PXRD patterns for phloroglucinol (blue), ROY (red), the product of the grind of a 1:1 molar 
ratio of ROY and phloroglucinol (green), a predicted pattern of phloroglucinol (orange) and a predicted 
pattern of phloroglucinol dihydrate (pink). 
 
5.2.2.2 Dynamic vapour sorption analysis of phloroglucinol 
Due to the presence of the hydrated form of phloroglucinol being detected by PXRD, a sample 
was analysed by DVS following the standard method detailed in Chapter 2, in order to better 
understand its hydration behaviour in relation to the investigations with ROY. 
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Figure 5.4 Isotherms (top) and change in mass plot (bottom) for phloroglucinol. 
The percentage mass gain and loss during the sorption and desorption cycles of the DVS 
isotherm plot for phloroglucinol (Figure 5.4) is consistent with the formation of the dihydrate 
from anhydrous phloroglucinol. The relative humidity range over which the transition between 
anhydrous and dihydrate occurs is within that often measured in the laboratory, however 
dehydration is not seen above approximately 20% relative humidity. Due to the low RH required 
for dehydration from the dihydrate to occur this is very unlikely to have taken place in the 
laboratory. These findings are in line with the analysis from PXRD and TGA. 
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5.2.2.3 Thermogravimetric analysis of phloroglucinol samples 
TGA profiles were recorded following the standard TGA method detailed in Chapter 2 for 
phloroglucinol and the product of the grind of the 1:1 molar ratio of ROY and phloroglucinol due 
to the suspected presence of a hydrated form of phloroglucinol from the PXRD and DVS analysis. 
 
Figure 5.5 TGA profile for the product of the grind of the 1:1 molar ratio of ROY and phloroglucinol. 
Figure 5.5 shows the TGA profile for the product of the grind of the 1:1 molar ratio of ROY and 
phloroglucinol. A mass loss of 8.188% occurs over the temperature range of approximately 25°C 
to 50°C. This equates to a molecular mass of 31.56 for each pair of ROY and phloroglucinol 
molecules, or 126.22 for every four pairs. The molecular weight of water is 18.02 and given that 
the grinding of materials occurred in a standard laboratory where relative humidity often falls 
within a 20 to 60% range it is possible from this evidence that a 4:4:7 ROY:phloroglucinol:water 
hydrate has formed. A potentially more likely scenario is that the dihydrate of phloroglucinol 
had formed leaving a small amount of anhydrous phloroglucinol which would explain the ratio 
of water molecules calculated from the mass loss being closer to seven than eight per four ROY 
and phloroglucinol molecules. The endothermic event in the DSC trace is however not consistent 
with this, and it is possible that, as necessarily a different sample must be used, as that in the 
TGA will be destroyed, the samples may have varying amounts of hydrated phloroglucinol 
present. 
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Figure 5.6 TGA profile for phloroglucinol. 
The TGA profile for phloroglucinol (Figure 5.6) shows a mass loss of 20.58% which is lower than 
expected if the sample was the dihydrate form (22.22%), but obviously more than if it were the 
anhydrous form. Given the results from PXRD and DVS it is likely that due to RH in the laboratory 
fluctuating within a range encompassing that in which hydration of anhydrous phloroglucinol 
occurs, partial hydration of the sample led to the intermediate mass loss during the TGA 
experiment. This would also explain the extra PXRD peaks observed and thereby indicate that 
co-crystalline material was not formed.  
5.2.2.4 Differential scanning calorimetry 
The pure co-formers and the products of the grind of a 1:1 molar ratio of ROY and the co-formers 
were analysed by DSC employing the standard heat/cool/heat method detailed in Chapter 2. 
This analysis was undertaken to allow comparison between their thermal behaviour and that 
seen in the ROY:pyrogallol system. Where necessary the sample was prepared by light grinding 
by hand to achieve a more uniform particle size, in the case of these samples this was only done 
for 1,2-cyclohexanediol. The maximum temperature for the DSC method was set slightly above 
the melting point for the sample based on the literature values for the pure co-formers and for 
the products of grinding with ROY, where this was not suitable due to degradation occurring, a 
repeat DSC analysis was carried out with the maximum temperature set in excess of the melting 
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point observed in the original analysis but below the temperature where degradation occurred. 
The samples which required the repeated analysis (and the maximum temperature set for the 
DSC method) were: ROY:hydroquinone (110°C), ROY:1,2-cyclohexanediol (120°C), ROY: 1,4-
cyclohexanediol (110°C) and ROY:phloroglucinol (120°C). 
The figures below group the DSC traces into pure co-formers (Figures 5.7-5.9) and products of 
the grind of a 1:1 molar ratio of ROY and the co-formers (Figures 5.10-5.12). These are further 
arranged by the cycle of the DSC method and the traces for pure ROY are included in all figures 
for comparison. i.e. Figure 5.7 shows the first heating cycle, Figure 5.8 cooling etc. 
 
Figure 5.7 DSC traces for the initial heating cycle of pure ROY (black) and pure co-formers: phloroglucinol 
(dark blue), 1,2,4-benzenetriol (blue), hydroquinone (purple), resorcinol (red), catechol (brown), 1,2-
cyclohexanediol (green) and 1,4-cyclohexanediol (olive). 
 
The DSC trace for resorcinol displays a small endothermic peak just before a much larger one. 
There are two polymorphs of resorcinol157 and it is possible that a small amount of the 
polymorph with the lower melting point was present in the sample leading to the initial melting 
peak. It is also possible that there was a larger amount of the lower melting point polymorph 
which melted while simultaneously some of the now molten resorcinol crystallised as the higher 
melting point polymorph before melting again at a higher temperature thereby leading to a 
smaller endothermic peak at the lower melting point temperature. Varying the heating rate 
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would be required to better separate the endothermic events. The minor endotherm in the 
initial heating cycle of 1,2-cyclohexanediol (Figure 5.7) is possibly due to a phase transition, 
evidence of which has been previously reported.158 The second endothermic peak in the second 
heating cycle of 1,2-cyclohexanediol (Figure 5.9) appears to be an artefact in the measurement 
due to the shape of the trace. 
 
Figure 5.8 DSC traces for the cooling cycle of pure ROY (black) and pure co-formers: phloroglucinol (dark 
blue), 1,2,4-benzenetriol (blue), hydroquinone (purple), resorcinol (red), catechol (brown), 1,2-
cyclohexanediol (green) and 1,4-cyclohexanediol (olive). 
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Figure 5.9 DSC traces for the second heating cycle of pure ROY (black) and pure co-formers: 
phloroglucinol (dark blue), 1,2,4-benzenetriol (blue), hydroquinone (purple), resorcinol (red), catechol 
(brown), 1,2-cyclohexanediol (green) and 1,4-cyclohexanediol (olive). 
 
Table 5.1 Data obtained from DSC analysis of the pure co-formers recording the temperature and type of 
events observed in the thermograms and the corresponding class of material. Pure ROY and pyrogallol 
data are included for comparison. 
Material 
Observations in cycle (Endo/Exo/Tg at temperature (°C)) 
Class Initial 
heating 
Cooling Second heating 
ROY Endo 109.9 - 
Tg -9.4, Exo 58.5, Endo 97.6, 
Endo 106.4 
II 
Pyrogallol Endo 132.5 Exo 100.4 Endo 132.5 I 
1,2,4-Benzenetriol Endo 140.9 - Tg -0.2, Exo 35.9, Endo 140.4 II 
Phloroglucinol Endo 220.3 Exo 132.1 Endo 205.1 I 
Catechol Endo 104.3 Exo 74.4 Endo 104.0 I 
Resorcinol 
Endo 105.4, 
Endo 109.7 
Exo 29.6 Exo 6.3, Exo 16.7, Endo 109.6 I 
Hydroquinone Endo 172.5 
Exo 167.2, 
Exo 161.2 
Endo 171.9 I 
1,2-Cyclohexanediol 
Endo 67.7, 
Endo 103.2 
Exo 71.2 Endo 102.9, 110.2 I 
1,4-Cyclohexanediol Endo 97.3 Exo 55.1 Exo 40.2, Endo 95.7 I 
 
 
-20
-10
0
10
20
H
e
a
t 
F
lo
w
 (
W
/g
)
-100 -50 0 50 100 150 200 250
Temperature (°C)
                  1,2-Cyclohexanediol–––––––
                  1,4-Cyclohexanediol–––––––
                  Catechol–––––––
                  Hydroquinone–––––––
                  Phloroglucinol–––––––
                  Resorcinol–––––––
                  ROY–––––––
                  1,2,4-Benzenetriol–––––––
Exo Up
120 
 
The data in Table 5.1 was obtained using TA Instruments Universal Analysis 2000 software 
(version 4.5A) and temperatures listed are the onset temperatures of peaks determined by 
integration were possible, or of peak maxima where integration was not possible for example 
superheating of samples in some of the cooling cycles giving rise to loops in the traces. The 
temperature reported for the glass transitions is the inflection point. The classes listed in Table 
5.1 refer to the classification of materials based their crystallisation tendency from the 
undercooled melt, following the classification system introduced by Baird et al.148 The same 
experiments were repeated for the products of the grind of a 1:1 molar ratio of ROY and the co-
formers and the resultant DSC traces shown in Figures 5.10 to 5.12 and summarised in Table 5.2. 
 
 
Figure 5.10 DSC traces for the initial heating cycle of the products of the grind of a 1:1 molar ratio of ROY 
and the co-formers: 1,2,4-benzenetriol (blue), hydroquinone (purple), resorcinol (red), catechol (brown), 
1,2-cyclohexanediol (green) and 1,4-cyclohexanediol (olive); and pure ROY (black) for comparison. 
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Figure 5.11 DSC traces for the cooling cycle of the products of the grind of a 1:1 molar ratio of ROY and 
the co-formers and pure ROY for comparison. Traces are coloured as in Figure 5.10. 
 
Figure 5.12 DSC traces for the second heating cycle of the products of the grind of a 1:1 molar ratio of 
ROY and the co-formers and pure ROY for comparison. Traces are coloured as in Figure 5.10. 
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Table 5.2 Data obtained from DSC analysis of the products of the grind of a 1:1 molar ratio of ROY and 
the co-formers, recording the temperature and type of events observed in the thermograms and the 
corresponding class of material. Pure ROY and ROY:pyrogallol data are included for comparison. 
Material 
Observations in cycle (Endo/Exo/Tg at temperature 
(°C)) 
Class 
Initial 
heating 
Cooling Second heating 
ROY Endo 109.9 - 
Tg -9.4, Exo 58.5, Endo 97.6, 
Endo 106.4 
II 
ROY:pyrogallol Endo 88.5 - Tg -6.3 III 
ROY:1,2,4-benzenetriol Endo 98.1 - Tg 1.75 III 
ROY:phloroglucinol 
Endo 91.9, 
Endo 107.0 
- 
Tg -6.2, Exo 33.3, Endo 103.3, 
Endo 106.5 
II 
ROY:catechol Endo 68.3 - Tg -23.0 III 
ROY:resorcinol Endo 70.1 - Tg -10.0 III 
ROY:hydroquinone Endo 100.6 - 
Tg -9.4, Exo 33.0, Exo 41.4, 
Endo 99.5, Endo 100.3 
II 
ROY:1,2-cyclohexanediol Endo 96.5 
Exo 68.3, 
Exo 65.7 
Tg -10.7, Exo 57.6, Endo 94.4 I 
ROY:1,4-cyclohexanediol 
Endo 95.2, 
Endo 103.3 
- 
Tg -9.8, Exo 62.1, Endo 93.0, 
Endo 94.5, Endo 100.0 
II 
 
The broad endothermic peak observed in the initial heating cycle of ROY:phloroglucinol (Figure 
5.10) is typical of dehydration, likely caused by hydration of the phloroglucinol to form the 
dihydrate to some extent, as discussed in the initial characterisation section. The multiple 
melting endotherms seen in the second heating phase of this sample and that of ROY:1,4-
cyclohexanediol, around 90-110°C is likely due to different polymorphs of ROY having 
crystallised and the interaction with the co-former present in the sample causing adjustment to 
the temperature at which melting occurs compared to that of the pure ROY polymorphs. 
 
5.2.3 Summary 
A summary of the amorphous behaviour of the ROY:co-former samples compared to the pure 
parent components is shown in Table 5.3, which lists the outcome, in terms of improvement in 
amorphous stability, based on DSC analysis of the 1:1 ROY:co-former grinds. The co-formers are 
listed by those affording the co-amorphous material with greatest increase in glass transition 
temperature compared to pure ROY.  
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Table 5.3 Summary of co-amorphous behaviour of ROY:co-former pairs as determined by DSC. 
Co-former 
Class 
co-
former 
Class 
ROY:co-
former grind 
Improvement in 
amorphous stability 
compared to 
Tg shift 
compared 
to ROY (°C) 
ROY Co-former 
1,2,4-Benzenetriol II III Yes Yes +11.2 
1,3,5-Benzenetriol 
(phloroglucinol) 
I II No Yes +3.2 
1,2,3-Benzentriol 
(pyrogallol) 
I III Yes Yes +3.1 
1,4-Dihydroxybenzene 
(hydroquinone) 
I II No Yes 0.0 
1,4-Cyclohexanediol I II No Yes -0.4 
1,3-Dihydroxybenzene 
(resorcinol) 
I III Yes Yes -0.6 
1,2-Cyclohexanediol I I No No -1.3 
1,2-Dihydroxybenzene 
(Catechol) 
I III Yes Yes -13.6 
 
Although the amorphous stability of the, in this case, model, API is of most concern, it is 
interesting to note that the presence of ROY improves the amorphous stability in relation to the 
co-former in all but the case of 1,2-cyclohexanediol. As the API component of a co-crystal is only 
determined by its medicinal use, and it is quite possible to use a drug as a co-former,65,159,160,161 
the overall high rate of improvement in amorphous stability is promising as applying to a large 
range of compounds. There does not appear to be a clear correlation between the shift in glass 
transition temperature and improved stability in relation to ROY. In both cases where large shifts 
in Tg were measured, improved amorphous stability in relation to ROY and the co-former were 
observed, however improved stability was also seen with smaller shifts in Tg, for example with 
resorcinol. There does appear to be a correlation between the structure of the co-former and 
the shift in Tg however, with benzenetriols causing a positive shift, and the dihydroxybenzenes 
and cyclohexanediols producing a neutral or negative shift. The presence of a third hydroxy 
group in the co-former molecule potentially altering the environment of the intermolecular 
bonding to produce the observed increased glass transition temperature as compared to the co-
formers with two OH groups. 
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Figure 5.13 Structures of the eight co-formers investigated and that of ROY. A. pyrogallol, B. 1,2,4-
benzenetriol, C. phloroglucinol, D. trans-1,2-cyclohexanediol, E. ROY, F. 1,4-cyclohexanediol, G. catechol, 
H. resorcinol and I. hydroquinone. 
 
The structures of the compounds (Figure 5.13) which do and do not improve the amorphous 
stability of ROY, suggest that aromaticity of the ring is necessary for the interactions involved in 
stabilisation of the amorphous form. This is apparent as neither trans-1,2-cyclohexanediol nor 
the racemic 1,4-cyclohexanediol cause an increase in amorphous stability compared to ROY and 
in all co-amorphous materials where stability is improved, the co-former is a benzene derivative. 
The position of the hydroxy group also appears to influence the interactions involved in 
stabilisation, as although the amorphous stability of all three dihydroxybenzenes are improved 
125 
 
when ground in a 1:1 molar ratio with ROY compared to co-former alone, only catechol and 
resorcinol also further stabilise the amorphous form in comparison to pure ROY. As these 
dihydroxybenzene isomers differ only in the position of their OH groups, the location must be 
of influence in the stabilisation of the co-amorphous material. 
In order to test the predictability of the co-amorphous behaviour in these ROY:co-former 
systems, COSMOtherm calculations were performed as for the ROY co-crystal screen (see 
Chapter 4, section 4.3.3.1), replacing the standard list of co-formers with the pyrogallol 
analogues used in this chapter. Preliminary data is displayed in Table 5.4, with the co-formers 
listed by excess enthalpy and an indication of whether an improvement in amorphous stability 
compared to ROY was seen experimentally. With the exception of phloroglucinol, all co-
formers which led to excess enthalpy being calculated to be less than -0.5kJ.mol-1 resulted in 
an experimentally observed improvement in amorphous stability compared to ROY and those 
which led to excess enthalpy being calculated to be greater than -0.5kJ.mol-1 resulted in no 
experimentally observed improvement. The results in these ROY:co-former systems lend 
further evidence to the feasibility of predicting co-amorphous behaviour and show the 
potential for the possibility of ranking co-formers based on likelihood of co-amorphous 
material formation. 
 
Table 5.4 Summary of COSMOtherm calculations for the co-formers paired with ROY. List ranked based 
on calculated excess enthalpy. 
Co-former 
Improvement in amorphous 
stability compared to ROY 
Calculated excess enthalpy 
(ΔH/kJ.mol-1) 
1,2,3-Benzentriol 
(pyrogallol) 
Yes -1.237 
1,2-Dihydroxybenzene 
(Catechol) 
Yes -0.795 
1,2,4-Benzenetriol Yes -0.738 
1,3,5-Benzenetriol 
(phloroglucinol) 
No -0.694 
1,3-Dihydroxybenzene 
(resorcinol) 
Yes -0.504 
1,4-Dihydroxybenzene 
(hydroquinone) 
No -0.334 
1,2-Cyclohexanediol No -0.033 
1,4-Cyclohexanediol No  0.634 
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5.3 Further investigation of materials displaying co-amorphous 
behaviour 
The timescale of the stability of the ROY:1,2,4-benzenetriol material was also investigated and 
compared to that previously measured for ROY:pyrogallol. 
5.3.1 Method 
To produce these results a molten drop of both samples was allowed to fall onto a silicon sample 
disc. The discs were immediately transferred to the X-ray diffractometer and measurements 
collected using the same source and slit parameters as the standard PXRD method (Chapter 2) 
but shortening the scan time to one minute and repeating the method continuously for 100 
scans. 
5.3.2 Powder X-ray diffractometry 
 
 
Figure 5.14 Evolution of crystallinity over a 100-minute period from an amorphous droplet of ROY:1,2,4-
benzenetriol 1:1 grind, scan lengths of approximately one minute repeating continuously for 100 
minutes. 
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Figure 5.15 Evolution of crystallinity over a 100-minute period from an amorphous droplet of 
ROY:pyrogallol 1:1 grind, scan lengths of approximately one minute repeating continuously for 100 
minutes. 
 
Figures 5.14 and 5.15 compare the evolution of crystallinity from a molten droplet of ROY:1,2,4-
benzenetriol 1:1 grind with that of ROY:pyrogallol 1:1 grind. With the ROY:pyrogallol 1:1 grind 
sample there is clearly significant crystalline material present after 100 minutes as evidenced by 
the multiple defined peaks present in the powder pattern at that time point. In comparison, the 
powder pattern for the ROY:1,2,4-benzenetriol 1:1 grind sample at 100 minutes contains only 
very slight peaks above the limit of detection, for example at around 22° 2θ, indicating a much 
lower level of crystallisation. The time point at which a peak above the limit of detection is 
observable is difficult to determine due to the short measuring time for each scan, however 
appears to be around 30 minutes for both samples suggesting a similar retardation time of 
crystallisation in both materials. The slight shifting of peak position over time, seen especially in 
the ROY:1,2,4-benzenetriol 1:1 grind sample, is likely due to the progressive change in shape of 
the droplet of sample as crystallisation occurred varying the overall height of the sample. 
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5.4 Conclusions 
By producing materials, combining ROY and co-formers in the same manner as in the previous 
chapters, but replacing pyrogallol with different co-formers with similar molecular structures, it 
has been possible to identify certain structural properties which influence the co-amorphous 
behaviours observed in some of these materials. The aromaticity of the ring structure along with 
the position of the hydroxy groups both play a part in determining whether intermolecular 
interactions sufficient to stabilise the amorphous form are formed. The results from the PXRD 
experiment investigating crystallisation from a molten drop of material suggests that pairing 
1,2,4-benzenetriol with ROY may afford an improvement in amorphous stabilisation compared 
to pyrogallol. It was also noted that even though the co-former may have poor amorphous 
stability itself, it may still bring about improved amorphous stability in combination with the API, 
and that the discovery of these stabilised co-amorphous systems stemmed from computational 
prediction of gas-phase interactions suggests that co-amorphous material formation may be 
predicable.
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Chapter 6 – Analysis of a co-crystal screen of 
ornidazole 
 
6.1 Introduction 
Many techniques have been reported for the analysis of co-crystals, ranging from simple 
detection of form change from starting components using PXRD to much more in-depth analysis 
of the physical properties of co-crystals.47,146,162 Techniques for investigating properties 
necessarily depend upon the properties being investigated and include for example DSC and 
TGA for probing thermal behaviour, DVS for looking at moisture sensitivity as an example and 
HPLC as an option for solubility determination. Improvements in chemical stability such as 
reduced photodegradation could also require HPLC for sample content determination,163 and 
the implementation of other techniques such as IR and NMR spectroscopy to analyse molecular 
changes. For immediate analysis of a physical co-crystal screen the main aim, especially in high-
throughput screening, is efficient identification of any API:co-former pairs which have interacted 
in a way leading to a form change from the parent materials. This allows further investigations, 
which require the investment of resources, to be limited to only those substances which may 
have potentially formed a co-crystalline material. For this reason, a technique that can quickly 
identify changes in physical form from a small quantity sample is needed. Raman and IR 
spectroscopy and PXRD are all examples of suitable techniques.29,121,164,165 
Infrared spectroscopy was used as the initial analytical technique for the ROY co-crystal screen 
and was a suitable method, as due to the nature of infrared spectroscopy, form changes could 
be identified from small samples and the process was relatively quick. Although PXRD can 
require longer analysis times than vibrational spectroscopy, especially with small sample sizes,29  
it is a better technique for detecting changes in solid form as needed for co-crystal screening. 
The quantity of API and co-former used per well in the co-crystal screening undertaken was 
specifically chosen to allow adequate material to be recovered for analysis and so PXRD was 
used for the initial analysis of the ornidazole co-crystal screen presented in this chapter. PXRD 
is the standard technique for solid form identification (inferior to single crystal X-ray diffraction, 
however this is usually saved for structure determination due to its many drawbacks) and is a 
more sensitive technique for the task of hit identification. 
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Once the hits from the screen have been identified, further characterisation of these materials 
are undertaken to better understand their nature. This may require the production of a larger 
scale of the materials for further characterisation to be feasible. Finally, the best co-crystal based 
on the material with the most desirable properties for the intended application will be identified 
for possible future development. In pharmaceutical terms, this would usually be an 
improvement in one or more properties that were identified as substandard for progressing an 
API further through development into a marketable product. For example: low solubility and 
ultimately bioavailability, high hygroscopicity or lack of crystallinity, preventing efficient or even 
feasible processing, or poor physical stability precluding the required shelf life from being 
achieved. 
Analysis from the co-crystal screen of ROY can be found in Chapter 4, a conclusion from this is 
the highlighting of the potential for analysis from a ‘failed’ co-crystal screen to lead to other 
discoveries related to the behaviour of the materials under investigation relevant to the desired 
outcome. Ornidazole was chosen as the API for this second co-crystal screen as it crystallises 
with Z’ = 3 (i.e., there are three molecules in the crystallographic asymmetric unit) and because 
it has been hypothesised that molecules which crystallise with Z’ > 1 in their pure form, are more 
likely to form co-crystals than those which do not.166,167 
 
6.2 Ornidazole co-crystal screen 
6.2.1 Method 
The ornidazole co-crystal screen was conducted using the same methods as that for the ROY co-
crystal screen for the computational pre-screen and the physical screen with some variations. 
The same COSMOtherm method was used to produce a ranked list of potential co-formers and 
a slight alteration was made to include two co-formers not ranked in the top 48 as positive 
controls for this screen (C1 and C2 in Table 6.1). The two compounds were 3,5-dinitrobenzoic 
acid and 4-aminobenzoic acid (PABA) which had both previously been reported in the literature 
to form co-crystals with ornidazole.166,168 PABA was ranked (before duplicates were removed, as 
detailed below) at position 109 with a minimum excess enthalpy of -0.22341 ΔH/kJ.mol-1 at a 
1:1 stoichiometric ratio, whereas 3,5-dinitrobenzoic acid did not feature in the list of potential 
co-formers. 
The full list of potential co-formers used to create the ranked list consisted of 314 compounds 
which is less than that used for the ROY calculations. This discrepancy was due to the list being 
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continuously updated as more compounds are added by the researchers at AZ. The calculations 
for the ornidazole pre-screen were performed before those for the ROY pre-screen, hence the 
lower number of compounds. Some duplicates existed in the list and were removed by sorting 
the list of co-formers alphabetically and deleting any obvious duplicates found next to each 
other. The chemical structures of all of the co-formers ranking in the top 48 were also checked 
to remove any which were listed under multiple names, for example 2,5-dihydroxybenzoic acid 
and gentisic acid. 
From the top 48 of the ranked list, three were removed due to duplication and one excluded 
due to lack of availability (#18 p-vinylphenol). The contents of the list were moved accordingly 
and the original numbers 49 to 52 were consequently included. The two compounds being used 
as positive controls were substituted in place of two compounds at the lower end of the top 48 
ranked list. Isoquinoline (position 46) and pyruvic acid (position 48) were substituted with 3,5-
dinitrobenzoic and 4-aminobenzoic acid and respectively. Isoquinoline rather than succinic acid 
(position 47) was chosen for substitution due to the easier handling of the latter and at such a 
low position in the ranked list the differences in calculated excess enthalpy are small enough to 
be insignificant for practical purposes. The final list of the top 46 ranked co-formers and two 
controls, after amendments, is presented in Table 6.1 below and the full list is presented in 
Appendix 6.1. 
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Table 6.1 Co-formers used for the physical co-crystal screen listed by rank based on calculated excess 
enthalpy and with positive controls highlighted. 
Rank Well Co-former Calculated excess enthalpy (ΔH/kJ.mol-1) 
1 A1 Oxalic acid -2.202 
2 A2 Sulfamic acid -1.957 
3 A3 Acesulfame -1.919 
4 A4 5-Nitroisophthalic acid -1.654 
5 A5 Isocitric acid -1.591 
6 A6 Piperazine -1.540 
7 A7 2,4-Dihydroxybenzoic acid -1.432 
8 A8 tert-Butylhydroquinone -1.345 
9 B1 Trimesic acid -1.337 
10 B2 4-Hexylresorcinol -1.328 
11 B3 3,5-Dihydroxybenzoic acid -1.327 
12 B4 Citric acid -1.319 
13 B5 Etidronic acid -1.289 
14 B6 Resorcinol -1.283 
15 B7 Carnitine -1.245 
16 B8 1-Hydroxy-2-naphthoic acid -1.220 
17 C1 Fumaric acid -1.202 
18 C2 2,5-Dihydroxybenzoic acid -1.155 
19 C3 5-Chlorosalicylic acid -1.147 
20 C4 Aconitic acid -1.127 
21 C5 3,4-Dihydroxybenzoic acid -1.016 
22 C6 Ketoglutaric acid -0.995 
23 C7 4,4-Bipyridine -0.973 
24 C8 m-Nitrobenzoic acid -0.960 
25 D1 o-Cresol -0.938 
26 D2 Malonic acid -0.934 
27 D3 Phenol -0.920 
28 D4 Tartaric acid -0.897 
29 D5 Salicylic acid -0.896 
30 D6 Methyl gallate -0.892 
31 D7 3-Hydroxybenzoic acid -0.881 
32 D8 3-Hydroxy-2-naphthoic acid -0.876 
33 E1 Octadecylamine -0.870 
34 E2 Thymol -0.846 
35 E3 Maleic acid -0.832 
36 E4 6-Hydroxy-2-naphthoic acid -0.816 
37 E5 2,5-Xylenol -0.802 
38 E6 4-Hydroxybenzoic acid -0.779 
39 E7 2,6-Dimethylpyrazine -0.772 
40 E8 2-Oxo-3-phenylpropionic acid -0.734 
41 F1 p-Cresol -0.724 
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Rank Well Co-former 
Calculated excess enthalpy 
(ΔH/kJ.mol-1) 
42 F2 L-Lysine -0.707 
43 F3 DL-Valine -0.704 
44 F4 3-Methyl-2-oxobutanoic acid -0.701 
45 F5 p-Ethylphenol -0.684 
46 F7 Succinic acid -0.669 
C1 F6 3,5-Dinitrobenzoic acid -1.765 
C2 F8 4-Aminobenzoic acid -0.223 
 
As 3,5-dinitrobenzoic acid did not feature in the original list of co-formers for the computational 
pre-screen, a directly comparable value was not determined at the time of COSMOtherm 
calculations. Access to software which performs similar calculations but on sigma surfaces of 
predetermined fragments of molecules (COSMOquick) rather than requiring the full molecule 
sigma surface to be determined ad hoc, and therefore much quicker but potentially less 
accurate,169,170 allowed at least a guide value to be calculated (at 1:1 stoichiometry) which is 
highlighted in Table 6.1. 
The physical screening followed the same method as that of the ROY screen except that the 48 
co-formers were only screened with ornidazole using acetone as the solvent as there were not 
repeats with the other solvents as there were for the ROY co-crystal screen. The follow-up 
analysis for the screen with acetone took priority over repeating with other solvents in this case, 
as the focus on characterisation of hits from this screen allowed the second optimisation 
experiment to be undertaken (presented in Chapter 3). The method was thus, 1.25g of 
ornidazole was dissolved in a DCM solution at a concentration of 100mg/ml. A 250µl aliquot 
equating to 25mg of ornidazole was added to an equimolar amount of solid, previously weighed, 
potential co-former in 48 wells of a borosilicate glass 96-well plate. After leaving the initial 
solvent to evaporate, 50µl of acetone was added to eight wells and the 8-tips of the ultrasonic 
probe were placed in these wells and sonicated at 50% power for 10 minutes using a Sonics 
Vibra Cell 130W 20kHz ultrasonic processor. This process was repeated for the remaining wells, 
one row of eight at a time. In Figure 6.1 the co-formers which had been weighed out and 
transferred to the wells can be seen in the photograph on the left. The photograph in the middle 
shows the material in the wells after ornidazole in DCM solution had been added and given time 
to dry, and the photograph on the right, after the addition of acetone and sonication. 
Table 6.1 (Continued) 
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Figure 6.1 Three photographs showing, on the left, the pure co-formers which had been weighed out and 
transferred into the wells, in the middle, the same plate after the addition of 25mg of ornidazole via a 
100mg/ml solution of DCM to each well and being left 14 hours for the solvent to evaporate, and on the 
right, after sonication. 
Both after the addition of DCM and the subsequent time for solvent evaporation, and after 
sonication of the wells, it was observed that many of the wells contained material which did not 
appear crystalline. 
6.2.2 Analysis of the screen by powder X-ray diffractometry 
X-ray diffraction is the ‘gold standard’ for solid state form identification and would ideally be 
used for analysis of all co-crystal screening products. Due to limited access to X-ray diffraction 
resources, previous screens have had to be analysed by FTIR and, if a hit detected, further 
analysis by PXRD would be warranted. For the ornidazole co-crystal screen analysis was entirely 
by PXRD rather than FTIR. 
When attempting to extract the material from the wells to enable preparation for PXRD analysis, 
it became apparent that in the wells where the material did not appear crystalline, it tended to 
be sticky and likely amorphous. Initially only the material from wells where crystalline material 
was present was removed from the plate for analysis. The rest of the wells were left for up to 
three months, giving chance for crystallisation to occur. 
The plots below (Figures 6.2 – 6.4) are examples of the three types of result that were obtained 
from the PXRD analysis of the co-crystal screen products. The first, shown in Figure 6.2, is a hit 
and is identified as such because there is at least one new peak detected that is not present in 
either of the parent components PXRD patterns. In this case, there are multiple new peaks, the 
most obvious of which is positioned at 9.7° 2θ, where there are clearly no peaks in the patterns 
of either of the parent compounds: ornidazole or 5-nitroisophthalic acid. 
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Figure 6.2 PXRD patterns for 5-nitroisophthalic acid (green), ornidazole (blue) and the product of the 
screen for these two compounds (red). 
 
 
Figure 6.3 PXRD patterns for 4-hexylresorcinol (green), ornidazole (blue) and the product of the screen 
for these two compounds (red). 
 
5 10 15 20 25 30 35
2Theta (°)
0
2500
10000
22500
40000
In
te
n
s
it
y
 (
c
o
u
n
ts
)
5 10 15 20 25 30 35
2Theta (°)
0
10000
40000
90000
In
te
n
s
it
y
 (
c
o
u
n
ts
)
136 
 
The second two examples are of screen products which were not counted as hits, the first, that 
of ornidazole and 4-hexylresorcinol shown in Figure 6.3, displays an almost flat line devoid of 
peaks which is typical of an amorphous material. This material, if left would likely eventually 
crystallise, and as stated above, where amorphous material was found in wells it was left for a 
significant period of time before analysis. The available timescale of the experiment meant that 
waiting longer was not possible and as the time before crystallisation occurs could be potentially 
limitless, such screen products featuring characteristic amorphous PXRD patterns were counted 
as fails. The final example is ornidazole and acesulfame potassium and is presented in Figure 6.4. 
The PXRD patterns here are an example of a product of the screen where crystalline material is 
produced, but which shares all of its peaks with those present in either of the parent 
compounds, thereby indicating that no new solid form has been produced and that the product 
is merely a physical combination of the two starting components. 
 
 
Figure 6.4 PXRD patterns for acesulfame potassium (green), ornidazole (blue) and the product of the 
screen for these two compounds (red). 
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6.2.3 Results 
Based on the PXRD analysis where a sample was considered a hit if a new peak, not present in 
either of the parent components PXRD patterns, was detected, a total of 23 hits were observed. 
The figures above are examples of the types of results observed and a full set of PXRD patterns 
are recorded in Appendix 6.2. Given that the potential co-formers were ranked based on their 
calculated propensity to co-crystallise with ornidazole, it might be expected that the hits would 
be gathered more towards the start of the list. This was not the case however, with a relatively 
even spread of hits throughout the range of co-formers screened, as displayed in Figure 6.5 
below. 
 
1 2 3 4 5 6 7 8 
A 
1 
Cryst. 
-2.2019 
2 
Cryst./Am. 
-1.9570 
3 
Cryst. 
-1.9194 
4 
Cryst. 
-1.6545 
5 
Cryst. 
-1.5914 
6 
Am. 
-1.5401 
7 
Cryst./Am. 
-1.4322 
8 
Cryst./Am. 
-1.3452 
B 
9 
Cryst. 
-1.3367 
10 
Am. 
-1.3280 
11 
Cryst. 
-1.3268 
12 
Cryst./Am. 
-1.3187 
13 
Cryst./Am. 
-1.2885 
14 
Am. 
-1.2826 
15 
Cryst. 
-1.2448 
16 
Cryst. 
-1.2198 
C 
17 
Cryst. 
-1.2018 
18 
Cryst. 
-1.1547 
19 
Cryst. 
-1.1470 
20 
Cryst./Am. 
-1.1273 
21 
Cryst./Am. 
-1.0162 
22 
Am. 
-0.9947 
23 
Cryst./Am. 
-0.9727 
24 
Cryst./Am. 
-0.9604 
D 
25 
Cryst. 
-0.9382 
26 
Am. 
-0.9345 
27 
Cryst. 
-0.9205 
28 
Cryst./Am. 
-0.8971 
29 
Cryst./Am. 
-0.8960 
30 
Cryst. 
-0.8919 
31 
Cryst. 
-0.8807 
32 
Cryst. 
-0.8760 
E 
33 
Cryst./Am. 
-0.8700 
34 
Cryst. 
-0.8460 
35 
Cryst./Am. 
-0.8315 
36 
Cryst./Am. 
-0.8163 
37 
Cryst. 
-0.8020 
38 
Cryst./Am. 
-0.7790 
39 
Cryst. 
-0.7717 
40 
Cryst. 
-0.7343 
F 
41 
Cryst./Am. 
-0.7241 
42 
Cryst./Am. 
-0.7073 
43 
Cryst. 
-0.7041 
44 
Cryst. 
-0.7009 
45 
Cryst./Am. 
-0.6841 
C1 
Cryst. 
-1.765 
46 
Cryst. 
-0.6689 
C2 
Cryst. 
-0.2234 
Figure 6.5 Diagrammatic representation of the results laid out in the format of the plate. Bold purple 
numbers represent hits and the two bold blue numbers represent the positive controls, also hits. Values 
in each ‘well’ refer to rank of co-former, whether the sample was identified as crystalline (Cryst.), 
amorphous (Am.) or a combination of both (Cryst./Am.) as determined by PXRD analysis, and the excess 
enthalpy (given in ΔH/kJ.mol-1) as calculated by COSMOtherm (with the exception of C1 (well F6) which 
was calculated by COSMOquick). 
 
The results in bold purple represent hits and the two bold blue results represent the positive 
controls, also hits. The initial value is the rank of co-former based on the excess enthalpy 
calculated by COSMOtherm which is the third value in each set. Based on analysis of the powder 
patterns obtained for the sample from the screen, they were identified as crystalline (where a 
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flat baseline with characteristic narrow peaks were present), amorphous (where no diffraction 
peaks were evident) or a combination of crystalline and amorphous where characteristic of both 
crystalline and amorphous patterns were identified. This last category ranged from one or two 
sharp peaks (indicating the presence of at least some crystalline material) in a pattern otherwise 
devoid of an peaks except for an amorphous halo, to a pattern consiting of many peaks typical 
of a crystalline sample but with relatively high very low 2θ counts and a halo, both characteristic 
of amorphous content within the sample. The counts at very low 2θ is common to all samples 
on a given diffractometer and is due to the X-ray source and detector being almost linear (i.e. 
pointing at each other) which leads to a greater amount of diffuse scattered X-rays being 
detected than at higher angles. The reason this is more often noticed in largly amorphous 
samples is that in relative terms, compared to the intensity of the highest peak in the full range 
of the scan, these low 2θ counts will constitute a larger ratio than in highly crystalline samples 
and due to scaling of the pattern, will appear more obvious. 
It is interesting to note that all five of the samples in which no crystallisation occurred within the 
given timeframe were ranked within the top 26 co-formers. It is possible that intermolecular 
interaction between the co-formers and ornidazole are leading to stabilisation of the amorphous 
phase, as seen with ROY and pyrogallol (Chapter 4), resulting in a co-amorphous material less 
prone to crystallising than either component individually. This would fit theoretically with the 
single molecule gas phase COSMOtherm calculations, as the interactions predicted are valid in 
any physical state. That lattice parameters are not taken into account in the calculations could 
explain the lack of crystallisation in the amorphous samples where predicted interactions may 
still be present leading to stabilisation of the phase.  
6.2.4 Summary 
Out of the 48 co-formers screened, 23 were detected as hits with ornidazole by PXRD, including 
the two positive controls. There were 25 co-formers which were not identified as hits, however 
that does not mean that under no circumstances will a co-crystal of ornidazole and any of these 
co-former never be obtainable. Many of the materials produced by the combination of 
ornidazole and these co-formers were amorphous and thus identified only as such by PXRD. Had 
these materials been left for even longer periods of time or crystallisation induced by some 
means, it is quite possible that co-crystalline material would have resulted from some if not 
many of these combinations. For the practical purposes of conducting a high-throughput screen 
in an efficient and timely manner, those ornidazole and co-former pairs which did not yield 
material with great enough crystallinity two be identified as containing a new form by PXRD 
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were treated as a fail. Crystallisation tendency is an important attribute, especially when 
selecting potential forms for further development; poor crystallisation tendency would hamper 
processing and therefore be a less suitable candidate, making the failure status from the screen 
appropriate in terms of form selection for drug development. 
 
6.3 Further investigations into co-crystal screen hits (materials in 
which form change was detected) 
As previously stated, detecting a hit from PXRD analysis of the products of the co-crystal screen, 
only indicates that form change has occurred. This could be caused by a number of possibilities 
such as polymorphic transition, degradation of either component or formation of a solvate or 
hydrate. Hence it is necessary to further analyse the material subsequent to it being identified 
as a hit. DSC and TGA were employed to examine the thermal behaviour of the materials 
recovered from the screen procedure and evaporative crystallisation was attempted for some 
of these ornidazole co-former pairs. The crystallisation was attempted to determine whether 
similar results would be achieved for the co-crystal screen by evaporative methods, i.e. 
removing the requirement for sonication, and additionally to ascertain a suitable method for 
scaled up production of the materials. Only the very first materials which were analysed by 
PXRD, i.e. those observed to be crystalline upon initial appearance immediately after the 
screening procedure, were subjected to the attempted evaporative crystallisation. 
6.3.1 Differential scanning calorimetry 
DSC thermograms were recorded for the material recovered from the 96-well plate for those 
determined to be hits, following the standard DSC ramp method detailed in Chapter 2. Figure 
6.6 shows the DSC traces for two of the materials analysed, the products of the ornidazole screen 
with 5-nitroisophthalic acid and 3,5-dihydroxybenzoic acid. These are examples of the two main 
results (a full set of which can be found in Appendix 6.3 and a summary in Table 6.2 below): a 
single endothermic peak at the melting point (ornidazole:5-nitroisophthalic acid) and a trace in 
which multiple endothermic events are observed (ornidazole:3,5-dihydroxybenzoic acid). In 
these samples, at temperatures greater than around 200°C, decomposition may occur giving rise 
to variation in heat flow and artefacts in the traces. The presence of multiple endothermic 
events suggests that the sample does not consist purely of a co-crystal, and in the case of 
ornidazole:3,5-dihydroxybenzoic acid the initial peak with an onset of 50.9°C is due to the 
presence of solvent as determined by the analysis of TGA data below. 
140 
 
 
Figure 6.6 DSC profiles of the products of the ornidazole screen with 5-nitroisophthalic acid (green) and 
3,5-dihydroxybenzoic acid (blue). The peak onset and peak maximum temperatures are displayed by the 
traces. 
 
The DSC traces for the product of the ornidazole screen with 5-nitroisophthalic acid is plotted in 
Figure 6.7 with those for pure ornidazole and 5-nitroisophthalic acid. Again, at higher 
temperatures decomposition causes variation in heat flow and artefacts in the traces. Each of 
the traces features a single endothermic peak indicative of melting of the sample. The onset 
temperatures of those peaks of 87.31°C, 172.61°C and 258.39°C for ornidazole, ornidazole:5-
nitroisophthalic acid and 5-nitroisophthalic acid respectively, establish that the melting point of 
the product of ornidazole and 5-nitroisophthalic acid is between that of the parent components. 
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Figure 6.7 DSC profiles of the product of the ornidazole screen with 5-nitroisophthalic acid (green), 
ornidazole (black) and 5-nitroisophthalic acid (red). The peak onset and peak maximum temperatures 
are display by the traces. 
 
6.3.2 Thermogravimetric analysis 
TGA profiles were recorded following the standard TGA method detailed in Chapter 2 for all 
materials which underwent DSC analysis. The TGA profile for the product of the ornidazole 
screen with 5-nitroisophthalic acid is presented in Figure 6.8 and shows no significant mass 
change until degradation of the sample above about 175°C. This is commensurate with the DSC 
trace for this material as the effects of degradation are seen at the same temperatures in both. 
Figure 6.9 shows the TGA profile for the product of the ornidazole screen with 3,5-
dihydroxybenzoic acid and displays a different sample behaviour. A mass loss of 3.1% occurs 
over the temperature range of approximately 45°C to 75°C. This could be due to residual solvent 
present in the sample, however the mass loss equates to a molecular mass of 11.586 for each 
pair of ornidazole and 3,5-dihydroxybenzoic acid molecules, or 57.93 for every five pairs. The 
molecular weight of acetone is 58.079 and given that acetone was used in the LAG step of the 
co-crystal screen it is possible from this evidence that a 5:5:1 ornidazole:3,5-dihydroxybenzoic 
acid:acetone solvate has formed. The endothermic event in the DSC trace is also consistent with 
this, occurring over the same temperature range as the mass loss seen in the TGA profile. 
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Figure 6.8 TGA profile of the product of the ornidazole screen with 5-nitroisophthalic acid showing no 
significant mass change until degradation of the sample above about 175°C. 
 
Figure 6.9 TGA profile of the product of the ornidazole screen with 3,5-dihydroxybenzoic acid showing 
mass change over the temperature range of approximately 45°C to 75°C, followed by mass loss due to 
degradation above around 150°C. 
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Table 6.2 Summary of the results from DSC and TGA analysis of materials from the ornidazole co-crystal 
screen which were identified as hits. In relation to the literature melting point, (s) and (d) refer to 
sublimation and decomposition respectively. 
Co-former 
Literature 
melting 
point (°C) 
Number of 
endothermic 
peaks 
Onset of 
major 
endothermic 
peak (°C) 
Melting 
point 
compared 
to parent 
materials 
Significant 
mass loss 
Oxalic acid 189.5 (d) 2 53.3 Lower Yes 
5-Nitroisophthalic 
acid 
259-261 1 172.6 Mid No 
2,4-Dihydroxybenzoic 
acid 
208-211 
(d) 
2 150.3 Mid No 
Trimesic acid >300 1 143.7 Mid No 
3,5-Dihydroxybenzoic 
acid 
236-238 
(d) 
2 116.2 Mid Yes 
1-Hydroxy-2-
naphthoic acid 
195-200 
(d) 
1 95.9 Mid No 
Fumaric acid 
298-300 
(s) 
2 125.4 Mid No 
2,5-Dihydroxybenzoic 
acid 
204-208 1 86.7 Lower No 
5-Chlorosalicylic acid 171-172 1 94.8 Mid No 
3,4-Dihydroxybenzoic 
acid 
197-200 
(d) 
2 60.3 Lower Yes 
m-Nitrobenzoic acid 139-141 2 78.0 Lower No 
Salicylic acid 158-161 2 85.6 Lower No 
3-Hydroxybenzoic acid 200-203 2 91.9 Mid No 
3-Hydroxy-2-
naphthoic acid 
218-221 1 127.2 Mid No 
Octadecylamine 52-55 2 50.6 Lower Yes 
Thymol 48-51 2 86.2 Mid No 
2,5-Xylenol 73-78 1 83.6 Mid Yes 
4-Hydroxybenzoic acid 213-217 2 113.3 Mid No 
2-Oxo-3-
phenylpropionic acid 
150-154 2 84.7 Lower Yes 
p-Cresol 32-34 2 74.5 Mid Yes 
3-Methyl-2-
oxobutanoic acid 
sodium salt 
220-230 
(d) 
3 86.8 Lower Yes 
3,5-Dinitrobenzoic 
acid 
236-238 
(d) 
1 130.3 Mid No 
4-Aminobenzoic acid 187-189 1 134.0 Mid No 
 
The results from DSC and TGA of the materials investigated are summarised in Table 6.2. The 
melting points for the co-formers are those listed by the supplier and that of 3-methyl-2-
oxobutanoic acid sodium salt is given as it was the chemical used in place of 3-methyl-2-
oxobutanoic acid as discussed in Chapter 2. The number of endothermic peaks present in the 
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DSC trace other than those at higher temperatures caused by degradation, and very small peaks 
possibly due to the melting of a slight excess of ornidazole, are listed and the temperature of 
onset of the most prominent of these also listed. It is this temperature that is used to determine 
the position of the melting point of the material in relation to the parent components. This 
relationship in melting points is of most value where only one endothermic peak and likely co-
crystalline material are present and where there is no mass loss, again, not due to degradation, 
present in the TGA profile, which is also listed in the table. Samples matching this description 
are highlighted in bold in Table 6.2. If complete conversion from starting materials to co-crystal 
had occurred, a single endothermic peak would be expected in the DSC trace and no mass loss 
should be seen in the TGA thermogram; an exception could be a small quantity of trapped non-
structural solvent which would lead to a very small mass loss. 
A survey of 50 co-crystalline samples conducted by Schultheiss and Newman found that 52% of 
the co-crystals had melting points between those of parent components, 39% were lower than 
either, 6% higher and 4% the same as either API of co-former.47 When considering all 23 hits 
from the co-crystal screen, the results correlate well with those previously published, 34.8% 
displaying a lower melting point than either API or co-former and 65.2% a melting point between 
the two. Narrowing the range to only those hits which met the thermal behaviour requirements 
set out above (materials highlighted in bold in Table 6.2) results in a greater percentage of 
materials displaying a melting point between those of the parent components (87.5%).  
This combination of DSC and TGA results is observed for only eight of the 23 materials from the 
co-crystal screen which were hits, allowing for very slight mass loss, a very small peak possibly 
due a slight excess of ornidazole and not considering anything above the temperature in which 
degradation of the material is apparent. The co-former constituents of these eight materials 
were: 5-nitroisophthalic acid, trimesic acid, 1-hydroxy-2-naphthoic acid, 2,5-dihydroxybenzoic 
acid, 5-chlorosalicylic acid, 3-hydroxy-2-naphthoic acid, 3,5-dinitrobenzoic acid and 4-
aminobenzoic acid. Of these, all had melting points between ornidazole and the co-former 
except ornidazole:2,5-dihydroxybenzoic acid which had a peak onset temperature of 86.7°C, just 
below ornidazole’s melting point of 87.3°C. The DSC trace for this sample (Figure 6.10) however, 
displayed signs of degradation from a relatively low temperature, around 150°C, which with the 
broad shape of its endothermic peak suggest that this was not a melting event of a pure co-
crystal. 
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Figure 6.10 DSC and TGA overlay plot for ornidazole:2,5-dihydroxybenzoic acid. 
 
Many of the samples have multiple endothermic peaks suggesting multiple phases present in 
the sample or that transformation occurs during the DSC measurement. These points do not 
mean that co-crystallisation did not occur, but that possibly complete conversion did not take 
place or a co-crystal of a stoichiometry other than 1:1 formed. Either of these situations would 
lead to excess of one or both of the starting materials which could lead to multiple endothermic 
peaks in the DSC trace unless eutectic mixtures were formed. In case of the formation of a 
eutectic mixture, a single lower melting peak would be expected, however this would not have 
given rise to a distinct PXRD pattern. 
Another explanation which lead to a new phase being detected by PXRD but not necessarily the 
formation of co-crystalline material may be that a solvate or hydrate of either of the materials 
(more likely the co-former otherwise it would be expected to be observed more frequently if it 
was the API) formed and desolvation gives rise to an initial endothermic peak prior to any 
melting events. This is the likely explanation for the occurrence of multiple endothermic peaks 
in the DSC trace (Figure 6.11) for the ornidazole:4-hydroxbenzoic acid sample, as an account of 
a similar DSC profile with a desolvation peak at around 67°C for 4-hydroxybenzoic monohydrate 
has previously been reported.171 The TGA profile for this material does not correlate with this 
explanation however as there is no mass loss seen which would occur with desolvation. There is 
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the possibility that desolvation occurred in the sample which underwent TGA analysis but not in 
that of the DSC sample due to the natural variation in ambient temperature and relative 
humidity within the laboratory. The article referenced suggested some degree of stability for 
the monohydrated form of 4-hydroxybenzoic acid, but without further analysis by DVS, ruling 
out the given explanation would not be possible. 
 
 
Figure 6.11 DSC and TGA overlay plot for ornidazole:4-hydroxybenzoic acid. 
 
Individual analysis of each material from the screen would be required to determine its nature 
(i.e. co-crystal or otherwise) and due to the focus of this project being on screening, resources 
were limited to only thoroughly characterising one hit from the co-crystal screen. As such, DSC 
and TGA plots for all materials identified as hits from the co-crystal screen are presented in 
Appendix 6.3 and the results summarised in Table 6.2, in depth analysis for each material was 
not performed but several examples are used in the preceding discussions. 
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6.3.3 Evaporative crystallisation from DCM solution 
Only five co-formers were selected for attempted evaporative crystallisation with ornidazole 
and all were chosen as they had been identified as hits from PXRD analysis and had been of the 
first materials to crystallise after the co-crystal screening procedure. These co-formers were: 5-
nitroisophthalic acid, trimesic acid, 3,5-dihydroxybenzoic acid, fumaric acid and 2-oxo-3-
phenylpropionic acid (phenylpyruvic acid). 
Ornidazole and 5-nitroisophthalic acid from DCM gives a PXRD pattern very similar to that from 
the screen as can be seen in Figure 6.12. Where there are any small peaks that are not the same, 
they appear at positions in which either of the parent materials has a peak suggesting that the 
sample is not pure and that some of the starting materials are present as well as the 
ornidazole:5-nitroisophthalic acid, i.e. full conversion did not occur. The same goes for the PXRD 
analysis of ornidazole and 3,5-dihydroxybenzoic acid from DCM, the plot of which can be found 
in Appendix 6.4 which contains the full set of results, a summary of which is presented in Table 
6.3. 
 
 
Figure 6.12 PXRD patterns for 5-nitroisophthalic acid (green), ornidazole (blue), the product of the screen 
for these two compounds (red) and the material produced by evaporative crystallisation of a 1:1 molar 
ratio of the two components from DCM (pink). Note the similarity of the red and pink patterns. 
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The PXRD patterns of the product of evaporative crystallisation for ornidazole and fumaric acid 
(Figure 6.13) and ornidazole and trimesic acid show new peaks at positions which none of the 
respective parent materials nor the respective products of the screen have peaks. This is 
indicative of new forms and would be considered a hit for screening purposes but produces a 
different form to that which the screening method applied gave. 
 
 
Figure 6.13 PXRD patterns for fumaric acid (green), ornidazole (blue), the product of the screen for these 
two compounds (red) and the material produced by evaporative crystallisation of a 1:1 molar ratio of the 
two components from DCM (pink). Note the difference between the red and pink patterns. 
 
The evaporative crystallisation of ornidazole and phenylpyruvic acid from a DCM solution 
produces a PXRD pattern which matches that of the product of the screen of these two materials 
i.e. the possible co-crystal. The evaporative crystallisation method would indicate a hit for 
screening purposes and produces the same form to that which the screening method applied 
gave (Figure 6.14). 
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Figure 6.14 PXRD patterns for phenylpyruvic acid (green), ornidazole (blue), the product of the screen for 
these two compounds (red) and the material produced by evaporative crystallisation of a 1:1 molar ratio 
of the two components from DCM (pink). Note the equivalence of the red and pink patterns. 
 
Table 6.3 Summary of the results from the evaporative crystallisation from DCM. 
Co-former 
‘Hit’ from evaporative 
crystallisation? 
Same form as from co-crystal 
screen? 
5-Nitroisophthalic acid Yes Yes – not full conversion 
Trimesic acid Yes No 
3,5-Dihydroxybenzoic acid Yes Yes – not full conversion 
Fumaric acid Yes No 
Phenylpyruvic acid Yes Yes 
 
6.3.4 Summary 
All five ornidazole:co-former pairs chosen for the evaporative crystallisation experiments 
resulted in form change detected by PXRD, however this was not always the same pattern as for 
the product of the co-crystal screen. These results suggest that the combination of ornidazole 
and these co-formers will routinely lead to the production of a new form, whether co-crystal or 
otherwise, but consideration should be given to the method of production when trying to 
reproduce a given material due to the variability seen in these PXRD patterns between the 
products of the ultrasonication based process and the evaporative crystallisation method. 
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Of all the further investigated hits from the screen, ornidazole:5-nitroisophthalic acid stood out 
as having a very clear characteristic peak in its PXRD pattern, along with a clean DSC thermogram 
with a single melting point and TGA thermogram showing no mass loss over a large temperature 
range until degradation. Few other of the hits had such qualities in their results and none had 
all of them, ornidazole:5-nitroisophthalic acid was also among the first ‘batch’/’set’ of wells to 
crystallise, making it a clear choice for further characterisation. The melting point for the 
ornidazole:5-nitroisophthalic acid material, as determined by DSC is 172.6°C which lies between 
that of both parent components, with ornidazole having a melting point of 87.3°C and 5-
nitroisophthalic acid 258.4°C. It is normal for the melting point of the co-crystal to fall between 
that of the two pure components, with the majority following this trend.47,21 A specific example 
is the 1:1 co-crystal of a sodium channel blocker (2-[4-(4chloro-2-
fluorophenoxy)phenyl]pyrimidine-4-carboxamide) and glutaric acid in which the co-crystal melts 
at 142°C and the API and co-former melt at temperatures either side of this at 206°C and 97.5°C 
respectively.50 
 
6.4 Further investigation into ornidazole:5-nitroisophthalic acid 
6.4.1 Production of material 
In order to carry out further experimentation on the ornidazole:5-nitroisophthalic acid system, 
a larger quantity of the material needed to be produced as that recovered from the screen had 
been depleted by the analyses already undertaken. An initial attempt by dry grinding a 1:1 molar 
ratio of the two components proved unsuccessful, as determined by PXRD (Figure 6.15, black 
pattern). Using acetone as a solvent drop, LAG using the same material achieved conversion to 
the form obtained from the screen, again as determined by PXRD (Figure 6.15, pink pattern). 
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Figure 6.15 PXRD patterns for 5-nitroisophthalic acid (green), ornidazole (blue), the product of the screen 
for these two compounds (red), the material produced by grinding a 1:1 molar ratio of the two 
components (black) and the material produced by LAG of that ground material using acetone as the 
solvent drop (pink). Note the equivalence of the red and pink patterns. 
 
6.4.2 Structure determination using single crystal X-ray diffraction 
6.4.2.1 Method 
Solid ornidazole was added to 1ml of acetone in a small sample vial until saturated at which 
point a little more acetone was added to ensure full dissolution of the ornidazole. To this, solid 
5-nitroisophthalic acid was added, again until saturation occurred and more acetone added to 
dissolve any remaining solid. The solution was covered with parafilm which was pierced and left 
to evaporate slowly. After approximately one month, crystalline material was visible in the vial 
and suitable single crystals were observed by polarised light microscopy (Figure 6.16). 
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Figure 6.16 Micrograph of a single crystal of ornidazole:5-nitroisophthalic acid (circled) on a larger 
crystalline mass viewed under cross polarised light. 
 
Single crystal X-ray diffraction was carried out in the Chemistry department at Durham 
University by Dr Katharina Edkins, following the procedure below. 
Experimental 
Single clear colourless block-shaped crystals of ornidazole:5-nitroisophthalic acid were obtained 
by recrystallisation from acetone. A suitable crystal (0.49×0.40×0.26) mm3 was selected and 
mounted on an Xcalibur, Sapphire3 diffractometer. The crystal was kept at T = 120K during data 
collection. Using Olex2,172 the structure was solved with the olex2.solve173 structure solution 
program, using the Charge Flipping solution method. The model was refined with a version of 
olex2.refine173 using Gauss-Newton minimisation. 
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6.4.2.2 Analysis 
Crystal Data 
C15H15ClN4O9, Mr = 430.76, orthorhombic, P212121 (No. 19), a = 6.04078(15)Å, b = 16.2494(4)Å, c 
= 18.5511(7)Å, α = β = γ = 90°, V = 1820.96(9)Å3, T = 120K, Z = 4, Z' = 1, µ(Mo Kα) = 0.270, 16703 
reflections measured, 3578 unique (Rint = 0.0597) which were used in all calculations. The final 
wR2 was 0.1430 (all data) and R1 was 0.0490 (I≥σ(I)). 
The asymmetric unit of the determined crystal structure is displayed in Figure 6.17 and confirms 
the 1:1 stoichiometric ratio of the crystal but certainty over its nature as a co-crystal or salt is 
not confirmed. It is unclear if the hydrogen bond between the OH of the carboxylic acid of 5-
nitroisophthalic acid and the N of the ring of ornidazole has proton transfer associated with it. 
The hydrogen bond distance (2.634Å) is within normal range174 and there is nothing to suggest 
that proton transfer has occurred. Aakeröy et al. reported on a method to sort over 80 
compounds synthesised from carboxylic acids and N-heterocycles between salts and co-crystals 
by examining the ratio of the two C–O bond lengths of the carboxylic acid and the endocyclic 
bond angles of the most basic nitrogen atom.175 Applying this method to the ornidazole:5-
nitroisophthalic acid structure results in identification as a co-crystal rather than a salt based on 
a ratio of 1.093Å for the C–O bond lengths of the carboxylic acid which is much more in line with 
the average for co-crystals (1.081Å) than salts (1.027Å). As further evidence of its co-crystalline 
nature, the increased endocyclic C–N–C bond angle only observed in the protonated examples 
in the referenced study is not present in the imidazole ring of ornidazole in the ornidazole:5-
nitroisophthalic acid binary system.  
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Figure 6.17 Asymmetric unit of the crystal structure of the ornidazole:5-nitroisophathlic acid crystal as 
determined by single crystal X-ray diffraction. 
 
Using the crystallographic information file (CIF) produced from the single crystal X-ray diffraction 
analysis for ornidazole:5-nitroisophthalic acid, and those from the CSD entries for ornidazole 
and 5-nitroisophthalic acid, the crystal structures were visualised in Mercury and the images in 
Figures 6.18 to 6.20 obtained displaying packing and hydrogen bonding within the respective 
crystal structures. 
 
Figure 6.18 Packing and hydrogen bonding within the ornidazole:5-nitroisophthalic acid crystal structure. 
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Figure 6.19 Packing and hydrogen bonding within the ornidazole crystal structure. 
 
 
Figure 6.20 Packing and hydrogen bonding within the 5-nitroisophthalic acid crystal structure. 
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The packing seen in both 5-nitroisophthalic acid and ornidazole:5-nitroisophthalic acid (Figures 
6.18 and 6.20) is very similar featuring a herringbone shape and hydrogen bonding occurring 
between planes of the molecules. The crystal structure of ornidazole differs significantly from 
that of 5-nitroisophthalic acid and the co-crystal, with hydrogen bonding between groups of 
molecules leading to a completely different packing arrangement. Due to the nature of this 
molecular arrangement, there are planes within the structure in which hydrogen bonding is not 
present and although further examination of the structure would be required to substantiate 
the theory, it is possible that these could be identified as slip planes. 
 
6.4.3 Compression and hardness testing 
Approximately 20mg of pure compound was weighed out and compressed with a maximum load 
setting of 200kg using a Gamlen tablet press with a 3mm die size. The tablet was ejected, its 
width measured using digital callipers and its hardness tested using a Sotax HT-1 hardness tester 
calibrated to 1N. This was repeated for each material to produce multiple tablets and the 
measurements recorded (Table 6.4). Production of tablets of reasonable integrity from the pure 
compounds was not straightforward and required multiple adjustments of the maximum load 
before a number of suitable tables could be formed. Measuring hardness in the normal manner 
across the diameter of the tablet also proved problematic in terms of obtaining reproducible 
results and so the hardness was measured across the height of the tablet (thickness). This 
precluded the calculation of tensile strength of the tablets, however led to more meaningful 
results, if still more varied than ideally desired. 
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Table 6.4 Measurements of the produced tablets of ornidazole (O), 5-nitroisophathlic acid (N) and 
ornidazole:5-nitroisophathlic acid (ON). 
Sample Mass (mg) Compression force (MPa) Thickness (mm) Hardness (N) 
O1 18.3 333.02 1.74 184 
O2 17.2 307.99 1.61 196 
O3 20 302.68 1.17 93 
Av (mean) 18.5 314.57 1.51 158 
sd 1.152 13.230 0.244 45.988   
 
  
N1 19.5 300.45 1.75 126 
N2 20.9 296.72 1.87 89 
N3 20.5 296.88 1.94 93 
Av (mean) 20.3 298.02 1.85 103 
sd 0.589 1.721 0.078 16.580   
 
  
ON1 20.5 289.43 1.74 109 
ON2 20.7 286.62 1.84 117 
ON3 22.5 286.55 1.91 107 
Av (mean) 21.2 287.53 1.83 111 
sd 0.899 1.344 0.070 4.320 
 
The results are presented in Table 6.4 and with the exception of those for the ornidazole:5-
nitroisophathlic acid tablets, were somewhat inconsistent. There are still some clear outcomes 
from these results though, namely that the ornidazole tablets had a far greater hardness than 
the tablets of the other two materials, and that although similar, the ornidazole:5-
nitroisophathlic acid tablets had less variability and a slight advantage in hardness. Taking the 
findings from the analysis of crystal packing of these materials into consideration, the possible 
presence of slip planes in the crystal structure of ornidazole, allowing better compaction, and 
lack thereof in 5-nitroisophthalic acid and ornidazole:5-nitroisophthalic acid, resulting in lower 
hardness, fits well with these results. It is well known that the presence of slip planes in a crystal 
structure can lead to greater plastic deformation and in turn, better compaction, this is 
exemplified by the superiority of form II of paracetamol in comparison to form I in this respect.176 
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6.4.4 Dynamic vapour sorption 
DVS analysis was undertaken for the ornidazole, 5-nitroisophthalic acid and ornidazole:5-
nitroisophthalic acid, following the standard DVS method detailed in Chapter 2. The resulting 
isotherm and change in mass plots are shown in Figures 6.21 to 6.23 below. 
 
Figure 6.21 Isotherm plot from DVS analysis of ornidazole (left) and plot showing percentage change in 
mass versus the target relative humidity over time (right). 
 
During the initial sorption cycle for ornidazole, as relative humidity is increased to 70%, mass 
reduces slightly before stabilising and varying by less than 0.05% for the rest of the sorption and 
desorption cycles. This is likely caused by the sample containing a very small amount of 
amorphous ornidazole; as the relative humidity is increased water is taken up by this amorphous 
material, causing plasticisation and increasing molecular mobility to the point that induces 
crystallisation in the remaining amorphous material. The mass loss seen is due to the loss of the 
water molecules from the sample as this small amount of amorphous material crystallises. Once 
the sample is fully crystalline, by 70% relative humidity of the initial cycle, any further mass 
change is negligible. 
 
Figure 6.22 Isotherm plot from DVS analysis of 5-nitroisophthalic acid (left) and plot showing percentage 
change in mass versus the target relative humidity over time (right). 
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For 5-nitroisophthalic acid all changes in mass measured during the two sorption and desorption 
cycles are within an approximate 0.05% range (note scale of y-axis Figure 6.22) and as such are 
likely explained by surface adsorption and desorption of water. 
 
Figure 6.23 Isotherm plot from DVS analysis of ornidazole:5-nitroisophthalic acid (left) and plot showing 
percentage change in mass versus the target relative humidity over time (right). 
Results from the DVS analysis of ornidazole:5-nitroisophthalic acid are presented in Figure 6.23 
and again, taking note of the scale of the y-axis, all changes in mass are likely due to surface 
adsorption and desorption of water, with less than 0.3% mass change. 
6.4.5 Intrinsic dissolution testing 
6.4.5.1 Method 
The Sirius surface dissolution imager (SDI) equipment was used to determine the intrinsic 
dissolution rate for ornidazole, 5-nitroisophthalic acid and the ornidazole:5-nitroisophthalic acid 
co-crystal. The SDI is a flow through cell approach that uses a laminar flow cell to determine 
intrinsic dissolution from a UV sensor array. FaSSIF-v2 is a biorelevant media produced (and 
purchased from) biorelevant.com, which simulates the intestinal fluid in the fasted state. It was 
chosen as the dissolution medium for this experiment to improve the biorelevance of the results 
compared to a simple buffer and was used at 37°C throughout and UV absorbance was 
measured at a wavelength of 280nm. The flow rates used were 0.8ml/min for 10 minutes and 
0.2ml/min for 10 minutes, which are the standard flow rates nominally equivalent to the fed 
and fasted states respectively, based on the Apparatus 4 volumetric rates when factored for 
flow cell volume. Intrinsic dissolution rate is calculated by the SDI software and requires the 
molar extinction coefficient for the compound being tested for this calculation. To determine 
the molar extinction coefficient (also called the molar absorptivity or molar attenuation 
coefficient) UV calibration curves were produced for each of the three compounds (ornidazole, 
5-nitroisophthalic acid and the ornidazole:5-nitroisophthalic co-crystal). 
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6.4.5.2 UV calibration curve preparation 
To produce the UV calibration standards, the pure substances were dissolved in a 20% ethanol 
80% acetonitrile mixture to give 400µg/ml stock solutions. Aliquots from these stock solutions 
were diluted with the appropriate amount of FaSSIF-v2 to produce the calibration standards at 
concentrations of 100, 50, 20, 10 and 5µg/ml. UV absorbance was measured using an Agilent 
Technologies Cary 100 UV-Vis spectrophotometer, the measurements listed in Table 6.5, and 
the calibration curves presented in Figure 6.24 below. 
Table 6.5 UV absorbance measurements for the calibration standards of ornidazole, 5-nitroisophthalic 
acid and ornidazole:5-nitroisophthalic acid. 
Concentration 
(µg/ml) 
Absorbance at 280nm 
Ornidazole 
5-Nitroisophthalic 
acid 
Ornidazole:5-
Nitroisophthalic acid 
5 0.0768 0.1777 0.1327 
10 0.1382 0.2450 0.2262 
20 0.2542 0.5050 0.3793 
50 0.5741 1.2020 0.9434 
100 1.1303 2.1150 1.7819 
 
 
Figure 6.24 UV calibration curves for ornidazole, 5-nitroisophthalic acid and ornidazole:5-nitroisophthalic 
acid in FaSSIF-v2 at 280nm. 
The trend lines for all three UV calibration curves gave equations with R2 values of greater than 
0.99 and are thus acceptable for use in the determination of intrinsic dissolution rate. The figure 
above was plotted with concentration in the units of µg/ml, however by plotting the same graph 
with molar concentrations the value for the gradient of the trend lines gives the molar extinction 
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coefficient. The values obtained for the molar extinction coefficients for each material are 
reported in Table 6.6. 
Table 6.6 Molar extinction coefficients determined from UV calibration curves. 
Material Molar extinction coefficient (M-1cm-1) 
Ornidazole 2505.5 
5-Nitroisophthalic acid 4620.4 
Ornidazole:5-Nitroisophthalic acid 7800.7 
 
6.4.5.3 Analysis 
The intrinsic dissolution testing was carried out as stated and the measurements recorded by 
the SDI software. Full results are reported in Appendix 6.5 and a selection of results at the two 
different flow rates have been consolidated in Table 6.5. The average intrinsic dissolution rate 
and surface concentration in one-minute segments were calculated throughout the 
experiments. The results for one-minute sections taken in the middle of the runs for both flow 
rates (5-6 minutes and 15-16 minutes for 0.2ml/min and 0.8ml/min flow rates respectively) are 
listed in Table 6.7 for each material. The full results set shows a relatively high consistency 
throughout the measurements within each flow rate for all three materials. At the start and end 
of each section (whenever the flow rate changes) higher variation is seen in IDR, which is the 
reason the segments chosen to include in the consolidated results table were from the middle 
of the time ranges. The main exceptions are the IDR for 5-nitroisophthalic acid at 0.2ml/min flow 
rate where there is a larger variation throughout that section of the experiment, and the surface 
concentration of ornidazole:5-nitroisophthalic acid which increased greatly during the 
0.8ml/min flow rate section.  
Table 6.7 Consolidated results for the intrinsic dissolution testing of ornidazole, 5-nitroisophthalic acid 
and ornidazole:5-nitroisophthalic acid in FaSSIF-v2. 
Material 
Time 
period 
(mins) 
Flow Rate 
(ml/min) 
Surface 
concentration 
(mg/ml) 
IDR 
(µg/min/cm2) 
Standard 
deviation 
Ornidazole 
5-6 0.2 222.63 190.18 4.80 
15-6 0.8 162.18 275.47 8.16 
5-Nitroisophthalic 
acid 
5-6 0.2 195.29 322.31 17.37 
15-16 0.8 161.51 269.45 3.64 
Ornidazole:5-
Nitroisophthalic 
acid 
5-6 0.2 102.09 59.17 1.13 
15-16 0.8 6.80 41.45 0.86 
 
 
162 
 
 
Figure 6.25 False colour snapshots of the measurements from the UV detector array at the midpoint (5 
minutes) of the 0.2ml/min flow rate section of the experiment for ornidazole (top), 5-nitroisophthalic 
acid (middle) and ornidazole:5-nitroisophthalic acid (bottom). 
163 
 
 
Figure 6.26 False colour snapshots of the measurements from the UV detector array at the midpoint (15 
minutes) of the 0.8ml/min flow rate section of the experiment for ornidazole (top), 5-nitroisophthalic 
acid (middle) and ornidazole:5-nitroisophthalic acid (bottom). 
 
Figures 6.25 and 6.26 show false colour images produced from the measurements from the UV 
detector array at a specific point during the experiments for each material. Figure 6.25 is at the 
5 minute timepoint of the experiment which is the midpoint for the 0.2ml/min flow rate section 
and Figure 6.26 is at the 15 minute timepoint, the midpoint for the 0.2ml/min flow rate section. 
These images give a visual representation of the concentration of each material throughout the 
flow cell, with higher absorbance values displayed in red and reducing to dark blue where no 
absorbance is occurring. In general, the images in Figures 6.25 and 6.26 match the calculated 
IDR results in that at the given flow rate, the material with the higher IDR value can be seen to 
have a greater area of high concentration. 
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The sample is situated in the centre of the image and flow of the dissolution media is from left 
to right. In the 5-nitroisophthalic image in Figure 6.25 there is an area of high concentration in 
the top right, above where it would be expected from looking at the rest of the concentration 
profile. A possible explanation for this would be that some material broke away from the 
compacted sample and allowed a greater surface area for dissolution. The production of this 
‘front’ which moved with the flow out of the flow cell could be the cause of the higher variation 
in IDR recorded for 0.2ml/min flow rate section of the experiment and would explain the higher 
IDR also seen throughout the middle section of the experiment in Figure 6.27. 
 
 
Figure 6.27 Intrinsic dissolution rate of ornidazole, 5-nitroisophthalic acid and ornidazole:5-
nitroisophthalic acid in FaSSIF-v2 at a flow rate of 0.2ml/min over 10 minutes (n=1). 
 
Figures 6.27 and 6.28 show the IDR plotted over the course of the full experiment, with a single 
average value plotted for the preceding 60 seconds. These results are split between the first 10 
minutes at 0.2ml/min and the second 10minutes at 0.8ml/min flow rates. The unusually high 
measurement at the start of the 0.8ml/min experiments is due to the change in flow rate as 
these measurements followed directly from the 0.2ml/min experiment. Once the flow rate had 
stabilised it is clear that IDR is consistent throughout the remaining experiment run time. 
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Figure 6.28 Intrinsic dissolution rate of ornidazole, 5-nitroisophthalic acid and ornidazole:5-
nitroisophthalic acid in FaSSIF-v2 at a flow rate of 0.8ml/min over 10 minutes (n=1). 
 
 
 
Figure 6.29 Cumulative mass of ornidazole, 5-nitroisophthalic acid and ornidazole:5-nitroisophthalic acid 
released over 10 minutes in FaSSIF-v2 at a flow rate of 0.2ml/min (n=1). 
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Figure 6.30 Cumulative mass of ornidazole, 5-nitroisophthalic acid and ornidazole:5-nitroisophthalic acid 
released over 10 minutes in FaSSIF-v2 at a flow rate of 0.8ml/min (n=1). 
 
The cumulative mass released from the samples at the 0.2ml/min and 0.8ml/min flow rates are 
shown in Figures 6.29 and 6.30 respectively. These correspond well with the IDR plots, with both 
ornidazole and 5-nitroisophthalic acid displaying much greater sample release over the 
equivalent period of time as the ornidazole:5-nitroisophthalic acid co-crystal at both flow rates. 
 
6.4.6 Summary 
Further investigation into the ornidazole:5-nitroisophthalic acid system by single crystal X-ray 
diffraction led to the determination of its crystal structure, which has been identified as a 1:1 
co-crystal. Analysis of the crystal structure in structure in comparison of those of pure 5-
nitroisophthalic acid and ornidazole showed greater similarity between the co-crystal and 5-
nitroisophthalic acid than with ornidazole, especially in terms of the presence of potential slip 
planes. Relating this to the outcome of the compression and hardness testing, it is likely that 
greater plastic deformation occurs in ornidazole than either 5-nitroisophthalic acid or the co-
crystal due to the features of the packing within the crystal structures, i.e. potential slip planes, 
and results in the greater hardness measured in the ornidazole tablets. 
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DVS analysis showed very little difference in water sorption between the three compounds, with 
no hydration occurring in any of the samples. The intrinsic dissolution experiments however, 
resulted in an unexpected outcome; the IDR measured for the co-crystal was lower than that of 
either parent component. Intrinsic dissolution rate has been shown to correlate with solubility 
in many systems,177,178 hence this outcome is unusual as co-crystals normally have a solubility 
between that of the parent materials,21 with more soluble co-formers leading to more soluble 
co-crystals.49,179 There are numerous examples of co-crystals in which intrinsic dissolution rate 
is improved compared to the parent drug for example flufenamic acid:theophylline159 and 
nitazoxanide:p-aminosalicylic acid.180 
The melting point of the ornidazole:5-nitroisophthalic acid co-crystal is between that of 
ornidazole and 5-nitroisophthalic acid, providing no suggestion of a lower IDR before the 
measurement. Although increasing the solubility and release rate of the parent API by co-
crystallisation is often the aim, the lower IDR measured for the co-crystal in this case shows the 
potential for co-crystal use in the development of a slow-release formulations. Such use of co-
crystals has previously been postulated,181  and examples of co-crystal of ribavirin with reduced 
release rates reported.182 
 
6.5 Conclusions 
The work presented in this chapter has served as further validation of the optimised co-crystal 
screening method as developed in Chapter 3 by proving its utility, applying the method to 
ornidazole as a model API and resulting in 23 hits of out the top 46 computationally predicted 
co-formers for the API and importantly including the two positive controls. Further investigation 
in the form of DSC and TGA analysis of the hits found that many of these materials were not 
pure co-crystal. Production of pure co-crystal phases is certainly not an expectation for a co-
crystal screen, and many new phases were correctly detected by the screening process. The 
evaporative crystallisation experiments showed that for potential future scaled up production, 
the method of manufacture would require further consideration as the materials produced did 
not always match those produced by the initial ultrasonication based co-crystal screening 
method. 
The ornidazole:5-nitrisophthalic acid system was identified for more thorough characterisation 
and was found to differ from the norm regarding its lower IDR compared to both parent 
components, but which does not correlate with its melting point which, like the majority of co-
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crystals, falls between those of both its parent materials. The lower dissolution rate is the 
opposite of the intention of most rationales for developing co-crystals however the 
ornidazole:5-nitroisophthalic acid co-crystal was found to crystallise much more readily than 
ornidazole alone. Although normally a reduction in solubility may negatively outweigh any 
benefits, in some cases such as with relatively soluble drugs (such as ornidazole) in which a slight 
reduction in solubility wouldn't have as negative an impact on bioavailability, the improvement 
in crystallisation kinetics and crystallinity may be worth the solubility hit for the vast 
improvement in processing ability. 
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Chapter 7 – Formulation and performance of 
zafirlukast:piperazine co-crystals 
 
7.1 Introduction 
This thesis, up until now has mainly focused on the processes involved in screening for and 
producing co-crystals/binary materials and has looked in depth at the properties of only one of 
these new forms – ornidazole:5-nitroisothalic acid in Chapter 6. This chapter therefore concerns 
the measurement of performance of the co-crystals in terms of properties relevant to the oral 
bioavailability of the form if it were to be administered to a patient. 
Areas of study which are important when considering the performance of a medicine to be 
administered to a patient include pharmacokinetics and pharmacodynamics, and stability (both 
chemical and physical) when thinking about storage and shelf life. When looking at different 
forms of the same drug, the aim is to improve the pharmacokinetics of the drug, specifically the 
efficiency of absorption processes. These can be broken down into a number of semi-
independent steps which include improving solubility of the drug and dissolution rate of the 
form, and permeability of the drug. Permeability is not something that is readily altered and 
generally requires chemical modification of the API or the addition of permeability enhances to 
the formulation. 
The work presented in this chapter has been to determine robust methods for the measurement 
and characterisation for an API (zafirlukast), and three stoichiometric co-crystals of this drug and 
piperazine.183 These co-crystal forms were discovered by Dr Rafel Prohens (CIRCE) as part of an 
AZ project and our group became involved to carry out further characterisation work. Zafirlukast 
is a leukotriene receptor antagonist and is used as an oral treatment for asthma.184 The original 
crystalline tablet formulation of zafirlukast used during development and early clinical trials 
resulted in unacceptably low bioavailability and was replaced by an amorphous formulation 
which is the form of the marketed product.185,186 Zafirlukast is a perfect candidate for co-
crystallisation then, as the solubility and hence bioavailability may be improved compared to 
the crystalline pure drug. Additionally, potential improvements to the ease of manufacturing 
compared to the amorphous form may be achieved and having a thermodynamically stable co-
crystalline form negates the concerns of crystallisation from an amorphous form with regard to 
physical stability and shelf life of the product. 
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7.2 Production of co-crystals 
Small samples of three co-crystals of zafirlukast and piperazine (1:1, 2:1 and a toluene solvate 
of a 1:1 co-crystal) in addition to a larger supply of pure zafirlukast were provided by AZ for this 
work. The quantity received was sufficient to carry out a number of characterisation and 
property determination experiments which will be presented within this chapter, however for 
more robust dissolution and in vivo experiments a greater supply was required. This necessitated 
the production of a greater quantity of the co-crystals in-house and this was mostly successfully 
achieved by scaling up the method used to produce the original batches by AZ. The original 
documented methods are presented in Appendix 7.1. The methods detailed below are adapted 
only by the quantity of material necessary to scale up and some of the timings. The only 
exception to this was the zafirlukast:piperazine co-crystal (2:1) Form A which required further 
modification to the method in order for robust scale up to be achieved. 
7.2.1 Zafirlukast:piperazine co-crystal (2:1) Form A 
Obtained by slurry in acetonitrile at room temperature after initial slow crystallization from a 
solution of zafirlukast:piperazine (1:1) in ethanol. Zafirlukast (2.0242 g) and piperazine (312.7 
mg), molar ratio 1:1, were dissolved in ethanol (500 mL) at 60-70°C. The solution was left to cool 
down to room temperature and the liquid evaporate. 
PXRD analysis, detailed below, showed that this process did not achieve production of the co-
crystal; a small sample of the material was removed and the rest of the material was then 
slurried in approximately 15ml ethanol at room temperature for 71 hours. This yielded (2:1) 
Form A (m.p. of product 220.6°C). Net amount of product after drying = 1.1421g (Yield = 52.5%) 
7.2.2 Zafirlukast:piperazine co-crystal (1:1) Form D 
Obtained by slurry in acetonitrile at room temperature. Zafirlukast (2.0246 g) and piperazine 
(438.9 mg), molar ratio 1:1.5, were slurred in acetonitrile (40 mL) at room temperature for 64 
hours. The solid was filtered and dried under vacuum for 48 hours. (m.p. of product 181.0°C). 
Net amount of product after drying = 1.9686g (Yield = 84.6%) 
7.2.3 Zafirlukast:piperazine co-crystal (1:1) toluene solvate Form E 
Obtained by slurry in toluene at room temperature. Zafirlukast (1.9993 g) and piperazine (444.9 
mg), molar ratio 1:1.5, were slurred in toluene (40 mL) at room temperature for 29 hours. The 
solid was filtered and dried under vacuum for 42 hours. (m.p. of product 119.2°C). Net amount 
of product after drying = 2.2356g (Yield = 89.0%) 
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7.3 Characterisation of co-crystals 
7.3.1 Powder X-ray diffractometry 
PXRD patterns were recorded for the produced co-crystals, following the standard XRPD method 
detailed in Chapter 2, and compared to those of the reference patterns of the co-crystals to 
confirm equivalence. These consistent PXRD patterns are displayed in Figure 7.1 and details of 
the different batches are presented in Table 7.1.  
 
Table 7.1 Details of zafirlukast:piperazine co-crystals. 
Material Batch Origin 
Zafirlukast:piperazine 2:1 
co-crystal 
Bx37b, Bx42, Bx45 Received from CIRCE/AZ 
ZP21CC Produced at Durham University 
Zafirlukast:piperazine 1:1 
co-crystal 
Bx24, Bx43 Received from CIRCE/AZ 
ZP11CC Produced at Durham University 
Zafirlukast:piperazine co-crystal 
toluene solvate (3:3:2) 
Bx26b, Bx44 Received from CIRCE/AZ 
ZPTSCC Produced at Durham University 
 
 
 
Figure 7.1 PXRD patterns of zafirlukast (red) and piperazine (blue) with those of the original co-crystals 
produced by AZ/CIRCE: 2:1 (light green), 1:1 (yellow) and toluene solvate (lilac), and those produced in-
house: 2:1 (ZP21CC, dark green), 1:1 (ZP11CC, orange) and toluene solvate (ZPTSCC, purple). 
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Each of the pairs of PXRD patterns for the co-crystals match, which confirms that the correct 
forms were produced in each case. PXRD patterns of a sample from the intermediate material 
produced after the initial attempt to produce the 2:1 co-crystal, along with those of the 
reference sample and parent components are shown in Figure 7.2. The presence of the peak at 
5.5° 2θ suggest that some conversion to the co-crystal has occurred but extra peaks, for example 
those at 11.3° and 17.1° 2θ, are evidence that the sample still contains some impurities, i.e. 
starting material. This analysis led to the application of the alternative slurry method to produce 
the desired co-crystal form displayed as the dark green pattern which is consistent with the 
reference 2:1 co-crystal pattern (light green, Figure 7.2). 
 
 
Figure 7.2 PXRD patterns of the intermediate material produced after the initial attempt to produce the 
2:1 co-crystal (light blue), with those of the starting materials: zafirlukast (red) and piperazine (blue); the 
original 2:1 co-crystal produced by AZ/CIRCE (light green), and the 2:1 co-crystal produced from the 
intermediate (ZP21CC, dark green). 
 
7.3.2 Differential scanning calorimetry 
DSC thermograms were recorded for the produced co-crystals, following the standard DSC ramp 
method detailed in Chapter 2. The DSC traces displayed in Figure 7.3 were obtained from 
samples of co-crystals received from CIRCE/AZ (Bx24, Bx26b and Bx42) and those in Figure 7.4 
from the co-crystals produced in-house and of zafirlukast and piperazine as received. The DSC 
traces for ZP11CC and ZP21CC correspond well with and display very similar melting points to 
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those of the reference materials. Together with the matching powder patterns shown above 
(Figure 7.1), this would be sufficient evidence to prove to a regulator that these were the same 
form for batch release. The profile for ZPTSCC has a lower onset temperature for the 
endothermic peak, compared to the reference material and could indicate a slight difference in 
desolvation behaviour which is also apparent in the TGA profiles of the two materials. 
 
 
Figure 7.3 DSC profiles of the 1:1 (olive), 2:1 (green) and toluene solvate (purple) zafirlukast:piperazine 
co-crystals received from CIRCE/AZ. The peak onset temperatures are displayed by the traces. 
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Figure 7.4 DSC profiles of Zafirlukast (red), piperazine (blue) and the produced co-crystals: ZP11CC 
(olive), ZP21CC (green) and ZPTSCC (purple). The peak onset temperatures are displayed by the traces. 
 
The DSC trace of zafirlukast shows a single melting peak, as expected, at 198.2°C, however the 
profile for piperazine has a lower, broad, endothermic peak at 46.7°C followed by a much 
sharper peak at 109.2°C.  Figure 7.5 shows the DCS traces for a full heat-cool-heat method for 
the same piperazine sample with the cycles separated. It is most likely that a hydrate of 
piperazine had formed causing this lower endothermic peak. The hexahydrate form has been 
previously reported featuring a melting point matching that of the initial peak observed in Figure 
7.5.187 On second heating, once dehydrated, the melting point of the now anhydrous sample, 
matches that of the second endothermic peak of the initial cycle and literature value (listed by 
the supplier) for the melting point of piperazine of 109-112°C. 
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Figure 7.5 Separated DSC traces for piperazine showing initial heating, cooling and second heating 
cycles. (Exo. up) 
 
In addition to being used for identification purposes, the melting point information obtained 
from the DSC experiments is interesting in understanding the modifications co-crystal formation 
has on the properties of the parent drug. The melting points observed for the co-crystals differ 
significantly from pure zafirlukast but also from each other. The peak onset temperature for 
piperazine, once dehydrated, is 109.3°C. The melting point of two of the co-crystals therefore 
fall between those of co-former and API and one, the 2:1 co-crystal, is higher than either of the 
components of the co-crystal. This is a less common outcome than a melting point for the co-
crystal being between those of the two parent compounds, however is also not novel having 
been observed previously.47  
 
7.3.3 Thermogravimetric analysis 
TGA profiles were recorded for both the newly produced and original co-crystals, following the 
standard TGA method detailed in Chapter 2. A full set of DSC and TGA plots are presented in 
Appendix 7.2 and show good similarity between the received and produced 1:1 and 2:1 
zafirlukast:piperazine co-crystals. The TGA analysis of the produced and received toluene 
solvates however have a discrepancy which is highlighted in Figure 7.6. 
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Figure 7.6 TGA profile of the produced zafirlukast:piperazine co-crystal toluene solvate showing mass 
change over the temperature range of approximately 50°C to 150°C. 
 
The calculated percentage mass loss based on the 3:3:2 zafirlukast:piperazine:toluene ratio 
should be 8.49%. The intermediate step in the TGA profile equates to an 8.755% weight loss and 
is more commensurate with the calculated value, suggesting that a large constituent of the 
sample is the expected co-crystal toluene solvate. A possible explanation for the observation of 
two mass losses is the presence of a second solvated form of the co-crystal, which is left after 
desolvation of the expected solvate form. For example, it is possible that a small amount of an 
isomorphic 3:3:1 co-crystal toluene solvate formed, which could explain the identical PXRD 
patterns but which could also give rise to the recorded TGA profile and account for the slight 
disparity in mass loss given the exact content of each solvated form remains unknown. 
 
7.3.4 Dynamic vapour sorption analysis 
DVS analysis was undertaken for the original co-crystals, following the standard DVS method 
detailed in Chapter 2. The scale of the y-axis should be borne in mind when comparing between 
the compounds’ DVS plots in Figures 7.7 to 7.11.  
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Figure 7.7 Isotherm plot from DVS analysis of zafirlukast (left) and plot showing percentage change in 
mass versus the target relative humidity over time (right). 
 
The zafirlukast sample demonstrates practically no change in mass over the 0-90% RH range 
measured other than for the initial decrease during the first sorption cycle (Figure 7.7). This is 
likely caused by the sample containing a very small amount of amorphous zafirlukast. The 
increasing relative humidity above ambient conditions causes plasticisation and increased 
molecular mobility as water is taken up by this amorphous material. Crystallisation is thus 
induced leading to the expulsion of water molecules and consequently a decrease in mass is 
observed. By 60% relative humidity of the initial cycle, no amorphous material remains and any 
further mass change over the course of the measurement is negligible. The same initial decrease 
in mass due to the presence of small quantities of amorphous material is seen in the 1:1 and 2:1 
zafirlukast:piperazine co-crystals (Figures 7.8 and 7.9).  
 
 
Figure 7.8 Isotherm plot from DVS analysis of the zafirlukast:piperazine 1:1 co-crystal (left) and plot 
showing percentage change in mass versus the target relative humidity over time (right). 
 
In the isotherm plot for the 1:1 co-crystal (Figure 7.8) the presence of hysteresis suggests that a 
structure change is occurring however taking into consideration the percentage mass changes 
measured, it is unlikely that it is a stoichiometric hydrate. 
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Figure 7.9 Isotherm plot from DVS analysis of the zafirlukast:piperazine 2:1 co-crystal (left) and plot 
showing percentage change in mass versus the target relative humidity over time (right). 
 
After the initial decrease in mass in the first sorption cycle, the 2:1 co-crystal displays a very 
minor increase in mass during sorption cycles and decrease during desorption cycles, this is very 
likely due to surface adsorption and desorption of water. 
 
 
 
Figure 7.10 Isotherm plot from DVS analysis of the zafirlukast:piperazine 1:1 co-crystal toluene solvate 
(left) and plot showing percentage change in mass versus the target relative humidity over time (right). 
 
The isotherm plot for the zafirlukast:piperazine co-crystal toluene solvate (Figure 7.10) is 
interesting as it shows that by the end of the first desorption cycle the total mass is lower than 
the initial sample mass. Mass increases with RH again in the second sorption cycle, but again 
ends at a lower mass than at the beginning of the second cycle. A potential cause of the observed 
behaviour would be that the uptake of water molecules disrupts the solvate crystal structure 
leading to the partial release of toluene from the sample, repeating with a less significant loss 
of toluene seen in the second cycle. 
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Figure 7.11 Isotherm plot from DVS analysis of piperazine (left) and plot showing percentage change in 
mass versus the target relative humidity over time (right). 
DVS analysis of piperazine resulted in large variations in sample mass during the first cycle and 
similar patterns of variation but proportionally less mass change in the second. Similarly to in 
the case of the toluene solvate, the mass of the sample after analysis was less than at the 
beginning. Piperazine is known to be deliquescent,188 justifying the very large percentage mass 
increase observed, and volatile,189 potentially the cause of sample loss. 
Zafirlukast and the 2:1 co-crystal show very little moisture sensitivity, however the 1:1 co-crystal 
does exhibit a small degree of hygroscopicity. Both piperazine and the zafirlukast:piperazine co-
crystal toluene solvate display sample loss, though likely through different mechanisms. Overall 
the introduction of secondary components to the zafirlukast crystal structure introduces varying 
levels of moisture sorption tendencies. With the 2:1 co-crystal this is limited to surface 
adsorption and would likely not pose a problem in terms of physical stability, however with the 
1:1 co-crystal and toluene solvate, this could not be guaranteed. 
 
7.3.5 Compression and hardness testing 
Approximately 50mg of pure compound was weighed out and compressed with a maximum load 
setting of 400kg using a Gamlen tablet press with a 6mm die size. The tablet was ejected and its 
hardness tested using a Sotax HT-1 hardness tester calibrated to 1N. This was repeated to 
produce three tablets for zafirlukast, piperazine and each of the three co-crystals and the 
measurements recorded (Table 7.2). 
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Table 7.2 Measurements of the produced tablets of zafirlukast (ZAF), piperazine (PIP), the 1:1 (1:1CC), 
2:1 (2:1CC) and toluene solvate (TSCC) zafirlukast:piperazine co-crystals. 
Sample Sample mass (mg) Compression force (MPa) Hardness (N) 
ZAF 1 49.0 150.56 13 
ZAF 2 49.6 150.09 16 
ZAF 3 50.2 150.13 12 
Av. (mean) 49.6 150.26 13.7 
s.d. 0.490 0.210 1.700     
PIP 1 48.7 151.09 48 
PIP 2 48.9 155.76 41 
PIP 3 50.6 153.25 44 
Av. (mean) 49.4 153.37 44.3 
s.d. 0.85 1.91 2.87     
2:1CC 1 50.5 145.18 16 
2:1CC 2 50.3 145.12 12 
2:1CC 3 47.7 145.33 12 
Av. (mean) 49.5 145.21 13.3 
s.d. 1.275 0.086 1.886     
1:1CC 1 50.8 146.64 28 
1:1CC 2 51.1 146.19 28 
1:1CC 3 50.3 146.55 28 
Av. (mean) 50.7 146.46 28.0 
s.d. 0.330 0.194 0.000     
TSCC 1 52.4 144.84 67 
TSCC 2 50.0 145.00 61 
TSCC 3 51.8 144.21 46 
Av. (mean) 51.4 144.69 58.0 
s.d. 1.020 0.341 8.832 
 
Large differences in hardness were measured between the tables of pure zafirlukast and 
piperazine and the co-crystals. Both the zafirlukast and the 2:1 co-crystal tablets displayed 
similarly low hardness with an average around 13N, piperazine tablets had much greater 
hardness with an average of 44.3N and the 1:1 co-crystal fell between these values with a 
measurement of 28N. The toluene solvate tablets displayed a far greater hardness than the 
other co-crystals and even more than that of piperazine at an average of 58N.  
The large variation in hardness of the tablets of the co-crystals suggest differences in the crystal 
structures of these materials leading to improved compaction and thus increased hardness. 
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Unfortunately not all crystal structures are available for the materials under investigation, 
however those of pure zafirlukast and the 2:1 zafirlukast:piperazine co-crystal have been 
reported by Llinas et al.183 and that of piperazine by Parkin et al.190 The packing and hydrogen 
bonding within these structures are displayed in Figures 7.12 to 7.14 below. The crystal structure 
of zafirlukast (Figure 7.12) contains intermolecular hydrogen bonds between amide groups 
forming ribbons of zafirlukast molecules. The structure of the co-crystal differs significantly from 
that of pure zafirlukast, with zafirlukast molecules forming chains and piperazine molecules 
occupying a cavity formed by four zafirlukast molecules and participating in hydrogen bonding 
(Figure 7.13). Although notably different, possible similarities between these two crystal 
structures, such as a potential lack of slip planes could lead to both materials possessing poor 
compressibility which would cause the low hardness observed. It is likely that features of the 
crystal structure of the zafirlukast:piperazine co-crystal toluene solvate support significant 
compressibility resulting in a comparably very high hardness of the material as measured. 
 
Figure 7.12 Packing and hydrogen bonding within the zafirlukast crystal structure. 
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Figure 7.13 Packing and hydrogen bonding within the 2:1 zafirlukast:piperazine crystal structure. 
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Figure 7.14 Packing and hydrogen bonding within the piperazine crystal structure. 
 
7.4 Solubility and dissolution determination 
7.4.1 Preliminary work 
HPLC was chosen as the analytical technique for solubility and dissolution determination as only 
the concentration of zafirlukast was sought, but as the dissolution of co-crystals produces a 
solution containing two solutes (API and co-former) chromatography would allow the separation 
and measurement of the concentration of the API alone. 
7.4.1.1 HPLC method development 
An HPLC method for the detection of zafirlukast was found to have been previously reported,191 
and after further development resulted in the following method which was used in this work. 
HPLC analyses were performed using an Agilent 1260 Infinity fitted with an Agilent Eclipse Plus 
C18 reverse-phase column (3.5µm particle size, 4.6 x 100mm). The mobile phase used was a 
30:70 ratio solution of pH 3.5 0.01M KH2PO4 buffer and acetonitrile. Injection volume was 100µl 
and elution of the sample constituents occurred over 6 minutes at a flow rate of 1ml/min, with 
column temperature set at 22-25°C. The detector used was an Agilent 1260 VWD 
spectrophotometer set at a wavelength of 223nm. 
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7.4.1.2 NMR investigation into potential degradation of zafirlukast 
Preliminary dissolution testing had produced dissolution profiles similar to those seen in Figure 
7.17 and an initial concern was that degradation of zafirlukast may be responsible for the 
reduction in concentration measured during the dissolution test. Given that the zafirlukast 
molecule contains amide functionality, and is therefore potentially liable to hydrolysis occurring, 
its stability in aqueous media was examined. Two samples of zafirlukast were prepared for NMR 
analysis one simply by dissolving in deuterated DMSO and the other by first leaving in water at 
37°C for approximately 12 hours, much in excess of the timescale of the dissolution experiments, 
filtering and drying. The spectra obtained by NMR analysis of the two samples are shown in 
Figures 7.15 and 7.16 for the unprocessed zafirlukast and the zafirlukast from aqueous solution 
samples respectively. As can be seen, there is no observable difference between the spectra, 
indicating that, at least within the timescale and temperature range investigated, zafirlukast 
remains stable in aqueous media and that degradation was not responsible for the irregular 
results obtained from the dissolution testing. 
 
Figure 7.15 1H NMR spectrum of a sample of pure zafirlukast. 
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Figure 7.16 1H NMR spectrum of a sample of zafirlukast which had been stirred in water at 37°C for 
approximately 12 hours prior to drying and analysis. Note the near identicality to the spectrum of pure 
zafirlukast (Figure 7.15). 
 
7.4.2 Solubility measurement 
Solubility of crystalline zafirlukast and the three co-crystals was measure in purified water at 
room temperature (20°C) by adding an excess amount of each material to a vial of purified water 
which was left stirring for approximately 24 hours. The solution was filtered, 1ml of each solution 
was diluted with 9ml of mobile phase and analysed by HPLC resulting in the concentrations listed 
in Table 7.3 below (accounting for the dilution). 
 
Table 7.3 Solubility measurements for zafirlukast and the three zafirlukast:piperazine co-crystals. 
Material 
Solubility in water at 20°C as 
measured by HPLC (µg/ml) 
Zafirlukast 3.018 
Zafirlukast:piperazine 2:1 co-crystal 4.957 
Zafirlukast:piperazine 1:1 co-crystal 42.805 
Zafirlukast:piperazine 1:1 co-crystal toluene solvate 293.0568 
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7.4.3 Dissolution testing with developed method 
7.4.3.1 Experimental details 
Calibration standards were produced from a 1mg/ml zafirlukast in acetonitrile stock solution by 
diluting with mobile phase to double the concentration required. These solutions were diluted 
with an equal volume of SGF to produce the calibration standards used. 
The mobile phase used was a 30:70 ratio solution of pH 3.5 0.01M KH2PO4 buffer and 
acetonitrile. Samples from dissolution testing were taken using an Agilent 850-DS auto sampler 
and diluted with an equal volume of mobile phase (400µl) before analysing by HPLC. The HPLC 
run parameters were as follows: 100µl injection volume, 6-minute run time, 1ml/min pump 
speed and 22°C column temperature. 
The samples used for dissolution testing were four capsules per vessel, three vessels for each 
material. The capsules contained the lactose blends of the four APIs and contained 
approximately 75mg (zafirlukast), 86mg (ZP11CC), 81mg (ZP21CC) and 94mg (ZPTSCC) per 
capsule, equating to approximately 30mg of zafirlukast per dissolution vessel. USP2 apparatus 
was used, with each vessel containing 600ml SGF dissolution medium at 37°C and the paddle 
speed was 150rpm throughout the 120-minute run time. 
7.4.3.2 Dissolution results 
The available results from the experiment are displayed below in Figure 7.17. Results for a repeat 
of the experiment substituting SGF for FaSSIF are not shown as every single sample from the 
dissolution test failed to produce a detectable zafirlukast peak in HPLC analysis. The four plots 
in Figure 7.17 are of the mean percentage dissolution (n=3, error bars showing standard error) 
calculated based on the dose of zafirlukast, taking into account per vessel capsule content mass 
but not the content uniformity of the powder blend i.e. the assumed content of the API may/will 
be different from actuality. A calibration curve for the HPLC analysis of zafirlukast can be found 
in Appendix 7.3. 
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Figure 7.17 Dissolution profiles for, clockwise from top left: zafirlukast (red), ZP11CC (orange), ZP21CC 
(green) and ZPTSCC (purple), formulated as capsules of API:lactose blends (n=3). 
 
A possible explanation for the reduction in zafirlukast concentration seen in the ZP21CC and 
ZPTSCC co-crystal results could be that the co-crystals possess higher aqueous solubility than 
that of zafirlukast resulting in zafirlukast crystallising from a supersaturated solution after 
dissociating from piperazine as the co-crystal dissolves. This reduction in concentration is not 
seen in the ZP11CC co-crystal but is seen in the pure zafirlukast results which casts doubt on the 
above explanation. The considerable variability apparent in the results, in terms of inconsistent 
trend and large error within most samples, suggests that the measured concentrations are not 
reliable. Observations from the dissolution experiments led to the conclusion that the most 
likely cause of the poor quality of data was the severe lack of wetting of the powder samples. 
Figure 7.18 shows a photograph of the content of one of the capsules taken 33 minutes after 
the start of the dissolution test and the mass of undispersed powder can be seen still inside the 
capsule sinker.  
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Figure 7.18 Photograph of undispersed powder still inside the capsule sinker 33 minutes after the start of 
the experiment. 
7.4.3.3 Summary 
The results from the dissolution testing are clearly erroneous showing unexpected profiles and 
large error. These results come after much method development and indicate that the method 
employed is unsuitable for the materials under investigation. This is believed to be due to 
difficulty to achieve representative dissolution caused by a lack of wetting of the powder based 
formulation. For this reason, intrinsic dissolution testing was employed to measure the 
dissolution of these materials without need for further formulation. 
7.4.4 Intrinsic dissolution testing 
The Sirius surface dissolution imager (SDI) equipment was used to for the intrinsic dissolution 
testing of zafirlukast and the three zafirlukast:piperazine co-crystals. The experiment used 
FaSSIF-v2 as the dissolution media at 37°C throughout and UV absorbance was measured at a 
wavelength of 280nm. Due to the very low solubility of zafirlukast in the aqueous medium used 
a very low flow rate was necessary which led to the IDR being unreliably calculated by the 
software. A second method for measuring the solubility/dissolution rate was devised using a 
mode in the software whereby detection zones can be manually set. A zone at the 6mm position 
was set, which can be identified in Figure 7.19 as the orange rectangle, slightly to the right of 
the centre of each image. 
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The concentration within the pre-defined zone was measured throughout the experiment. This 
required the molar extinction coefficient of the combine component, determined by producing 
a calibration curve for each of the co-crystals and zafirlukast independently using the same 
method as described in Chapter 6 (Section 6.4.5.2). The calibration curves and determined molar 
extinction coefficients are presented in Appendix 7.4. The use of calibration curves of each co-
crystal provided well-fitting linear trend lines appropriate for the application of the Beer-
Lambert law and was deemed suitable to use for this purpose given the complication added by 
the negative correlation of concentration to absorbance observed in the piperazine calibration 
curve. Table 7.4 lists the highest peak concentration recorded within the pre-defined zone 
throughout the experiment for each of the materials and a visual representation of the 
dissolution at the midpoint of the experiment is provided by the false colour images in Figure 
7.19. 
Table 7.4 Highest peak concentration detected for each of the three co-crystals and pure zafirlukast at 
different measurement points manually selected using the IDT analysis software (n=1). 
Material Highest peak concentration at 6mm X-axis outlet (µg/ml) 
Zafirlukast 97.6844 
ZP11CC 195.507 
ZP21CC 97.9169 
ZPTSCC 182.993 
 
 
 
Figure 7.19 False colour images from the UV detector array showing the release of the four samples at 
the same time point within the respective experiments. Clockwise from top left: zafirlukast, ZP11CC, 
ZP21CC and ZPTSCC. 
 
As the concentration recorded takes into account the co-former and is not purely based on the 
concentration of zafirlukast it is not directly comparable with the solubility measurements. 
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However, it is clear to see from the images in Figure 7.19 and the measured peak concentrations 
in Table 4 that both co-crystals provide an increase in solubility and dissolution rate compared 
to zafirlukast and that the improvement is far more significant in the 1:1 co-crystal.   
 
7.5 In vivo study 
To accurately assess the effect of co-crystallisation on bioavailability, which is a much more 
important metric than simple solubility or in vitro dissolution profiles for determining the 
improvement a co-crystal product could have in the clinic, in vivo investigation is required. 
Neither the facility, nor ethical approval for this to take place on site at Durham was available, 
however through collaboration with AZ on this project it was possible to organise this testing to 
take place externally. The involvement of the author in this work was to formulate and 
characterise the dosage units to be used in the study. 
7.5.1 Formulation of capsules for in vivo study 
In order to enable a robust comparison of the co-crystals to the parent drug in the animal model 
study, the materials were formulated as capsules. Using a formulation common in early studies, 
such as a solution or suspension, is not representative of the typical use co-crystals are lauded 
for, which is oral solid dosage forms (due to the improvements in physical properties that can 
be achieved). By using a solution for example, barring any solubility enhancement in solution of 
the co-former and API, possible benefits of the co-crystalline form would be negated before the 
administration of the dose. The characterisation of the formulation in terms of content 
uniformity of the powder blend was necessary to ensure that the formulation is of an acceptable 
quality. This also serves to ensure differences seen in the results of the study are due to inherent 
differences between the APIs/co-crystals and not due to significant differences between the 
formulations. 
7.5.1.1 Powder blend and capsule production 
Excess amounts of zafirlukast, zafirlukast:piperazine co-crystal (2:1) Form A and 
zafirlukast:piperazine co-crystal (1:1) Form D were sieved to obtain the particle size fraction 
between 38 µm and 75 µm. Zafirlukast:piperazine co-crystal (1:1) toluene solvate Form E was 
not suitable for sieving and instead optical microscopy was employed to determine an 
approximate particle size of the material. A Leica DM 2700P with attached QImaging QICAM was 
used to take micrographs at 500x magnification of four samples from the material and a total of 
74 particles were measured manually. The mean diameter recorded was 8.5 µm with a standard 
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deviation of 3.39. Grades of lactose were selected with a similar particle size to the APIs, thus 
Zafirlukast, the 1:1 and the 2:1 co-crystals were blended in a 1:9 ratio by mass with Granulac 70 
and the 1:1 co-crystal toluene solvate was blended with Sorbolac 400 at the same ratio. Mixing 
was by Turbula mixer (WAB, Type T2F) and for at least 30 minutes for each blend. The resultant 
powder was weighed out into three size 9 capsules per material and the mass recorded. 
 
Table 7.5 Details of the powder blends produced, showing for each compound: molecular weight (per 
molecule of zafirlukast) (MW), number of moles required (nmol), the equivalent weight in milligrams, the 
mass of API used in the powder blend, the calculated mass of lactose required for a 1:9 API:lactose ratio, 
the actual mass of lactose used, the resulting API:lactose ratio and the calculated mass of powder blend 
required per capsule. 
Compound MW nmol 
Weight 
(mg) 
Powder blend 
Mass 
used 
(mg) 
Lactose 
required 
(mg) 
Lactose 
used 
(mg) 
API to 
lactose 
ratio 
(mg/mg) 
Mass 
required 
per 
capsule 
(mg) 
Zafirlukast 575.68 2.171 1.250 10.357 93.215 93.21 0.10001 12.499 
ZP11CC 661.82 2.171 1.437 12.560 113.036 113.06 0.09998 14.371 
ZP21CC 618.75 2.171 1.343 13.627 122.641 122.69 0.09996 13.438 
ZPTSCC 723.24 2.171 1.570 7.845 70.606 70.58 0.10003 15.696 
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Table 7.6 Details of the capsule content. 
API Capsule 
Mass of full 
capsule (mg) 
Mass of empty 
capsule (mg) 
Mass of 
blend used 
(mg) 
API (mg) 
% of 
stated 
dose 
ZAF 1 22.45 9.9 12.55 1.255058 100.405% 
 2 23.71 11.31 12.4 1.240057 99.205% 
 3 23.4 10.95 12.45 1.245058 99.605% 
    Av (mean) 1.246724 99.738% 
    sd 0.006236  
1:1 CC 1 24.81 10.49 14.32 1.431721 99.646% 
 2 24.75 10.33 14.42 1.441719 100.342% 
 3 24.5 10.12 14.38 1.437720 100.064% 
    Av (mean) 1.437053 100.018% 
    sd 0.004109  
2:1 CC 1 24.28 10.94 13.34 1.333522 99.272% 
 2 23.84 10.26 13.58 1.357514 101.058% 
 3 24.02 10.41 13.61 1.360513 101.281% 
    Av (mean) 1.350516 100.537% 
    sd 0.012079  
Tol. 
Sol. 
1 26.24 10.35 15.89 1.589525 101.237% 
 2 26.21 10.62 15.59 1.559515 99.326% 
 3 26.19 10.32 15.87 1.587524 101.110% 
    Av (mean) 1.578855 100.558% 
    sd 0.013700  
 
 
7.5.1.2 Uniformity of content determination 
For each of the four powder blends produced, three samples were taken for analysis. This was 
accomplished by first pouring the powder out of its container into a line on a sheet of clean 
paper. The three samples were taken approximately equidistantly along the line. The samples 
which were approximately 5-40 mg were weighed and the accurate mass recorded. To this 1.5 
ml of solvent was added and sonication used to aid dissolution. A 1 in 100 dilution was 
performed and the resultant solution analysed by HPLC. The concentration of Zafirlukast of each 
sample solution was determined and compared to the calculated expected mass for each 
material taking into account the differences in stoichiometry. 
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Table 7.7 Results of the uniformity of content determination. 
Sample 
Mass of 
Zafirlukast as 
analysed by 
HPLC (mg) 
Calculated mass 
of zafirlukast 
(mg) 
Zafirlukast 
content 
(as % of 
calculated) 
Mean 
Standard 
deviation 
ZAF 1 0.7106 0.8815 80.60%   
ZAF 2 0.7783 0.9575 81.28% ZAF  
ZAF 3 0.3915 0.4500 87.01% 82.96% 3.52% 
ZP11CC 1 0.6163 0.6427 95.90%   
ZP11CC 2 0.6581 0.7758 84.84% ZP11CC  
ZP11CC 3 1.0299 1.1119 92.63% 91.12% 5.68% 
ZP21CC 1 0.7916 0.9435 83.89%   
ZP21CC 2 0.7435 0.8808 84.42% ZP21CC  
ZP21CC 3 0.7403 0.7919 93.48% 87.27% 5.39% 
ZPTSCC 1 0.2600 0.3269 79.54%   
ZPTSCC 2 0.4940 0.4682 105.51% ZPTSCC  
ZPTSCC 3 0.2614 0.2843 91.95% 92.33% 12.98% 
 
7.5.2 Pharmacokinetic study 
7.5.2.1 Details 
The capsules were sent to Pharmaron (China) for dosing to male Wistar Han rats. The in vivo 
study was performed with the specifications listed in Table 7.8 and full details of the method are 
given in Appendix 7.5. A limited number of rats were available for this study and as such it is 
likely not statistically significant. Ideally a larger number of rats would have been used, sufficient 
to meet that determined by a power analysis but not in excess, to prevent unnecessary and 
unethical waste of animals. This study therefore should be thought of as a pilot and the results 
potentially indicative of the modification of properties between the solid forms but with the 
caveat of variability between the rats and doses with such a small sample size introducing 
unavoidable limitations to the study as performed. 
 
Table 7.8 Tabulated in vivo study details. 
Material (API/CC) Route Dose 
Number 
of rats 
Time points (hours) 
Zafirlukast IV 1 mg/kg 2 0, 0.033, 0.083, 0.167, 0.5, 1, 2, 4, 8, 24 
Zafirlukast PO 5 mg/kg 2 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 24 
Zaf:pip (1:1) PO 5 mg/kg 2 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 24 
Zaf:pip (2:1) PO 5 mg/kg 2 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 24 
Zaf:pip:tol (3:3:2) PO 5 mg/kg 2 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 24 
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7.5.2.2 Results 
Figure 7.20 shows the plasma concentration over time for the three co-crystals and pure 
zafirlukast, plots showing individual profiles versus the IV dose can be found in Appendix 7.6. 
Table 7.9 contains a summary of the results from the in vivo study and Table 7.10 details the 
measured pharmacokinetic parameters. 
 
 
Figure 7.20 Plasma concentration of zafirlukast vs time profile for pure zafirlukast and the three 
zafirlukast:piperazine co-crystals (n=2). 
 
Table 7.9 Summary of results of the in vivo study showing for each compound: the stated weight of API 
per capsule, dose in mg/kg, route of administration – either intravenous (IV) or oral (PO), area under the 
curve for the duration of the experiment measured for zafirlukast, and for piperazine and the calculated 
percentage oral bioavailability of zafirlukast (F% zafirlukast). 
Compound 
Weight of API 
contained 
within capsule 
(mg) 
Dose 
(mg/Kg) 
Route 
AUC0-t 
zafirlukast 
(h*µmol/L) 
AUC0-t 
piperazine 
(h*µmol/L) 
F (%) 
Zafirlukast 
Zafirlukast 
- 1 IV 39.4 NA NA 
1.250 5 PO 21.8 NA 11.1 
ZP11CC 1.437 5 PO 132 2.4 67.0 
ZP21CC 1.343 5 PO 28.1 1.12 14.3 
ZPTSCC 1.570 5 PO 53.8 2.1 27.3 
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Table 7.10 Measured pharmacokinetic parameters of zafirlukast and the zafirlukast:piperazine co-
crystals. 
Pharmacokinetic 
Parameter 
IV (mean, 
n=2) 
PO (mean, n=2) 
 Zafirlukast Zafirlukast ZP11CC ZP21CC ZPTSCC 
CL (mL/min/Kg) 0.69 ± 0.19 - - - - 
Vss (L/Kg) 0.35 ± 0.08 - - - - 
Vz (L/Kg) 0.50 ± 0.11 - - - - 
T1/2 (h) 8.55 ± 0.44 8.2 ± 0.8 5.4 ± 0.5 7.1 ± 0.7 7 ± 2 
F (%) - 11.3 ± 0.3 63 ± 8 14± 3 28 ± 6 
Cmax (µM) 35 ± 4 2.3 ± 0.0 19 ± 4 3.9 ± 0.9 5 ± 2 
Tmax (h) 0.0333 ± 0.00 1.5 ± 0.7 1.2 ± 0.3 3.0 ± 0.0 3.5 ± 0.7 
AUC (µM*h) 44 ± 12 24.9 ± 0.8 138 ± 17 32 ± 7 62 ± 13 
AUC0-24 (µM*h) 39 ± 10 21.8 ± 0.2 132 ± 15 28 ± 6 54 ± 7 
 
A significant improvement in absorption compared to zafirlukast was seen with all three co-
crystals. The 1:1 co-crystal showed the largest improvement of 5.6 times the bioavailability of 
the free drug, broadly comparable to that seen in the commercial amorphous form,185 with the 
2:1 co-crystal attaining a 1.2 times increase. This matches the in vitro solubility and dissolution 
measurements almost exactly and is an indicator of the potential ability to rank the in vivo 
performance of different stoichiometries of co-crystal based on their in vitro measurements. 
The co-crystal toluene solvate also shows an improvement in bioavailability compared to 
zafirlukast but not to the same extent as the improvement seen in the in vitro measurements. 
The presence of a third component as well as a slightly lower particle size range in the 
formulation are potential factors for causing variability of the toluene solvate performance 
compared to the other materials. 
7.6 Conclusions 
In this work, the formulation and characterisation of a poorly soluble drug and its co-crystal 
derivatives have allowed robust in vitro and in vivo performance comparisons of these materials 
to be undertaken. The significant characterisation of the formulation was necessary to achieve 
the robust comparison of the co-crystal performance to that of the API and characterisation to 
a similar extent is seen in few comparable studies.21,192 The improvements seen between the 1:1 
and 2:1 co-crystals and zafirlukast in vitro have been found to be mimicked in vivo which 
suggests that future prediction of the performance of multiply stoichiometric co-crystals may be 
possible. Should this be achievable, a reduction in the amount of animal studies required would 
be possible by utilising in vitro observations as a predictive means to enable form selection. 
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Chapter 8 – Conclusions and future work 
 
8.1 Introduction 
This chapter is split into sections which draw conclusions from, and propose potential future 
work relating to, each of the aims set out in Chapter 1. The sections are further apportioned by 
some of the objectives devised to address the aims. 
8.2 Production of co-crystals 
8.2.1 Optimisation of co-crystal screening 
The computational pre-screening element of the screening process was shown to be of value 
by, where interactions between API and co-former occurred, consistently having ranked these 
compounds highly, i.e. leading to hit detection. It was noted though, that exact values calculated 
for excess enthalpy differences are not enough by themselves for prediction of co-formers that 
will form co-crystals with any API. This is seen in the outcomes of the ROY and ornidazole co-
crystal screen where significant differences in excess enthalpy calculations did not match the 
experimental outcomes in terms of co-crystalline material forming. The excess enthalpy 
calculated for a number of co-formers which were hits from the ornidazole screen would have 
ranked very highly for the ROY screen, yet no hits were detected in the initial ROY screen. 
The optimisation presented in Chapter 3 resulted in a process and set of parameters which have 
been shown to successfully perform co-crystal screening as indicated by the outcome of the 
ornidazole co-crystal screen. Further optimisation is likely unnecessary for the current process, 
however inclusion of additional steps within the process may be warranted under certain 
circumstances. An example would be where potential co-amorphous material is produced from 
the screen, as was the case for many of the ornidazole:co-former pairs, but crystalline material 
is required. A potential solution to this could be to add a crystallisation inducement step at the 
end of the current process, for example by cycling humidity of the plate before analysis with 
PXRD. If any extra stages to the screening procedure were to be added, then optimisation before 
their implementation would be worthy of consideration. 
8.2.2 Implementation of co-crystal screen 
Two co-crystal screens were undertaken within this work, that of ROY presented in Chapter 4 
and that of ornidazole, Chapter 6. The screen applied to ROY did not find any co-crystals which 
does not reflect poorly on the screening method as not every compound will necessarily form 
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co-crystals, or at least not using a reasonable amount of resources to probe for co-crystal 
formation. Further screening of the top 10 predicted co-formers was nonetheless undertaken 
to ensure the robustness of the screen and this led to the discovery of the co-amorphous form 
of ROY and pyrogallol. The ornidazole co-crystal screen proved more successful in the traditional 
sense for a co-crystal screen, detecting 23 hits, including the two co-formers included as positive 
controls. 
Further co-crystal screening would be required in future work in order to efficiently discover a 
larger number of co-crystals for analysis and ultimate structure-property determination. Use of 
a robotics platform for which the screening method is optimised for would be necessary to 
achieve the required efficiency. 
8.2.3 Analysis of co-crystal screen products 
The initial analysis of the products of a co-crystal screen is purely to detect form change in the 
sample, i.e. a hit. In the co-crystal screens undertaken in this work both FTIR and PXRD analysis 
have been employed. Although FTIR analysis is less time consuming, PXRD analysis is preferred 
due to the more definitive conclusions as to form change which can be determined. Automated 
(96-well plate reader) Raman spectrometers are more readily available than the equivalent 
powder diffractometers and as such future work would be to compare the quality of hit 
detection between these platforms to see if the screening method could be further automated 
and available to a wider audience. 
8.3 Characterisation of co-crystals 
Identification of the product of a co-crystal screen hit follows from the initial analysis of the 
screen products for form change and was demonstrated in this thesis in Chapters 4 and 6. The 
thermal methods employed allowed the determination of the ROY:pyrogallol co-amorphous 
material and the shortlisting of the screen products most likely to be co-crystals from the 23 hits 
of the ornidazole screen. One of these products, ornidazole:5-nitroisophthalic acid, was further 
characterised using single crystal X-ray diffraction and confirmed to be a 1:1 co-crystal of these 
components. Other than the two positive controls and one further co-former (4-hydroxybenzoic 
acid) for which a co-crystal with ornidazole has previously been reported,168 that leaves 19 hits 
from the screen which are potential ornidazole co-crystals which could be further investigated 
in future work. 
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8.4 Measurement of co-crystal properties 
8.4.1 Properties closely related to bioavailability 
In Chapter 6 the intrinsic dissolution rates of ornidazole, 5-nitroisophthalic acid and the co-
crystal of these two components were measured, allowing a comparison between the co-crystal 
and the pure API. Both the solubility and intrinsic dissolution were investigated for zafirlukast 
and its three co-crystals with piperazine, again allowing comparison of property improvement 
in the co-crystalline forms compared to the drug alone. The absorption, and oral bioavailability 
compared to an IV dose of zafirlukast, were also measured for zafirlukast and the co-crystals in 
an in vivo study. 
8.4.2 Properties related to processing 
Compression and hardness testing was conducted on samples of ornidazole co-crystal and 
parent components and of the zafirlukast co-crystals and parent components in Chapters 6 and 
7 respectively. In both cases variation in the hardness measured for the compressed tablets of 
each material was observed. The presence of certain features in the crystal structures of some 
but not all of the materials are thought to contribute to the differences in compressibility and 
the measured hardness. These findings highlighted the potential for a co-crystal to enable 
improved formulation by more efficient tabletting. It was noted during the ornidazole co-crystal 
screen that some of the products, including the 5-nitroisophthalic acid co-crystal, crystallise 
more readily than pure ornidazole. In some cases, this improvement in processing ability may 
outweigh potential reductions in other properties, such as solubility, as long as they are not 
severe enough to reduce the utility of the product. 
The measurement of properties both relating to bioavailability and processing, of further co-
crystals and parent components, are of continued importance to build a large enough dataset 
to be able to determine robust relationships between parent and co-crystal properties. Future 
work would include collecting data on many more co-crystal systems to move towards this goal. 
8.5 Predictability of property modification 
In Chapter 4 it was shown that although no co-crystals of ROY were found, the computational 
pre-screen had ranked pyrogallol at a high position, indicating a likelihood for molecules of ROY 
and pyrogallol to display intermolecular interaction, based on calculation of interaction in the 
gas phase. The hit rate of 21 out of 46 (discounting the positive controls) seen in the ornidazole 
co-crystal screen presented in Chapter 6 also agrees with reports in the literature103 that support 
the use of computational pre-screening for shortlisting potential co-formers. From the work in 
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Chapter 7, a correlation between the in vitro and in vivo performance between the 1:1 and 2:1 
co-crystals and the pure API was apparent. This is promising for the future predictability of not 
only of improved properties compared to the parent drug but also of the effect of differing 
stoichiometry of the co-crystal forms.  
The idea of being able to accurately predict the physical properties and in vivo performance of 
a co-crystal simply by knowing the structure of the parent components and having measured 
some of their properties is still currently unattainable. It is hoped that this work has 
demonstrated that current research is progressing towards that goal and that such prediction, 
restricted to a specific co-crystal system, is certainly a possibility. Future work to achieve this 
goal would require the study of many more co-crystal systems, using the methods employed 
and developed within this work, to build a large dataset and, in combination with further data 
in the literature allow the construction of widely applicable structure-property relationships for 
future co-crystal systems. 
 
8.6 Summary 
Although the work presented in this thesis has used multiple model compounds between 
chapters, most of the steps for taking an API, with identified potentially unsatisfactory 
properties, through the drug development process, are covered. Chapters 3, 4 and 6 deal with 
screening for a co-crystalline form of the API with potentially improved properties; Chapter 5 
looks at how substitution with a similar co-former may be able to further modify properties of 
interest in binary materials, in this case co-amorphous rather than co-crystalline. Improvements 
in physical properties of the co-crystal compared to the pure API are investigated in Chapter 6 
and 7, and the formulation and in vivo testing of a potential co-crystalline product are explored 
in Chapter 7. The utility of co-crystals, or co-amorphous material, has been highlighted at each 
stage of drug development covered in this work and the need for further research to be able to 
predict the properties of co-crystals based on those of their parent components realised. 
In summary, a robust multi-step co-crystal screening method has been optimised which 
demonstrates utility to efficiently identify co-crystals and co-amorphous materials. The 
feasibility to predict those co-formers likely to form binary compounds with an API and the 
potential to use in vitro results to inform expected in vivo improvements in the systems studied 
have also been demonstrated.
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Appendix 3 
 
3.1 IR Spectra of caffeine, malonic acid and the calibration standards 
 
 
 
Figure 1. Infrared spectrum of caffeine. 
 
 
 
Figure 2. Infrared spectrum of malonic acid. 
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Figure 3. Infrared spectra of the calibration standards from 0% (bottom) to 100% co-crystal content (top) in 20% 
increments. 
 
3.2 IR spectra of DOE optimisation experiment samples 
 
 
Figure 4. Measured IR spectra of samples from experiments: 1 (dark blue), 2 (blue) and 3 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
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Figure 5. Measured IR spectra of samples from experiments: 4 (dark blue), 5 (blue) and 6 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
 
 
 
 
 
Figure 6. Measured IR spectra of samples from experiments: 7 (dark blue), 8 (blue) and 9 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
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Figure 7. Measured IR spectra of samples from experiments: 10 (dark blue), 11 (blue) and 12 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
 
 
 
 
 
Figure 8. Measured IR spectra of samples from experiments: 13 (dark blue), 14 (blue) and 15 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
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Figure 9. Measured IR spectra of samples from experiments: 17 (dark blue), 18 (blue) and 19 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
 
 
 
 
 
Figure 10. Measured IR spectra of samples from experiments: 21 (dark blue), 22 (blue) and 24 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
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Figure 11. Measured IR spectra of samples from experiments: 25 (dark blue), 26 (blue) and 27 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
 
 
 
 
 
Figure 12. Measured IR spectra of samples from experiments: 28 (dark blue), 29 (blue) and 30 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
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Figure 13. Measured IR spectra of samples from experiments: 33 (dark blue), 34 (blue) and 35 (teal), with spectra of 
caffeine:malonic acid standards containing: 0% co-crystal (brown) and 100% co-crystal (red), for reference. 
 
3.3 DOE contour plots 
 
 
Figure 14. A 4D contour plot showing the relationship between temperature, solvent amount, ultrasonication power 
and time, on the conversion of starting material to co-crystal, with the acetone as the solvent. 
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Figure 15. A 4D contour plot showing the relationship between temperature, solvent amount, ultrasonication power 
and time, on the conversion of starting material to co-crystal, with the ethanol as the solvent. 
 
Figure 16. A 4D contour plot showing the relationship between temperature, solvent amount, ultrasonication power 
and time, on the conversion of starting material to co-crystal, with the hexane as the solvent. 
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Figure 17. A contour plot showing the relationship between ultrasonication power and solvent amount on the 
conversion of starting material to co-crystal when using ethanol as the solvent, with all other parameters fixed at 
their optimum levels, showing the best possible response in the plot area. Ultrasonication time: 10 minutes, 
Temperature: 20°C, Solvent: ethanol. 
 
Figure 18. A contour plot showing the relationship between ultrasonication power and solvent amount on the 
conversion of starting material to co-crystal when using hexane as the solvent, with all other parameters fixed at 
their optimum levels, showing the best possible response in the plot area. Ultrasonication time: 20 minutes, 
Temperature: 60°C, Solvent: hexane. 
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3.4 List of previously determined co-crystal systems and production methods. 
Unpublished work supplied by Dr David Berry, Durham University. 
Table 1. Confirmed co-crystal production by different methods of manufacture. 
API Co-former 
Reaction 
Crystallisation 
Liquid 
assisted 
grinding 
Crystallisation 
from melt 
Liquid 
assisted 
sonication 
Caffeine Oxalic Acid Y Y Y Y 
Caffeine Maleic Acid Y Y Y Y 
Caffeine Malonic Acid Y Y N Y 
Caffeine Glutaric Acid Y Y ? Y 
Sulfamethazine Aspirin Y Y N Y 
Sulfamethazine Benzoic Acid Y Y N Y 
Trimethoprim Sulfamethoxypyridazine Y N N Y 
Carbamazepine Saccharin Y Y N Y 
Carbamazepine Nicotinamide Y Y Y Y 
Paracetamol 4,4-bipyridyl Y Y Y Y 
Aspirin 4,4-bipyridyl Y Y N Y 
Ibuprofen 4,4-bipyridyl Y Y Y Y 
Ibuprofen Nicotinamide ? Y ? Y 
 
3.5 IR spectra of validation APIs, co-formers and experimental samples 
Each figure shows the spectra of the API (red), the co-former (green), the product of applying 
the optimised physical screening process to a 1:1 molar ratio of the two components (blue) 
and 2:1 molar ratio (purple), where applicable. The figures are labelled by API and co-former. 
 
Figure 19. Caffeine and oxalic acid. 
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Figure 20. Caffeine and maleic acid. 
 
 
 
 
Figure 21. Caffeine and malonic acid. 
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Figure 22. Caffeine and glutaric acid. 
 
 
 
 
Figure 23. Sulfamethazine and aspirin. 
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Figure 24. Sulfamethazine and benzoic acid. 
 
 
 
 
Figure 25. Trimethoprim and sulfamethoxypyridazine. 
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Figure 26. Carbamazepine and saccharin. 
 
 
 
 
Figure 27. Carbamazepine and nicotinamide. 
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Figure 28. Paracetamol and 4,4-bipyridine. 
 
 
 
 
Figure 29. Aspirin and 4,4-bipyridine. 
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Figure 30. Ibuprofen and 4,4-bipyridine. 
 
 
 
 
Figure 31. Ibuprofen and nicotinamide. 
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3.6 PXRD patterns of ornidazole, select co-formers and samples from the second DOE 
optimisation experiment 
 
 
 
Figure 32. PXRD patterns of ornidazole, 5-nitroisophthalic acid and the experimental samples from Well A1 of Plates 
1 to 7 (co-former: 5-nitroisothalic acid; solvent: acetonitrile). 
 
 
Figure 33. PXRD patterns of ornidazole, 5-nitroisophthalic acid and the experimental samples from Well B1 of Plates 
1 to 7 (co-former: 5-nitroisothalic acid; solvent: ethanol). 
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Figure 34. PXRD patterns of ornidazole, 5-nitroisophthalic acid and the experimental samples from Well A2 of Plates 
1 to 7 (co-former: 5-nitroisothalic acid; solvent: THF). 
 
 
 
 
Figure 35. PXRD patterns of ornidazole, 5-nitroisophthalic acid and the experimental samples from Well B2 of Plates 
1 to 7 (co-former: 5-nitroisothalic acid; solvent: toluene). 
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Figure 36. PXRD patterns of ornidazole, trimesic acid and the experimental samples from Well G1 of Plates 1 to 7 (co-
former: trimesic acid; solvent: acetonitrile). 
 
 
 
 
Figure 37. PXRD patterns of ornidazole, trimesic acid and the experimental samples from Well H1 of Plates 1 to 7 (co-
former: trimesic acid; solvent: ethanol). 
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Figure 38. PXRD patterns of ornidazole, trimesic acid and the experimental samples from Well G2 of Plates 1 to 7 (co-
former: trimesic acid; solvent: THF). 
 
 
 
 
Figure 39. PXRD patterns of ornidazole, trimesic acid and the experimental samples from Well H2 of Plates 1 to 7 (co-
former: trimesic acid; solvent: toluene). 
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3.7 DOE model summary plots 
Model summaries for ornidazole:5-nitroisophthalic acid and ornidazole:trimesic acid data 
based on measured responses: FWHM, net peak height and calculated FWHM:peak height 
value. One model for each response for both co-formers, six summaries in total, each as 
follows:  Clockwise from top left: Replicates (results of repeated experiments shown by 
blue squares), summary of fit (R2 (green), Q2 (dark blue), model validity (yellow) and 
reproducibility (light blue)), residuals and coefficients. 
 
 
Figure 40. Model summary for ornidazole:5-nitroisophthalic acid based on measured FWHM. 
 
 
 
Figure 41. Model summary for ornidazole:5-nitroisophthalic acid based on measured net peak height. 
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Figure 42. Model summary for ornidazole:5-nitroisophthalic acid based on calculated FWHM:peak value. 
 
 
 
 
 
Figure 43. Model summary for ornidazole:trimesic acid based on measured FWHM. 
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Figure 44. Model summary for ornidazole:trimesic acid based on measured net peak height. 
 
 
 
 
 
Figure 45. Model summary for ornidazole:trimesic acid based on calculated FWHM:peak height value. 
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Appendix 4 
 
4.1 Full list co-formers from the computational pre-screen for ROY  
Table 1. List of co-formers with excess enthalpy calculated for the given stoichiometry with ROY as produced by 
COSMOtherm. 
Co-Former Name ΔH / kJ.mol-1 Stoichiometry 
Pentafluorophenol_c0 -1.95304667 "1:2" 
Pentafluorophenol_c0 -1.83812 "1:1" 
Acesulfame -1.508955 "1:1" 
Acesulfame -1.38306667 "1:2" 
Pentafluorophenol_c0 -1.37965333 "2:1" 
OXALIC_ACID -1.345755 "1:1" 
Quercetin -1.296365 "1:1" 
Quercetin -1.29356 "2:1" 
Acesulfame -1.26151667 "2:1" 
OXALIC_ACID -1.22758 "2:1" 
SULFAMIC_ACID -1.22224 "1:1" 
3_5_Dinitrobenzoic_Acid -1.19337 "1:1" 
OXALIC_ACID -1.1712 "1:2" 
1,2,3-Trihydroxybenzene -1.144635 "1:1" 
SULFAMIC_ACID -1.12732333 "2:1" 
SULFAMIC_ACID -1.08531667 "1:2" 
3_5_Dinitrobenzoic_Acid -1.06875333 "1:2" 
2,4-dihydroxybenzoic_acid -1.04422 "1:1" 
3_5_Dinitrobenzoic_Acid -1.04109333 "2:1" 
5-nitroisophthalic_acid -1.036695 "1:1" 
Quercetin -1.03450333 "1:2" 
Gallic_acid -1.031715 "1:1" 
1,2,3-Trihydroxybenzene -1.03138333 "2:1" 
TERT-BUTYLHYDROQUINONE -1.02651 "1:1" 
5-nitroisophthalic_acid -0.99448 "2:1" 
1-hydroxy-2-naphthoic_acid -0.99384 "1:1" 
Catechol -0.98762 "1:1" 
1,2,3-Trihydroxybenzene -0.98737 "1:2" 
4-Hexylresorcinol -0.98664 "1:1" 
1-hydroxy-2-naphthoic_acid -0.95433 "1:2" 
2,4-dihydroxybenzoic_acid -0.95418667 "2:1" 
TERT-BUTYLHYDROQUINONE -0.94342 "1:2" 
Gallic_acid -0.942 "2:1" 
Catechol -0.92858667 "1:2" 
2,4-dihydroxybenzoic_acid -0.90741 "1:2" 
4-Hexylresorcinol -0.90391667 "1:2" 
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5-chlorosalicylic_acid -0.902455 "1:1" 
Gallic_acid -0.90101667 "1:2" 
RESORCINOL -0.897925 "1:1" 
P-VINYLPHENOL_c0 -0.89657 "1:1" 
P-VINYLPHENOL_c0 -0.89029333 "1:2" 
TERT-BUTYLHYDROQUINONE -0.87088 "2:1" 
3,5-dihydroxybenzoic_acid -0.86552 "1:1" 
5-nitroisophthalic_acid -0.86511 "1:2" 
4-Hexylresorcinol -0.84925667 "2:1" 
RESORCINOL -0.83844 "1:2" 
5-chlorosalicylic_acid -0.8336 "1:2" 
Catechol -0.82803667 "2:1" 
3,5-dihydroxybenzoic_acid -0.81828667 "2:1" 
1-hydroxy-2-naphthoic_acid -0.81693333 "2:1" 
RESORCINOL -0.77271 "2:1" 
5-chlorosalicylic_acid -0.76804333 "2:1" 
Orcinol -0.768 "1:1" 
2,5-dihydroxybenzoic_acid -0.762985 "1:1" 
gentisic_acid -0.756395 "1:1" 
3,5-dihydroxybenzoic_acid -0.74557667 "1:2" 
P-VINYLPHENOL_c0 -0.71876667 "2:1" 
Orcinol -0.71534333 "1:2" 
2,5-dihydroxybenzoic_acid -0.69776667 "2:1" 
gentisic_acid -0.69399333 "2:1" 
O-CRESOL -0.68783 "1:1" 
O-CRESOL -0.67925 "1:2" 
3_4-DIHYDROXYBENZOIC_acid -0.675945 "1:1" 
2,5-dihydroxybenzoic_acid -0.67136333 "1:2" 
THYMOL -0.66492 "1:1" 
gentisic_acid -0.66227333 "1:2" 
Orcinol -0.66176333 "2:1" 
THYMOL -0.66030667 "1:2" 
PHENOL_c0 -0.65244 "1:2" 
trimesic_acid -0.64779667 "2:1" 
PHENOL_c0 -0.645445 "1:1" 
trimesic_acid -0.625265 "1:1" 
3_4-DIHYDROXYBENZOIC_acid -0.61500667 "2:1" 
INDOLE_c0 -0.598635 "1:1" 
INDOLE_c0 -0.59816 "1:2" 
3_4-DIHYDROXYBENZOIC_acid -0.59177333 "1:2" 
3-hydroxy-2-naphthoic_acid -0.58607 "1:1" 
2,5-Xylenol -0.582905 "1:1" 
2_5-XYLENOL -0.58251 "1:1" 
2,5-Xylenol -0.57731 "1:2" 
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2_5-XYLENOL -0.57632333 "1:2" 
salicylic_acid -0.569225 "1:1" 
m-nitrobenzoic_acid -0.566095 "1:1" 
SKATOLE_c0 -0.55596 "1:2" 
O-CRESOL -0.55326 "2:1" 
SKATOLE_c0 -0.552105 "1:1" 
Hydroquinone_c0 -0.552085 "1:1" 
FUMARIC_ACID -0.549575 "1:1" 
3-hydroxy-2-naphthoic_acid -0.53992 "1:2" 
Hydroquinone_c0 -0.53467333 "1:2" 
FUMARIC_ACID -0.53440667 "2:1" 
THYMOL -0.52590333 "2:1" 
methylgallate -0.524405 "1:1" 
salicylic_acid -0.5235 "1:2" 
PHENOL_c0 -0.51339333 "2:1" 
m-nitrobenzoic_acid -0.50407667 "2:1" 
3-hydroxy-2-naphthoic_acid -0.50406 "2:1" 
m-nitrobenzoic_acid -0.50092 "1:2" 
trimesic_acid -0.49986667 "1:2" 
P-CRESOL -0.49931333 "1:2" 
salicylic_acid -0.48972 "2:1" 
P-CRESOL -0.4879 "1:1" 
Methanesulfonic -0.482445 "1:1" 
Methanesulfonic -0.47865333 "2:1" 
INDOLE_c0 -0.47527333 "2:1" 
methylgallate -0.47443667 "1:2" 
P-ETHYLPHENOL_c0 -0.47219333 "1:2" 
3-HYDROXYBENZOIC_ACID -0.469155 "1:1" 
2_5-XYLENOL -0.46777333 "2:1" 
2,5-Xylenol -0.46765333 "2:1" 
FUMARIC_ACID -0.46547667 "1:2" 
methylgallate -0.46515667 "2:1" 
Hydroquinone_c0 -0.46011333 "2:1" 
P-ETHYLPHENOL_c0 -0.459365 "1:1" 
6-hydroxy-2-naphthoic_acid -0.449685 "1:1" 
Ethanesulfonic_acid -0.448055 "1:1" 
SKATOLE_c0 -0.43566 "2:1" 
Ethanesulfonic_acid -0.43312667 "2:1" 
3-HYDROXYBENZOIC_ACID -0.43194 "2:1" 
ALLOCITRIC_ACID -0.42774 "1:1" 
p-tButyl-PHENOL_c0 -0.42679333 "1:2" 
3,4-Xylenol_c0 -0.41840667 "1:2" 
ISOCITRIC_ACID -0.41742 "1:1" 
3_4-xylenol_c0 -0.41659667 "1:2" 
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3-HYDROXYBENZOIC_ACID -0.4129 "1:2" 
p-tButyl-PHENOL_c0 -0.40929 "1:1" 
6-hydroxy-2-naphthoic_acid -0.40685333 "2:1" 
ALLOCITRIC_ACID -0.40594333 "1:2" 
3,4-Xylenol_c0 -0.40526 "1:1" 
3_4-xylenol_c0 -0.40316 "1:1" 
6-hydroxy-2-naphthoic_acid -0.39945667 "1:2" 
2_6-xylenol_c0 -0.39238333 "1:2" 
P-CRESOL -0.38472667 "2:1" 
ISOCITRIC_ACID -0.38090667 "2:1" 
2_6-xylenol_c0 -0.3799 "1:1" 
ISOCITRIC_ACID -0.37862 "1:2" 
Methanesulfonic -0.37413667 "1:2" 
citric_acid -0.373535 "1:1" 
Etidronic_acid -0.36914333 "1:2" 
4-HYDROXYBENZOIC_ACID -0.367105 "1:1" 
ALLOCITRIC_ACID -0.36153 "2:1" 
P-ETHYLPHENOL_c0 -0.36051333 "2:1" 
O-PHENYLPHENOL -0.35926 "1:1" 
Ethanesulfonic_acid -0.3506 "1:2" 
Etidronic_acid -0.350515 "1:1" 
citric_acid -0.34377333 "1:2" 
O-PHENYLPHENOL -0.33863 "1:2" 
citric_acid -0.33800667 "2:1" 
4-HYDROXYBENZOIC_ACID -0.33745667 "1:2" 
4-HYDROXYBENZOIC_ACID -0.32179333 "2:1" 
2-OXO-3-PHENYLPROPIONIC_ACID -0.32097 "1:1" 
3,4-Xylenol_c0 -0.31694667 "2:1" 
p-tButyl-PHENOL_c0 -0.31617667 "2:1" 
3_4-xylenol_c0 -0.31507667 "2:1" 
O-PHENYLPHENOL -0.30168333 "2:1" 
2_6-xylenol_c0 -0.29408 "2:1" 
2-OXO-3-PHENYLPROPIONIC_ACID -0.28822667 "1:2" 
2-OXO-3-PHENYLPROPIONIC_ACID -0.28083667 "2:1" 
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4.2 IR spectra of samples from the ROY co-crystal screen 
Each figure shows the spectra of ROY (red), the co-former (brown) and the three experimental 
samples (one from each screen with acetone (dark blue), ethanol (blue) and hexane (teal) as 
the solvent). The figures are labelled by co-former. 
 
 
 
Figure 1. Pentafluorophenol. 
 
 
 
Figure 2. Acesulfame potassium. 
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Figure 3. Oxalic acid. Hydrate of oxalic acid (purple) is included for comparison. 
 
 
 
 
Figure 4. Quercetin. 
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Figure 5. Sulfamic acid. 
 
 
 
 
Figure 6. 3,5-Dinitrobenzoic acid. 
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Figure 7. Pyrogallol. 
 
 
 
 
Figure 8. 2,4-Dihydroxybenzoic acid. 
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Figure 9. 5-Nitroisophthalic acid. 
 
 
 
 
Figure 10. Gallic acid. 
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Figure 11. tert-Butylhydroquinone. 
 
 
 
 
Figure 12. 1-Hydroxy-2-naphthoic acid. 
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Figure 13. Catechol. 
 
 
 
 
Figure 14. 4-Hexylresorcinol. 
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Figure 15. 5-Chlorosalicylic acid. 
 
 
 
 
Figure 16. Resorcinol. 
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Figure 17. 3,5-Dihydroxybenzoic acid. 
 
 
 
 
Figure 18. Orcinol. 
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Figure 19. 2,5-Dihydroxybenzoic acid. 
 
 
 
 
Figure 20. o-Cresol. 
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Figure 21. 3,4-Dihydroxybenzoic acid. 
 
 
 
 
Figure 22. Thymol. 
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Figure 23. Phenol. 
 
 
 
 
Figure 24. Trimesic acid. 
 
 
 
 
254 
 
 
 
 
Figure 25. Indole. 
 
 
 
 
Figure 26. 3-Hydroxy-2-naphthoic acid. 
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Figure 27, 2,5-Xylenol. 
 
 
 
 
Figure 28. Salicylic acid. 
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Figure 29. m-Nitrobenzoic acid. 
 
 
 
 
Figure 30. Skatole. 
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Figure 31. Hydroquinone. 
 
 
 
 
Figure 32. Fumaric acid. 
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Figure 33. Methyl gallate. 
 
 
 
 
Figure 34. p-Cresol. 
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Figure 35. Methanesulfonic acid. 
 
 
 
 
Figure 36. p-Ethylphenol. 
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Figure 37. 3-Hydroxybenzoic acid. 
 
 
 
 
Figure 38. 6-Hydroxy-2-naphthoic acid. 
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Figure 39. Ethanesulfonic acid. 
 
 
 
 
Figure 40. Isocitric acid trisodium salt hydrate. 
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Figure 41. p-tert-Butylphenol. 
 
 
 
 
Figure 42. 3,4-Xylenol. 
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Figure 43. 2,6-Xylenol. 
 
 
 
 
Figure 44. Citric acid. 
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Figure 45. Etidronic acid monohydrate. 
 
 
 
 
Figure 46. 4-Hydroxybenzoic acid. 
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Figure 47. o-Phenylphenol. 
 
 
 
 
Figure 48. Phenylpyruvic acid. 
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4.3 IR spectra of samples from the LAG experiments 
Each figure shows the spectra of ROY (red), the co-former (brown) and the product of LAG of a 
1:1 molar mixture of these two components (LAG, blue). The figures are labelled by co-former. 
 
 
 
Figure 49. Pentafluorophenol. 
 
 
 
Figure 50. Acesulfame potassium. 
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Figure 51. Oxalic acid. Hydrate of oxalic acid (purple) is included for comparison. 
 
 
 
 
Figure 52. Quercetin. 
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Figure 53. Sulfamic acid. 
 
 
 
 
Figure 54. 3,5-Dinitrobenzoic acid. 
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Figure 55. Pyrogallol. 
 
 
 
 
Figure 56. 2,4-Dihydroxybenzoic acid. 
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Figure 57. 5-Nitroisophthalic acid. 
 
 
 
 
Figure 58. Gallic acid. 
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4.4 PXRD patterns from the evaporative and reaction crystallisation experiments 
PXRD patterns comparing the co-formers (blue patterns) with the product of the reaction 
crystallisation (‘slurry’) (green patterns) and evaporative crystallisation experiments (pink 
patterns). The PXRD patterns of the product of the reaction and evaporative crystallisation 
experiments were compared to those of the ROY polymorphs that have patterns available (i.e. 
the seven which have a CSD entry). The patterns of the ROY polymorphs present are displayed 
in the plots and are coloured by polymorph colour. The plots are labelled by co-former. 
 
  
 
Figure 59. Acesulfame potassium. 
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Figure 60. Oxalic acid. 
 
 
 
Figure 61. Quercetin. 
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Figure 62. Sulfamic acid. 
 
 
 
Figure 63. 3,5-Dinitrobenzoic acid. 
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Figure 64. Pyrogallol. 
 
 
 
Figure 65. 2,4-Dihydroxybenzoic acid. 
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Figure 66. 5-Nitroisophthalic acid. 
 
 
 
Figure 67. Gallic acid. 
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4.5 DSC thermograms of samples from the LAG experiments 
 
Figure 68. DSC traces for the initial heating cycle of the products of LAG of ROY and co-formers: pentafluorophenol 
(black), acesulfame potassium (green), oxalic acid (blue), quercetin (purple) and sulfamic acid (teal). 
 
Figure 69. DSC traces for the initial heating cycle of the products of LAG of ROY and co-formers: 3,5-dinitrobenzoic 
acid (black), pyrogallol (green), 2,4-dihydroxybenzoic acid (blue), 5-nitroisophthalic acid (purple) and gallic acid 
(teal). 
-10
0
10
H
e
a
t 
F
lo
w
 (
W
/g
)
40 60 80 100 120
Temperature (°C)
                  ROY:Pentafluorophenol–––––––
                  ROY:Acesulfame potassium–––––––
                  ROY:Oxalic acid–––––––
                  ROY:Quercetin–––––––
                  ROY:Sulfamic acid–––––––
Exo Up
-10
-5
0
5
10
H
e
a
t 
F
lo
w
 (
W
/g
)
40 60 80 100 120
Temperature (°C)
                  ROY:3,5-Dinitrobenzoic acid–––––––
                  ROY:Pyrogallol–––––––
                  ROY:2,4-Dihydroxybenzoic acid–––––––
                  ROY:5-Nitroisophthalic acid–––––––
                  ROY:Gallic acid–––––––
Exo Up
277 
 
 
Figure 70. DSC traces for the cooling cycle of the products of LAG of ROY and co-formers: pentafluorophenol (black), 
acesulfame potassium (green), oxalic acid (blue), quercetin (purple) and sulfamic acid (teal). 
 
 
Figure 71. DSC traces for the cooling cycle of the products of LAG of ROY and co-formers: 3,5-dinitrobenzoic acid 
(black), pyrogallol (green), 2,4-dihydroxybenzoic acid (blue), 5-nitroisophthalic acid (purple) and gallic acid (teal). 
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Figure 72. DSC traces for the second heating cycle of the products of LAG of ROY and co-formers: pentafluorophenol 
(black), acesulfame potassium (green), oxalic acid (blue), quercetin (purple) and sulfamic acid (teal). 
 
Figure 73. DSC traces for the second heating cycle of the products of LAG of ROY and co-formers: 3,5-dinitrobenzoic 
acid (black), pyrogallol (green), 2,4-dihydroxybenzoic acid (blue), 5-nitroisophthalic acid (purple) and gallic acid 
(teal). 
4.6 DSC thermograms of ROY, pyrogallol and the product of their 1:1 molar ratio grind 
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Figure 74. Initial heating phase DSC curves of pyrogallol (red), ROY (blue) and ROY:pyrogallol 1:1 grind (green). 
 
 
Figure 75. Cooling phase DSC curves of pyrogallol (red), ROY (blue) and ROY:pyrogallol 1:1 grind (green). 
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Figure 76. Focused area of second heating cycle DSC curves of ROY (blue) and ROY:pyrogallol 1:1 grind (green) 
showing glass transitions. 
 
4.7 DSC thermograms of grinds of ROY and pyrogallol in varying molar ratios 
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Figure 77. Cooling phase DSC curves of ROY:pyrogallol: 1:1 grind (green), 10%w/w (purple) and 1%w/w (pink). 
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Figure 78. Second heating phase DSC curves of ROY:pyrogallol 1:1 grind (green), 10%w/w (purple) and 1%w/w (pink) 
including glass transitions. 
 
4.8 Full data set from hydrogen bonding propensity prediction 
 
Table 2. Coefficients for logit_model_1 applied to ROY (QAXMEH01). 
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Coefficients: Estimate Std.Error Z value Pr(>|z|) 
Significance 
code 
Lower 
Bound 
Upper 
Bound 
(Intercept) 0.633 0.234 2.709 0.00675519 ** 0.165 1.083 
Donoratom_2 of 
ar_hydroxy 
-0.391 0.074 -5.258 1.45444e-07 *** -0.537 -0.246 
Donorother 0.611 0.066 9.221 2.9478e-20 *** 0.482 0.742 
Acceptoratom_2(3) of 
ar_nitro 
2.242 0.195 11.519 1.06424e-30 *** 1.874 2.639 
Acceptoratom_2 of 
ar_hydroxy 
1.883 0.193 9.756 1.73657e-22 *** 1.519 2.277 
Acceptoratom_2 of 
cyano 
2.361 0.196 12.017 2.89222e-33 *** 1.989 2.761 
Acceptorother 4.313 0.183 23.549 1.28037e-122 *** 3.969 4.689 
competition -0.086 0.005 -17.931 6.78803e-72 *** -0.096 -0.077 
Donor_steric_density -0.023 0.002 -12.486 8.87143e-36 *** -0.027 -0.019 
Acceptor_steric_density -0.045 0.002 -20.515 1.58124e-93 *** -0.050 -0.041 
Donor_aromaticity -0.805 0.177 -4.545 5.49985e-06 *** -1.154 -0.459 
Acceptor_aromaticity -0.529 0.164 -3.228 0.00124467 ** -0.850 -0.208 
Donoratom_0 of 
sec_amine_1 
0.000 N/A N/A N/A N/A N/A N/A 
Acceptoratom_1 of 
cyclic_thioether 
0.000 N/A N/A N/A N/A N/A N/A 
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Table 3. Goodness of fit. 
Log Likelihood -5207.380 
Area under ROC curve 0.860968 
Akaike Information Criterion (AIC) 10438.8 
Null deviance 15325.3 on 11218 degrees of freedom 
Residual deviance 10414.8 on 11207 degrees of freedom 
 
 
 
Table 4. Predicted inter-molecular hydrogen bond propensities. 
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N1 of sec 
amine 1 
N3 of 
cyano 
4.00 62.75 27.57 0.58 0.58 0.31 0.22 0.42 36.8 
N1 of sec 
amine 1 
O2 of 
ar_nitro 
4.00 62.75 31.19 0.58 0.58 0.25 0.17 0.35 11.7 
N1 of sec 
amine 1 
O1 of 
ar_nitro 
8.00 62.75 31.19 0.58 0.58 0.19 0.13 0.28 18.2 
N1 of sec 
amine 1 
S1 of cyclic 
thioether 
8.00 62.75 62.75 0.58 0.58 0.01 0.01 0.01 1.1 
 
 
 
Table 5. Predicted intra-molecular hydrogen bond propensities. 
Donor Acceptor 
Donor 
sybyl 
atom 
type 
DA Pair 
constrained 
connectivity 
DA 
Pair 
path 
string 
Donor 
count 
Propensity 
Lower 
bound 
Upper 
bound 
N1 O1 N.pl3 1 0 1 0.890416 0.890416 0.890416 
N1 O2 N.pl3 1 0 1 0.890416 0.890416 0.890416 
N1 N3 N.pl3 1 0 1 0.0918711 0.0918711 0.0918711 
 
 
 
 
 
283 
 
4.9 Hydrogen bonding within the ROY:pyrogallol amorphous cell 
 
Figure 79. Amorphous cell displaying strong hydrogen bond contacts between ROY and pyrogallol. N.B. All non-
bonded molecules and those containing ROY:ROY contacts and pyrogallol:pyrogallol interactions have been removed 
for clarity. 
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4.10 DSC thermograms of grinds of ROY and PVP in varying molar ratios 
 
Figure 80. Initial heating phase DSC curves of ROY:pyrogallol 1:1 grind (green), ROY:PVP 1:1 grind (teal) and ROY:PVP 
10%w/w grind (maroon). 
 
Figure 81. Cooling phase DSC curves of ROY:pyrogallol 1:1 grind (green), ROY:PVP 1:1 grind (teal) and ROY:PVP 
10%w/w grind (maroon).
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Appendix 5 
 
PXRD patterns of ROY, co-formers and the product of the 1:1 grinds of these components 
PXRD patterns comparing the pure parent components: ROY (red patterns) and co-formers 
(blue patterns), with the 1:1 molar ratio grind of the two compounds (green patterns). The 
figures are labelled by co-former. 
 
 
Figure 1. 1,2,4-benzenetriol. 
 
 
Figure 2. 1,2-cyclohexanediol. 
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Figure 3. 1,4-cyclohexanediol. 
 
 
 
 
Figure 4. Catechol. 
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Figure 5. Hydroquinone. 
 
 
 
 
Figure 6. Phloroglucinol. 
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Figure 7. Resorcinol. 
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Appendix 6 
 
6.1 COSMOtherm ranked co-former list for ornidazole co-crystal computational pre-screen 
Table 1. List of co-formers with excess enthalpy calculated for three stoichiometric ratios with ornidazole as 
produced by COSMOtherm. 
Co-former 
Calculated ΔH / kJ.mol-1 
Stoichiometric ratio (Ranked by) 
Minimum 1:1 2:1 1:2 
OXALIC_ACID -2.2019 -1.8773 -2.1114 -2.2019 
SULFAMIC_ACID -1.9570 -1.7648 -1.7619 -1.9570 
Acesulfame -1.9194 -1.7157 -1.6617 -1.9194 
5-nitroisophthalic_acid -1.6533 -1.3260 -1.6545 -1.6545 
ISOCITRIC_ACID -1.5488 -1.2633 -1.5914 -1.5914 
piperazine -1.5401 -1.2682 -1.4240 -1.5401 
2,4-dihydroxybenzoic_acid -1.4322 -1.1597 -1.4167 -1.4322 
2_4-DIHYDROXYBENZOIC_acid -1.4274 -1.1597 -1.4094 -1.4274 
TERT-BUTYLHYDROQUINONE -1.3452 -1.1881 -1.2083 -1.3452 
trimesic_acid -1.2152 -0.9117 -1.3367 -1.3367 
4-Hexylresorcinol -1.3280 -1.1757 -1.2041 -1.3280 
3,5-dihydroxybenzoic_acid -1.2627 -0.9875 -1.3268 -1.3268 
citric_acid -1.3187 -1.1098 -1.2907 -1.3187 
Etidronic_acid -1.2885 -1.0996 -1.2727 -1.2885 
RESORCINOL -1.2826 -1.1166 -1.1933 -1.2826 
CARNITINE -1.2429 -1.0127 -1.2448 -1.2448 
1-hydroxy-2-naphthoic_acid -1.2198 -1.1163 -1.0466 -1.2198 
FUMARIC_ACID -1.1847 -0.9511 -1.2018 -1.2018 
ALLOCITRIC_ACID -1.1788 -1.0042 -1.0940 -1.1788 
P-VINYLPHENOL_c0 -1.1598 -1.1165 -0.9601 -1.1598 
gentisic_acid -1.1519 -0.9233 -1.1547 -1.1547 
5-chlorosalicylic_acid -1.1470 -1.0059 -1.0199 -1.1470 
ACONITIC_Acid -1.1224 -0.9178 -1.1273 -1.1273 
3_4-DIHYDROXYBENZOIC_acid -0.9570 -0.7301 -1.0162 -1.0162 
Keto_glutaric_acid -0.9878 -0.8023 -0.9947 -0.9947 
4_4-bipyridine -0.9727 -0.8480 -0.8719 -0.9727 
m-nitrobenzoic_acid -0.9604 -0.8242 -0.8695 -0.9604 
O-CRESOL -0.9382 -0.8964 -0.7780 -0.9382 
Malonic_acid -0.9345 -0.8235 -0.8710 -0.9345 
PHENOL_c0 -0.9205 -0.8801 -0.7687 -0.9205 
TARTARIC_ACID -0.8712 -0.7347 -0.8971 -0.8971 
salicylic_acid -0.8960 -0.7679 -0.8117 -0.8960 
methylgallate -0.8764 -0.6987 -0.8919 -0.8919 
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3-HYDROXYBENZOIC_ACID -0.8566 -0.6706 -0.8807 -0.8807 
3-hydroxy-2-naphthoic_acid -0.8760 -0.7527 -0.7947 -0.8760 
OCTADECYLAMINE -0.8143 -0.8700 -0.5269 -0.8700 
THYMOL -0.8460 -0.8217 -0.6839 -0.8460 
Maleic_acid -0.8315 -0.7199 -0.7710 -0.8315 
6-hydroxy-2-naphthoic_acid -0.7959 -0.6260 -0.8163 -0.8163 
2_5-XYLENOL -0.8020 -0.7671 -0.6636 -0.8020 
4-HYDROXYBENZOIC_ACID -0.7523 -0.5869 -0.7790 -0.7790 
2-6-DIMETHYLPYRAZINE_c0 -0.7717 -0.7256 -0.6476 -0.7717 
2_6-DIMETHYLPYRAZINE_c0 -0.7717 -0.7256 -0.6476 -0.7717 
2-OXO-3-PHENYLPROPIONIC_ACID -0.7343 -0.6332 -0.6692 -0.7343 
P-CRESOL -0.7241 -0.6905 -0.6069 -0.7241 
L-LYSINE -0.6694 -0.5186 -0.7073 -0.7073 
DL-VALINE -0.7041 -0.6490 -0.6026 -0.7041 
3-METHYL-2-OXOBUTANOIC_ACID -0.7009 -0.6153 -0.6287 -0.7009 
P-ETHYLPHENOL_c0 -0.6841 -0.6548 -0.5713 -0.6841 
ISOQUINOLINE_c0 -0.6722 -0.6637 -0.5375 -0.6722 
SUCCINIC_ACID -0.6567 -0.5301 -0.6689 -0.6689 
PYRUVIC_ACID -0.6649 -0.6005 -0.5828 -0.6649 
PROPYL_GALLATE -0.5934 -0.4437 -0.6450 -0.6450 
THIODIPROPIONIC_ACID -0.5903 -0.4438 -0.6364 -0.6364 
3-HYDROXY-2-OXOPROPIONIC_ACID -0.6291 -0.5330 -0.6020 -0.6291 
MALIC_ACID -0.6244 -0.5216 -0.6124 -0.6244 
3_4-xylenol_c0 -0.6214 -0.5925 -0.5206 -0.6214 
p-tButyl-PHENOL_c0 -0.6207 -0.6010 -0.5122 -0.6207 
PHENOXYACETIC_ACID -0.6198 -0.5094 -0.5885 -0.6198 
ALPHA-KETOBUTYRIC_ACID -0.5988 -0.5370 -0.5267 -0.5988 
PYRAZINE_c0 -0.5712 -0.5314 -0.4845 -0.5712 
CAPROLACTAM_c0 -0.5684 -0.4957 -0.5280 -0.5684 
OCTYL_GALLATE -0.5231 -0.4113 -0.5475 -0.5475 
O-PHENYLPHENOL -0.5354 -0.4706 -0.4785 -0.5354 
Mandelic_acid -0.5276 -0.4271 -0.5124 -0.5276 
Glutaric_acid -0.4728 -0.3681 -0.4972 -0.4972 
METHYL_NICOTINATE_c0 -0.4834 -0.4590 -0.4032 -0.4834 
PIPERINE_c0 -0.4803 -0.3991 -0.4548 -0.4803 
DIHYDROXYACETOPHENONE_c0 -0.4705 -0.3831 -0.4486 -0.4705 
4-5-DIMETHYLTHIAZOLE_c0 -0.4693 -0.4685 -0.3724 -0.4693 
M-METHOXYBENZOIC_ACID -0.4599 -0.3771 -0.4334 -0.4599 
INDOLE_c0 -0.4572 -0.4471 -0.3675 -0.4572 
ERYTHORBIC_ACID -0.4312 -0.3540 -0.4407 -0.4407 
2_6-xylenol_c0 -0.4250 -0.4399 -0.3279 -0.4399 
adipic_acid -0.4129 -0.3167 -0.4392 -0.4392 
BENZOIC_ACID -0.4204 -0.3392 -0.4005 -0.4204 
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ASCORBIC_ACID -0.3919 -0.3221 -0.4036 -0.4036 
D-ISOASCORBIC_ACID -0.3919 -0.3221 -0.4036 -0.4036 
HYDROQUINONE_MONOETHYL_ETHER_c0 -0.3904 -0.3383 -0.3519 -0.3904 
NOOTKATONE -0.3851 -0.3562 -0.3255 -0.3851 
PHENYLACETIC_ACID -0.3803 -0.3124 -0.3598 -0.3803 
CAFFEINE_c0 -0.3789 -0.3114 -0.3660 -0.3789 
SKATOLE_c0 -0.3772 -0.3712 -0.3009 -0.3772 
METHYL_P-HYDROXYBENZOATE_c0 -0.3740 -0.2947 -0.3681 -0.3740 
methyl-4-hydroxy_benzoate_c0 -0.3740 -0.2947 -0.3681 -0.3740 
Homovanillic_ACID -0.3598 -0.2780 -0.3677 -0.3677 
3-PHENYLPROPIONIC_ACID -0.3477 -0.2846 -0.3288 -0.3477 
Hydrocinnamic_acid -0.3477 -0.2846 -0.3288 -0.3477 
camphoric_acid -0.2647 -0.1674 -0.3244 -0.3244 
P-METHOXYBENZOIC_ACID -0.3193 -0.2596 -0.3042 -0.3193 
MALTOL_PROPIONATE -0.3137 -0.2666 -0.2917 -0.3137 
PIPERITONE -0.3105 -0.2984 -0.2541 -0.3105 
P-METHOXYCINNAMALDEHYDE -0.3087 -0.2649 -0.2813 -0.3087 
ethyl-4-hydroxy_benzoate -0.2941 -0.2240 -0.2970 -0.2970 
CIS-2-HEXENAL -0.2798 -0.2636 -0.2338 -0.2798 
Rubenamin -0.2683 -0.2095 -0.2778 -0.2778 
2-METHOXY-4-VINYLPHENOL -0.2681 -0.2703 -0.2134 -0.2703 
5-METHYLQUINOXALINE_c0 -0.2699 -0.2622 -0.2201 -0.2699 
Propionic_acid -0.2651 -0.2158 -0.2542 -0.2651 
O-METHOXYCINNAMALDEHYDE -0.2596 -0.2273 -0.2318 -0.2596 
4-PHENYL-3-BUTEN-2-ONE -0.2591 -0.2286 -0.2295 -0.2591 
LEVULINIC_ACID -0.2583 -0.2278 -0.2316 -0.2583 
CINNAMIC_ACID -0.2531 -0.2009 -0.2462 -0.2531 
P-METHYLCINNAMALDEHYDE -0.2452 -0.2153 -0.2178 -0.2452 
VERATRALDEHYDE -0.2448 -0.2050 -0.2272 -0.2448 
PROPYL_P-HYDROXYBENZOATE -0.2342 -0.1722 -0.2426 -0.2426 
4-2-FURYL-3-BUTEN-2-ONE -0.2288 -0.1975 -0.2075 -0.2288 
LACTIC_ACID -0.2171 -0.1662 -0.2250 -0.2250 
P-AMINOBENZOIC_ACID -0.2234 -0.1916 -0.2080 -0.2234 
ACETYLPYRAZINE -0.2204 -0.1989 -0.1931 -0.2204 
butyric_acid -0.2116 -0.1627 -0.2108 -0.2116 
ACETANISOLE_c0 -0.2036 -0.1786 -0.1808 -0.2036 
METHYL_ANISATE_c0 -0.2036 -0.1786 -0.1808 -0.2036 
P-METOXYACETOPHENONE_c0 -0.2036 -0.1786 -0.1808 -0.2036 
3-2-FURYL_ACROLEIN -0.1988 -0.1687 -0.1830 -0.1988 
BUTYL_P-HYDROXIBENZOATE -0.1865 -0.1317 -0.1981 -0.1981 
L-PROLINE -0.1824 -0.1606 -0.1659 -0.1824 
glycolic_acid -0.1564 -0.1118 -0.1811 -0.1811 
3-METHYLCROTONIC_ACID -0.1764 -0.1339 -0.1761 -0.1764 
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VANILLYL_ALCOHOL -0.1756 -0.1424 -0.1715 -0.1756 
5-ETHYL-3-HYDROXY-4-METHYL-2_5H-FURANONE -0.1733 -0.1558 -0.1516 -0.1733 
SORBIC_ACID -0.1637 -0.1275 -0.1628 -0.1637 
4-HYDROXY-3-5-DIMETHOXYBENZALDEHYDE -0.1627 -0.1471 -0.1420 -0.1627 
THEOBROMINE_c0 -0.1621 -0.1343 -0.1571 -0.1621 
O-METHOXYBENZOIC_ACID -0.1601 -0.1421 -0.1453 -0.1601 
5-OXOOCTANOIC_ACID -0.1579 -0.1381 -0.1427 -0.1579 
TRANS-2-METHYL-2-BUTENOIC_ACID -0.1484 -0.1074 -0.1544 -0.1544 
GUAIACOL -0.1486 -0.1515 -0.1165 -0.1515 
2-FURYL_METHYL_KETONE -0.1492 -0.1291 -0.1339 -0.1492 
4-_P-HYDROXYPHENYL-2-BUTANONE -0.1477 -0.1199 -0.1430 -0.1477 
4-METHYLACETOPHENONE_c0 -0.1411 -0.1284 -0.1205 -0.1411 
Vanillin -0.1396 -0.1247 -0.1237 -0.1396 
6-METHYLCOUMARIN_c0 -0.1348 -0.1116 -0.1246 -0.1348 
TRANS-2-HEXENOIC_ACID -0.1244 -0.0872 -0.1325 -0.1325 
trans-2-hexanoic_acid -0.1244 -0.0872 -0.1325 -0.1325 
4-HYDROXY-2_5-DIMETHYL-3_2H-FURANONE -0.1277 -0.1186 -0.1091 -0.1277 
L-HISTIDINE -0.1146 -0.0878 -0.1193 -0.1193 
MALTOL -0.1123 -0.1014 -0.0987 -0.1123 
O-METHOXYBENZALDEHYDE -0.1123 -0.0960 -0.1005 -0.1123 
4-HYDROXY-5-METHYL-3_2H-FURANONE -0.1079 -0.0998 -0.0926 -0.1079 
4-HYDROXYBENZYL_ALCOHOL -0.1069 -0.0877 -0.1072 -0.1072 
hippuric_acid -0.0994 -0.0723 -0.1071 -0.1071 
N-ETHYL-2_2-DIISOPROPYLBUTANAMIDE -0.1047 -0.1066 -0.0811 -0.1066 
nicotinic_acid -0.1055 -0.0868 -0.0996 -0.1055 
3-ethoxy-4-hydroxy_benzaldehyde -0.1053 -0.0954 -0.0924 -0.1053 
METHYLCYCLOPENTENOLONE_c0 -0.1053 -0.0826 -0.0997 -0.1053 
2-METHYL-2-PENTENOIC_ACID -0.0876 -0.0509 -0.1023 -0.1023 
METHYLCYCLOPENTENOLONE_tautomer -0.1019 -0.1004 -0.0826 -0.1019 
PHTHALIDE_c0 -0.1016 -0.0802 -0.0971 -0.1016 
D-GLUCONIC_ACID -0.0990 -0.0923 -0.0983 -0.0990 
5-OXODECANOIC_ACID -0.0961 -0.0853 -0.0846 -0.0961 
saccharin_c0 -0.0925 -0.0738 -0.0909 -0.0925 
L-ARGININE -0.0642 -0.0535 -0.0863 -0.0863 
HEPTYLPARABEN -0.0727 -0.0401 -0.0858 -0.0858 
PIPERONAL_c0 -0.0855 -0.0679 -0.0812 -0.0855 
CAMPHOR_c0 -0.0795 -0.0855 -0.0553 -0.0855 
Imidazole_c0 -0.0677 -0.0375 -0.0837 -0.0837 
pyroglutamic_acid -0.0790 -0.0713 -0.0730 -0.0790 
CYCLOHEXANECARBOXYLIC_ACID -0.0561 -0.0196 -0.0765 -0.0765 
VANILLIN_ACETATE -0.0656 -0.0388 -0.0749 -0.0749 
N-ACETYL-L-METHIONINE -0.0736 -0.0706 -0.0600 -0.0736 
2-ACETYL-2-THIAZOLINE_c0 -0.0733 -0.0579 -0.0683 -0.0733 
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GLUCOSE_PENTAACETATE -0.0357 -0.0029 -0.0653 -0.0653 
BUTYLATED_HYDROXYTOLUENE 0.0687 -0.0599 0.1431 -0.0599 
SUCRALOSE -0.0396 -0.0277 -0.0513 -0.0513 
Piperonylacetone -0.0486 -0.0317 -0.0512 -0.0512 
VITAMIN_K3_c0 -0.0447 -0.0233 -0.0502 -0.0502 
NEOTAME -0.0386 -0.0225 -0.0478 -0.0478 
2-CYCLOHEXYL_ACETIC_ACID -0.0139 0.0180 -0.0390 -0.0390 
L-TYROSINE -0.0310 -0.0179 -0.0386 -0.0386 
ZINGERONE -0.0364 -0.0338 -0.0309 -0.0364 
METHYL_BETA-NAPHTHYL_KETONE_c0 -0.0328 -0.0215 -0.0330 -0.0330 
METHYL_PHENYLACETATE -0.0260 -0.0110 -0.0302 -0.0302 
Benzoin -0.0282 -0.0190 -0.0291 -0.0291 
5-OXODODECANOIC_ACID -0.0249 -0.0263 -0.0162 -0.0263 
PROPENYLGUAETHOL -0.0151 -0.0255 -0.0046 -0.0255 
BIOTIN -0.0151 -0.0131 -0.0148 -0.0151 
10-UNDECENOIC_ACID -0.0053 0.0087 -0.0133 -0.0133 
2-6-DIMETHOXYPHENOL -0.0115 -0.0110 -0.0097 -0.0115 
2_6-DIMETHOXYPHENOL -0.0115 -0.0110 -0.0097 -0.0115 
ASPARTAME 0.0049 0.0120 -0.0086 -0.0086 
LEVULOSE 0.0002 -0.0082 0.0059 -0.0082 
METHYL_CINNAMATE 0.0054 0.0191 -0.0044 -0.0044 
SCLAREOLIDE_c0 0.0032 0.0035 0.0081 0.0032 
2-HYDROXY-4-METHOXYBENZALDEHYDE_c0 0.0195 0.0324 0.0077 0.0077 
BENZOPHENONE_c0 0.0321 0.0419 0.0203 0.0203 
L-HYDROXYPROLINE 0.0318 0.0216 0.0341 0.0216 
ISOEUGENYL_METHYL_ETHER 0.0378 0.0407 0.0304 0.0304 
METHYL_2-PYRROLYL_KETONE 0.0378 0.0366 0.0308 0.0308 
GUAIACYL_ACETATE 0.0594 0.0747 0.0383 0.0383 
ISOEUGENYL_ETHYL_ETHER 0.0485 0.0440 0.0451 0.0440 
P-TOLYL_ACETATE_c0 0.0586 0.0657 0.0444 0.0444 
2-HYDROXY-4-METHYLBENZALDEHYDE 0.0659 0.0753 0.0481 0.0481 
METHYL_ANTHRANILATE 0.0644 0.0655 0.0508 0.0508 
2-HYDROXY-5-METHYLACETOPHENONE_c0 0.0724 0.0796 0.0552 0.0552 
ACETAMIDE_c0 0.0915 0.1028 0.0554 0.0554 
DL-PHENYLALANINE 0.0763 0.0760 0.0600 0.0600 
L-ISOLEUCINE 0.0835 0.0837 0.0643 0.0643 
DL-ALANINE 0.0810 0.0786 0.0647 0.0647 
METHIONINE 0.0807 0.0786 0.0653 0.0653 
1_3-DIPHENYL-2-PROPANONE 0.0879 0.0969 0.0662 0.0662 
2-PROPIONYLPYRROLE 0.0824 0.0791 0.0682 0.0682 
Nicotinamide_c0 0.1002 0.1029 0.0740 0.0740 
D-RIBOSE 0.0907 0.0765 0.0834 0.0765 
Xylose 0.0907 0.0765 0.0834 0.0765 
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NIACINAMIDE_c0 0.1041 0.1068 0.0773 0.0773 
ALPHA_ALPHA-DIMETHYLPHENETHYL_ALCOHOL 0.0901 0.0823 0.0784 0.0784 
Cinnamyl-BETA-D-GLUCOPYRANOSIDE 0.0938 0.0794 0.0861 0.0794 
Aspartic_acid_c0 0.1857 0.0832 0.2297 0.0832 
Cysteine 0.0984 0.0921 0.0833 0.0833 
2-NAPHTHALENTHIOL_c0 0.1322 0.1607 0.0910 0.0910 
L-LEUCINE 0.1173 0.1142 0.0942 0.0942 
DIHYDROXYACETONE 0.1158 0.1099 0.0962 0.0962 
PYRIDOXINE 0.1134 0.1045 0.0963 0.0963 
TYRAMINE 0.1153 0.1017 0.1053 0.1017 
GLUCONO-DELTA_LACTONE 0.1369 0.1286 0.1030 0.1030 
ISOEUGENYL_ACETATE_c0 0.1365 0.1446 0.1057 0.1057 
BUTYRAMIDE_c0 0.1542 0.1635 0.1085 0.1085 
Barbital_c0 0.1235 0.1101 0.1088 0.1088 
P-DIMETHOXYBENZENE_c0 0.1481 0.1626 0.1112 0.1112 
ALLYL_ANTHRANILATE 0.1396 0.1428 0.1116 0.1116 
SORBOSE 0.1326 0.1121 0.1228 0.1121 
RIBOFLAVIN 0.1365 0.1126 0.1317 0.1126 
METHYL_ISOTHIOCYANATE_c0 0.1629 0.1936 0.1154 0.1154 
UNDECANOIC_ACID 0.1395 0.1355 0.1183 0.1183 
FOLIC_ACID 0.1520 0.1256 0.1434 0.1256 
BENZYL_CINNAMATE 0.1600 0.1634 0.1277 0.1277 
BENZYLCINNAMATE 0.1630 0.1663 0.1302 0.1302 
OMEGA-PENTADECALACTONE_c0 0.1647 0.1338 0.1684 0.1338 
3-amino-1_2-propanediol 0.2087 0.2318 0.1353 0.1353 
L-TRYPTOPHAN 0.1580 0.1394 0.1426 0.1394 
2-TRIDECANONE 0.1918 0.1411 0.2064 0.1411 
GLYCERYL_TRIBENZOATE 0.1789 0.1804 0.1419 0.1419 
P-AMINOBENZALDEYDE_c0 0.1644 0.1503 0.1423 0.1423 
Capsaicin 0.1793 0.1455 0.1762 0.1455 
L-THREONINE 0.1674 0.1523 0.1458 0.1458 
TAUROCHOLIC_ACID 0.1803 0.1476 0.1737 0.1476 
GLYCINE 0.1803 0.1700 0.1494 0.1494 
PHENETHYL_PHENYLACETATE 0.1857 0.1842 0.1528 0.1528 
Xylitol 0.1782 0.1604 0.1559 0.1559 
L-RHAMNOSE 0.1811 0.1587 0.1631 0.1587 
LAURIC_ACID 0.1804 0.1667 0.1607 0.1607 
2-HYDROXYPIPERITONE 0.1835 0.1681 0.1608 0.1608 
GUAIACYL_PHENYLACETATE 0.2041 0.2097 0.1615 0.1615 
2-METHYL-4-PHENYL-2-BUTANOL 0.1857 0.1682 0.1624 0.1624 
CINNAMYL_CINNAMATE 0.2024 0.2009 0.1663 0.1663 
L-MENTHYL_LACTATE 0.2115 0.1705 0.2080 0.1705 
Paradol 0.2105 0.1707 0.2069 0.1707 
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P-TOLYL_PHENYLACETATE 0.2167 0.2206 0.1749 0.1749 
6-ACETOXYDIHYDROTHEASPIRANE 0.2105 0.1756 0.2044 0.1756 
PHENETHYL_ANTHRANILATE 0.2123 0.2076 0.1763 0.1763 
PHENETHYL_CINNAMATE 0.2152 0.2115 0.1779 0.1779 
1-4-DITHIANE_c0 0.2436 0.2711 0.1811 0.1811 
P-ISOPROPYLBENZYL_ALCOHOL 0.2118 0.1933 0.1839 0.1839 
UREA_c0 0.2443 0.1903 0.2273 0.1903 
Sulfacetamide 0.2281 0.1984 0.2082 0.1984 
L-GLUTAMIC_ACID 0.2465 0.1985 0.2502 0.1985 
PHENYL_SALICYLATE 0.2517 0.2583 0.1997 0.1997 
L-GLUTAMINE 0.2286 0.2019 0.2020 0.2019 
D-SORBITOL 0.2502 0.2110 0.2336 0.2110 
2-MERCAPTOANISOLE_c0 0.2819 0.3089 0.2126 0.2126 
INOSITOL 0.2585 0.2191 0.2355 0.2191 
BENZOYL_PEROXIDE 0.2793 0.2876 0.2207 0.2207 
EUGENOL_BENZOATE_c0 0.2688 0.2634 0.2230 0.2230 
MALTOSE 0.2807 0.2267 0.2720 0.2267 
L-SERINE 0.2639 0.2410 0.2286 0.2286 
MYRISTIC_ACID 0.2638 0.2300 0.2479 0.2300 
EUGENYL_ISOVALERATE_c0 0.2746 0.2628 0.2345 0.2345 
BETA-NAPHTHYL_METHYL_ETHER_c0 0.3039 0.3212 0.2355 0.2355 
ISOEUGENYL_BENZYL_ETHER 0.2823 0.2706 0.2389 0.2389 
MANNITOL 0.2941 0.2501 0.2727 0.2501 
LACTOSE 0.3189 0.2527 0.3206 0.2527 
TRANS-ANETHOLE_c0 0.3286 0.3416 0.2587 0.2587 
4-THUJANOL 0.2976 0.2641 0.2646 0.2641 
PHENETHYL_SALICYLATE 0.3273 0.3244 0.2690 0.2690 
PALMITIC_ACID 0.3234 0.2716 0.3158 0.2716 
SUCROSE 0.3422 0.2730 0.3409 0.2730 
GLYCERIN 0.3271 0.3067 0.2775 0.2775 
2-THIENYL_DISULFIDE 0.3703 0.3917 0.2872 0.2872 
BETA-NAPHTHYL_ETHYL_ETHER 0.3704 0.3816 0.2940 0.2940 
PHENETHYL_OCTANOATE 0.3296 0.2944 0.3011 0.2944 
L-ARABINOSE 0.3439 0.3125 0.2978 0.2978 
DIPHENYL_ETHER_c0 0.3823 0.4010 0.2986 0.2986 
ALPHA-TERPINEOL 0.3518 0.3196 0.3073 0.3073 
CHOLIC_ACID 0.3748 0.3082 0.3623 0.3082 
ISOBUTYL_N-METHYLANTHRANILATE 0.3619 0.3435 0.3089 0.3089 
Biphenyl 0.3993 0.4225 0.3099 0.3099 
STEARIC_ACID 0.3796 0.3106 0.3805 0.3106 
AlPHA-D-GLUCOPYRANOSE 0.3612 0.3208 0.3165 0.3165 
4-HYDROXYMETHYL-2-6-DI-TERTBUTYLPHENOL_c0 0.3654 0.3177 0.3333 0.3177 
VITAMIN_A_ACETATE 0.3668 0.3198 0.3443 0.3198 
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L-ASPARAGINE 0.3646 0.3224 0.3252 0.3224 
VITAMIN_A 0.4016 0.3351 0.3831 0.3351 
GLYCOCHOLIC_ACID 0.4316 0.3430 0.4352 0.3430 
4-METHYLBIPHENYL 0.4625 0.4786 0.3658 0.3658 
TRITHIOACETONE 0.4671 0.4718 0.3779 0.3779 
Citronellol 0.4257 0.3805 0.3779 0.3779 
BENZYL_DISULFIDE 0.4759 0.4851 0.3818 0.3818 
FENCHYL_ALCOHOL_c0 0.4453 0.4121 0.3827 0.3827 
BORNEOL 0.4547 0.4223 0.3895 0.3895 
ISOBORNEOL 0.4574 0.4250 0.3917 0.3917 
BETA-NAPHTHYL_ISOBUTYL_ETHER 0.5210 0.5181 0.4276 0.4276 
MENTHOL 0.4978 0.4533 0.4346 0.4346 
TAURINE_c0 0.5504 0.5338 0.4613 0.4613 
AZODICARBONAMIDE 0.5500 0.4758 0.5096 0.4758 
OCIMENE 0.5989 0.6018 0.4870 0.4870 
ETHYL_PALMITATE 0.5940 0.4937 0.5812 0.4937 
Vitamin_D 0.6931 0.5628 0.6842 0.5628 
ETHYL_OCTADECANOATE_c0 0.6842 0.5665 0.6733 0.5665 
CAMPHENE_c0 0.7094 0.7115 0.5767 0.5767 
LAURYL_ALCOHOL 0.6755 0.5857 0.6195 0.5857 
MYRISTYL_ALCOHOL 0.7550 0.6431 0.7060 0.6431 
2-DECYLFURAN 0.8346 0.7888 0.7198 0.7198 
STEARYL_ALCOHOL 0.8716 0.7215 0.8422 0.7215 
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6.2 PXRD plots from ornidazole co-crystal screen analysis 
PXRD patterns comparing the pure parent components: ornidazole (blue patterns) and co-
formers (green patterns), with the product of the co-crystal screen for those two components 
(red patterns). The figures are labelled by co-former. 
 
 
Figure 1. Oxalic acid. 
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Figure 2. Sulfamic acid. 
 
 
Figure 3. Acesulfame potassium. 
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Figure 4. 5-Nitroisophthalic acid. 
 
 
Figure 5. Isocitric acid trisodium salt hydrate. 
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Figure 6. Piperazine. 
 
 
 
Figure 7. 2,4-Dihydroxybenzoic acid. 
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Figure 8. tert-Butylhydroquinone. 
 
 
Figure 9. Trimesic acid. 
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Figure 10. 4-Hydroxyresorcinol. 
 
 
 
 
Figure 11. 3,5-Dihydroxybenzoic acid. 
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Figure 12. Citric acid. 
 
 
Figure 13. Etidronic acid monohydrate. 
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Figure 14. Resorcinol. 
 
 
Figure 15. Carnitine hydrochloride. 
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Figure 16. 1-Hydroxy-2-naphthoic acid. 
 
 
Figure 17. Fumaric acid. 
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Figure 18. 2,5-Dihydroxybenzoic acid. 
 
 
Figure 19. 5-Chlorosalicylic acid. 
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Figure 20. Aconitic acid. 
 
 
Figure 21. 3,4-Dihydroxybenzoic acid. 
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Figure 22. alpha-Ketoglutaric acid. 
 
 
Figure 23. 4,4-Bipyridine. 
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Figure 24. m-Nitrobenzoic acid. 
 
 
Figure 25. o-Cresol. 
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Figure 26. Malonic acid. 
 
 
 
Figure 27. Phenol. 
5 10 15 20 25 30 35
2Theta (°)
0
2500
10000
22500
In
te
n
s
ity
 (
c
o
u
n
ts
)
5 10 15 20 25 30 35
2Theta (°)
0
10000
40000
90000
In
te
n
s
it
y
 (
c
o
u
n
ts
)
311 
 
 
Figure 28. L-Tartaric acid. 
 
 
Figure 29. Salicylic acid. 
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Figure 30. Methyl gallate. 
 
 
 
Figure 31. 3-Hydroxybenzoic acid. 
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Figure 32. 3-Hydroxy-2-naphthoic acid. 
 
 
 
Figure 33. Octadecylamine. 
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Figure 34. Thymol. 
 
 
Figure 35. Maleic acid. 
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Figure 36. 6-Hydroxy-2-naphthoic acid. 
 
 
Figure 37. 2,5-Xylenol. 
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Figure 38. 4-Hydroxybenzoic acid. 
 
 
Figure 39. 2,6-Dimethylpyrazine. 
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Figure 40. Phenylpyruvic acid. 
 
 
Figure 41. p-Cresol. 
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Figure 42. L-Lysine. 
 
 
Figure 43. L-Valine. 
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Figure 44. 3-Methyl-2-oxobutanoic acid. 
 
 
Figure 45. p-Ethylphenol. 
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Figure 46. 3,5-Dinitrobenzoic acid. 
 
 
Figure 47. Succinic acid. 
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Figure 48. 4-Aminobenzoic acid. 
 
 
6.3 DSC and TGA overlay plots from analysis of further investigations into hits 
Plots showing an overlay of the DSC and TGA traces for the product of ornidazole and each of 
the co-formers from the co-crystal screen which resulted in a ‘hit’ are presented here. 
Although values for endothermic peaks and mass losses are not displayed, it is still clear to see 
from the plots whether a single or multiple melting points are present (DSC) and whether 
desolvation occurs (TGA). Plots are labelled by co-former. 
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Figure 49. Oxalic acid. 
 
 
Figure 50. 5-Nitroisophthalic acid. 
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Figure 51. 2,4-Dihydroxybenzoic acid. 
 
 
Figure 52. Trimesic acid. 
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Figure 53. 3,5-Dihydroxybenzoic acid. 
 
 
Figure 54. 1-Hydroxy-2-naphthoic acid. 
 
-6
-4
-2
0
2
H
e
a
t 
F
lo
w
 (
W
/g
)
40
60
80
100
120
W
e
ig
h
t 
(%
)
0 50 100 150 200 250 300
Temperature (°C)
TGA_Ornidazole_screen_AB3_3_5_Dihydroxybenzoic_acid_repeat.001
DSC_Ornidazole_Screen_AB3_3_5_Dihydroxybenzoic_acid.001
Exo Up
-10
-8
-6
-4
-2
0
2
H
e
a
t 
F
lo
w
 (
m
W
)
20
40
60
80
100
120
W
e
ig
h
t 
(%
)
0 50 100 150 200 250 300
Temperature (°C)
TGA_Ornidazole_screen_AB8_1_Hydroxy_2_naphthoic_acid.001
DSC_Ornidazole_AB8_1_Hydroxy_2_naphthoic_acid.001
Exo Up
325 
 
 
Figure 55. Fumaric acid. 
 
 
Figure 56. 2,5-Dihydroxybenzoic acid. 
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Figure 57. 5-Chlorosalicylic acid. 
 
 
Figure 58. 3,4-Dihydroxybenzoic acid. 
 
-8
-6
-4
-2
0
2
H
e
a
t 
F
lo
w
 (
W
/g
)
0
20
40
60
80
100
120
W
e
ig
h
t 
(%
)
0 50 100 150 200 250 300
Temperature (°C)
TGA_Ornidazole_screen_AC3_5_Chlorosalicylic_acid.001
DSC_Ornidazole_screen_AC3_5_Chlorosalicylic_acid.001
Exo Up Universal V4.5A TA Instruments
-2.0
-1.5
-1.0
-0.5
0.0
0.5
H
e
a
t 
F
lo
w
 (
W
/g
)
0
20
40
60
80
100
120
W
e
ig
h
t 
(%
)
0 50 100 150 200 250 300
Temperature (°C)
TGA_Ornidazole_screen_AC5_3_4_Dihydroxybenzoic_acid.001
DSC_Ornidazole_AC5_3_4_Dihydroxybenzoic_acid.001
Exo Up
327 
 
 
Figure 59. m-Nitrobenzoic acid. 
 
 
Figure 60. Salicylic acid. 
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Figure 61. 3-Hydroxybenzoic acid. 
 
 
Figure 62. 3-Hydroxy-2-naphthoic acid. 
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Figure 63. Octadecylamine. 
 
 
Figure 64. Thymol. 
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Figure 65. 2,5-Xylenol. 
 
 
Figure 66. 4-Hydroxybenzoic acid. 
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Figure 67. Phenylpyruvic acid. 
 
 
Figure 68. p-Cresol. 
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Figure 69. 3-Methyl-2-oxobutanoic acid. 
 
 
Figure 70. 3,5-Dinitrobenzoic acid. 
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Figure 71. 4-Aminobenzoic acid. 
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6.4 PXRD plots from analysis of evaporative crystallisation from DCM solution 
PXRD patterns comparing the pure parent components: ornidazole (blue patterns) and co-
formers (green patterns), with the product of evaporation of a 1:1 molar solution of the two 
compounds from DCM (pink patterns) and the product of the co-crystal screen for those two 
components (red patterns). The figures are labelled by co-former. 
 
 
 
Figure 72. 5-Nitroisophthalic acid. 
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Figure 73. Trimesic acid. 
 
 
 
Figure 74. 3,5-Dihydroxybenzoic acid. 
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Figure 75. Phenylpyruvic acid. 
 
 
 
Figure 76. Fumaric acid. 
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6.5 Full Intrinsic Dissolution Test Results 
 
Table 2. Full IDT results for ornidazole. 
Segment 
Index 
End Time 
(seconds) 
Flow 
Rate 
(mL/min) 
Surface 
Conc. 
(mg/mL) 
Intrinsic 
Dissolution 
Rate 
(µg/min/cm²) 
Standard 
Deviation 
Sample 
Mass 
Released 
(mg) 
Sample 
Mass % 
of 
7.40mg 
1 60 0.2 225.5786 125.2183 42.9135 0.0039 0.05 
2 120 0.2 225.4976 191.4404 5.2656 0.0099 0.13 
3 180 0.2 224.5979 199.6776 3.1584 0.0162 0.22 
4 240 0.2 222.0206 191.2116 1.7229 0.0222 0.3 
5 300 0.2 220.9665 189.9449 2.9125 0.0282 0.38 
6 360 0.2 222.6274 190.1822 4.8005 0.0342 0.46 
7 420 0.2 222.1879 189.6431 2.0433 0.0401 0.54 
8 480 0.2 233.7058 205.0606 5.2824 0.0466 0.63 
9 540 0.2 231.004 206.1359 5.916 0.053 0.72 
10 600 0.2 234.0041 209.7367 1.8926 0.0596 0.81 
11 660 0.8 186.0086 478.3918 155.6717 0.0747 1.01 
12 720 0.8 172.0074 285.3286 10.6294 0.0836 1.13 
13 780 0.8 170.4847 279.4885 4.5671 0.0924 1.25 
14 840 0.8 165.3619 274.5224 3.6465 0.101 1.37 
15 900 0.8 162.9261 274.0695 4.8602 0.1096 1.48 
16 960 0.8 162.1826 275.4703 8.1595 0.1183 1.6 
17 1020 0.8 163.5007 274.9784 4.103 0.1269 1.72 
18 1080 0.8 162.0631 268.2534 8.0213 0.1354 1.83 
19 1140 0.8 163.1435 264.9276 7.5862 0.1437 1.94 
20 1200 0.8 167.8849 276.6576 5.5243 0.1524 2.06 
 
 
 
 
 
 
 
 
 
 
 
 
338 
 
 
 
Table 3. Full IDT results for 5-nitroisophthalic acid. 
Segment 
Index 
End Time 
(seconds) 
Flow 
Rate 
(mL/min) 
Surface 
Conc. 
(mg/mL) 
Intrinsic 
Dissolution 
Rate 
(µg/min/cm²) 
Standard 
Deviation 
Sample 
Mass 
Released 
(mg) 
Sample 
Mass % 
of 
7.68mg 
1 60 0.2 190.9367 85.6288 38.6518 0.0027 0.04 
2 120 0.2 218.214 169.2779 16.8344 0.008 0.1 
3 180 0.2 215.666 213.7102 8.6692 0.0147 0.19 
4 240 0.2 205.0801 241.4155 8.9947 0.0223 0.29 
5 300 0.2 197.543 274.3597 10.6067 0.0309 0.4 
6 360 0.2 195.2916 322.3068 17.372 0.0411 0.53 
7 420 0.2 193.8619 333.2427 15.0946 0.0515 0.67 
8 480 0.2 192.5753 263.8173 22.9992 0.0598 0.78 
9 540 0.2 192.0376 206.0547 9.6573 0.0663 0.86 
10 600 0.2 192.1486 178.4634 8.5123 0.0719 0.94 
11 660 0.8 180.899 417.638 94.1552 0.085 1.11 
12 720 0.8 179.244 308.8658 6.655 0.0947 1.23 
13 780 0.8 163.1604 309.3789 27.9119 0.1044 1.36 
14 840 0.8 161.1805 273.2671 3.9043 0.113 1.47 
15 900 0.8 161.2518 266.1076 3.2178 0.1214 1.58 
16 960 0.8 161.5072 269.4507 3.6373 0.1298 1.69 
17 1020 0.8 161.5256 269.8275 3.0725 0.1383 1.8 
18 1080 0.8 162.4197 269.0384 2.3373 0.1468 1.91 
19 1140 0.8 162.6555 266.7259 2.5925 0.1551 2.02 
20 1200 0.8 162.6295 262.7568 2.933 0.1634 2.13 
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Table 4. Full IDT results for ornidazole:5-nitroisophthalic acid. 
Segment 
Index 
End Time 
(seconds) 
Flow 
Rate 
(mL/min) 
Surface 
Conc. 
(mg/mL) 
Intrinsic 
Dissolution 
Rate 
(µg/min/cm²) 
Standard 
Deviation 
Sample 
Mass 
Released 
(mg) 
Sample 
Mass 
% of 
5.58mg 
1 60 0.2 93.3978 28.4115 14.9526 0.0009 0.02 
2 120 0.2 101.0084 73.6409 9.4622 0.0032 0.06 
3 180 0.2 109.0524 65.5784 7.6925 0.0053 0.09 
4 240 0.2 105.4413 56.5881 0.8129 0.007 0.13 
5 300 0.2 111.3491 59.3317 1.5037 0.0089 0.16 
6 360 0.2 102.0853 59.1742 1.1266 0.0108 0.19 
7 420 0.2 108.4724 62.0071 1.0147 0.0127 0.23 
8 480 0.2 99.4316 60.669 0.9159 0.0146 0.26 
9 540 0.2 103.2655 62.0892 1.4813 0.0166 0.3 
10 600 0.2 102.3913 59.4011 1.0227 0.0184 0.33 
11 660 0.8 16.4747 97.7319 59.0962 0.0215 0.39 
12 720 0.8 4.0097 40.898 1.263 0.0228 0.41 
13 780 0.8 3.0513 40.9952 2.8987 0.0241 0.43 
14 840 0.8 2.3886 40.4625 1.5066 0.0254 0.45 
15 900 0.8 3.7503 40.5445 1.0618 0.0266 0.48 
16 960 0.8 6.7978 41.4478 0.8596 0.0279 0.5 
17 1020 0.8 10.2023 40.5244 1.4364 0.0292 0.52 
18 1080 0.8 11.5785 40.6874 1.6732 0.0305 0.55 
19 1140 0.8 16.7941 42.1832 1.554 0.0318 0.57 
20 1200 0.8 21.9102 42.9036 0.7518 0.0332 0.59 
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Appendix 7 
 
7.1 Original zafirlukast co-crystal production methods 
Piperazine cocrystal (2:1) Form A. It was obtained by slow crystallization from a solution of 
zafirlukast:piperazine (1:1) in ethanol. Zafirlukast (20mg) and piperazine (3mg), molar ratio 1:1, 
were dissolved in ethanol (0.3mL) at 60°C. The solution was cooled down at room temperature 
in 30 minutes and crystals appeared after 4 days, (m.p. 218°C). 
Piperazine cocrystal (1:1) Form D. It was obtained by slurry in methanol, IPA, acetonitrile, 
acetone, methyl isobutyl ketone (MiBK) or ethyl acetate (AcOEt) at room temperature. For 
instance, zafirlukast (50mg) and piperazine (11mg), molar ratio 1:1.5, were slurred in 
acetonitrile (preferred solvent) (1.0 mL) at room temperature during 24 hours. The solid was 
filtered and dried under vacuum 48 hours, (m.p. 181°C). 
Piperazine cocrystal (1:1) toluene solvate Form E. It was obtained by slurry in toluene at room 
temperature. Zafirlukast (50mg) and piperazine (11mg), molar ratio 1:1.5, were slurred in 
toluene (1.0mL) at room temperature during 24 hours. The solid was filtered and dried under 
vacuum 48 hours, (m.p. 106°C). 
 
7.2 DSC and TGA overlay plots from analysis of received and produced co-crystals 
 
 
Figure 1. DSC and TGA overlay plot for the received zafirlukast:piperazine 2:1 co-crystal. 
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Figure 2. DSC and TGA overlay plot for the produced zafirlukast:piperazine 2:1 co-crystal (ZP21CC). 
 
 
Figure 3. DSC and TGA overlay plot for the received zafirlukast:piperazine 1:1 co-crystal. 
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Figure 4. DSC and TGA overlay plot for the produced zafirlukast:piperazine 1:1 co-crystal (ZP11CC). 
 
 
Figure 5. DSC and TGA overlay plot for the received zafirlukast:piperazine 1:1 co-crystal toluene solvate. 
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Figure 6. DSC and TGA overlay plot for the produced zafirlukast:piperazine 1:1 co-crystal toluene solvate (ZPTSCC). 
 
 
7.3 Calibration curve for HPLC analysis 
 
 
Figure 7. Calibration curve for the HPLC analysis of zafirlukast in SGF at 223nm. 
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7.4 Calibration curves for intrinsic dissolution testing 
 
 
Figure 8. Calibration curves for the intrinsic dissolution testing of zafirlukast and the three zafirlukast:piperazine co-
crystals in FaSSIF-v2 at 280nm 
 
 
 
Table 1. Molar extinction coefficients determined from UV calibration curves. 
Material Molar extinction coefficient (M-1cm-1) 
Zafirlukast 8630.2 
ZP11CC 8446.3 
ZP21CC 8702.2 
ZPTSCC 8111.9 
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Figure 9. Calibration curve for piperazine in FaSSIF-v2 at 280nm. 
 
7.5 Method details for in vivo study 
 
The pharmacokinetic parameters of zafirlukast cocrystals (ZP11CC, ZP21CC and ZPTSCC) were 
compared to those of pure Zafirlukast following oral administration with capsule and 
intravenously to male Wistar Han Rats (7-9 weeks, approx. 200-300 g). Pure zafirlukast and the 
cocrystals were encapsulated and orally administered at 5 mg/Kg (with equivalent amounts of 
pure zafirlukast corrected for each cocrystal stoichiometry). The final number of moles of 1 
was 2.171 µmoles in all capsules. The Zaf:Pip:Tol cocrystal dose was calculated based on a 
3:3.2 stoichiometry, as suggested by NMR and solid characterisation. Each form was first 
mixed in a 1:9 ratio with lactose to decrease the error by weight (Granulac 70 for zafirlukast, 
ZP11CC and ZP21CC and Sorbolac 400 for ZPTSCC). Zafirlukast, ZP11CC and ZP21CC were milled 
and sieved to achieve same PSD. It was observed that ZPTSCC changed form after the milling, 
so a different procedure was used; as described in the section on capsule production. The final 
doses were all within 1.3% of the aimed dose. 
IV formulation of zafirlukast: Appropriate weight of zafirlukast was weighed and dissolved into 
the required volume of vehicle with vortex and sonication applied to reach the target 
concentration. The vehicle was composed of 5% DMSO, 95% SBE-B-CD (30% w/v in water). This 
solution was pH adjusted with 1M HCl and 1M NaOH, to the final pH of 7.5. This IV bolus was 
filtered before administration with formulations stirred at room temperature for at least 2 
minutes before dosing. The final measured dose was 1.08 and 1.15 mg/Kg respectively for the 
two animals. Animals were administered the IV bolus via tail vein. Blood samples (0.2 mL) were 
collected from the jugular vein at the following intervals: Pre-dose, 2, 5, 10, 30 min, 1, 2, 4, 8, 
24 hours post dose.  
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PO formulations (zafirlukast, ZP11CC, ZP21CC and ZPTSCC): Animals were administered a 
capsule orally via a dosing needle (Torpac, capsule size 9). Blood samples (0.2 mL) were 
collected from Jugular vein at the following time intervals: Pre-dose, 15, 30 min, 1, 1.5, 2, 3, 4, 
8, 24 hours after oral dosing. Each sample was transferred into plastic micro centrifuge tubes 
containing K2-EDTA and placed on wet ice prior to centrifugation for plasma. Blood samples 
were centrifuged at 10000 rpm for 2 min. at 4ºC to obtain plasma. Samples were stored in a 
freezer at -75±15 ºC prior to analysis. Plasma samples were analysed by an LC-MS/MS method. 
Pharmacokinetic calculations were performed using WinNonlin (PhoenixTM, version 6.1) 
 
7.6 Plasma concentration plots from the in vivo study data 
 
 
 
Figure 10. Plasma concentration of zafirlukast over time plot for orally dosed pure zafirlukast (5mg/Kg, blue) vs IV 
zafirlukast (1mg/Kg, red) in male Wistar Han rats. 
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Figure 11. Plasma concentration of zafirlukast over time plot for orally dosed zafirlukast:piperazine 1:1 co-crystal 
(5mg/Kg, blue) vs IV zafirlukast (1mg/Kg, red) in male Wistar Han rats. 
 
 
 
 
Figure 12. Plasma concentration of zafirlukast over time plot for orally dosed zafirlukast:piperazine 2:1 co-crystal 
(5mg/Kg, blue) vs IV zafirlukast (1mg/Kg, red) in male Wistar Han rats. 
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Figure 13. Plasma concentration of zafirlukast over time plot for orally dosed zafirlukast:piperazine co-crystal 
toluene solvate (3:3:2) (5mg/Kg, blue) vs IV zafirlukast (1mg/Kg, red) in male Wistar Han rats. 
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